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ABSTRACT
In view of the potential therapeutic and diagnostic
applications of human monoclonal antibodies a series of
experiments were undertaken to optimise the production of
human monoclonal antibodies by existing cell lines and to
develop other human monoclonal antibodies.
Initial studies were performed to improve the
stability, antibody secreting capacity and growth
characteristics of an anti-tetanus antibody secreting
line (ES12) previously produced in the department. The
studies involved forming hybridomas of ES12 and various
existing partner lines. The partners used were KR4 and
Hmy2 (human lymphoblastoid cell lines) and NSO (murine
myeloma cell line). Three hybrids were chosen and their
growth characteristics and antibody secretion were
studied. It was found that GF5/9.13 (ES12/KR4 hybrid)
secreted the largest amount of antibody but that GF4/1.1
(ES12/NS0 hybrid) was the most convenient line to grow.
Later experiments attempted to produce new cell lines
secreting antibodies specific for Hepatitis B surface
antigen (HBs). The methods used included transformation
and direct fusion of peripheral blood lymphocytes as well
as a combination of the two. The fusion partners used in
this case were Hmy2 and NSO. Despite the fact that many
antibody secreting lines were isolated, only one proved
to be semi-stable. This line was produced by fusing an
EBV transformed line with Hmv2.
The isolation of appropriately immune lymphocytes can
X
be a problem in human monoclonal antibody production. In
an attempt to improve the yield of immune lymphocytes a
series of in vitro stimulation experiments were
undertaken. The stimulants used included PWM, PHA, human
AB serum and recombinant HBs vaccine. From these
experiments an antibody secreting line arose
spontaneously. It is assumed that the line is EBV
transformed as its DNA profile appears normal.
Preliminary experiments were under taken to show that
lymphocytes obtained from sources other than blood
(initially spleen) could be used to form hybridomas.
Donors for these experiments had high anti-HIV and anti-
blood group antibodies. despite the high yield of
hybrids, no specific lines were isolated.
As a follow up to initial experiments carried out in
the department which show that cell lines produced from a
normal healthy donor bind structures in human brain,
samples from transformation experiments were screened
against brain sections. The results here show how
transformation experiments can be used to'' dissect the
immune response even when permanent cell lines are not
produced.
Finally it is obvious that the production of human
monoclonal antibodies is far from easy. Improvements are
necessary in several areas which include: the isolation
of immune lymphocytes, immortalisation techniques,
cloning procedures and an under standing of the growth





Monoclonal antibodies are antibodies of a single
specificity produced by a cell line derived from the
progeny of a single B cell. The whole procedure is
entirely dependent on the fact that a single antibody
producing cell secretes only one specific antibody as
demonstrated by Nossal and Lederberg (1958). During the
fifties cell culture in vitro was developed as a routine
process, Barski et al (1960) observed spontaneous fusion
of cultured mouse cells and it was also noted that the
frequency of fusion could be enhanced using certain
viruses (Okada and Tadoka, 1962).
The selection of fused cells from the resultant mixture
was a problem until Littlefield (1964) produced a cell
line deficient in enzymes, which could be selected in
medium. It is this same basic method which is still used
today. Because the hybrids produced by this mechanism
tended to be genetically unstable and lose chromosomes,
the method was widely used to map genes to their
chromosomes (Croce et al., 1980, Erikson et al., 1981)
At around the same time research workers discovered
that myelomas were a neoplasm of antibody secreting cells
and that each tumour was derived from a single clone
(Cohn 1967). The artificial induction of myelomas in
mice using mineral oil (Potter and Boyce, 1962) , coupled
with in vitro cell culture techniques led to the
development of many well characterised immunoglobulin
secreting lines, although the epitopes recognised by the
antibodies were undefined (Cohn, 1967; Potter et al.,
1
1977)
Several viruses were used in alternative
immortalisation procedures to transform lymphocytes.
Strasberg (1974) used Simian virus 40 (SV40) to transform
cells from a rabbit immunised with pneumococcal type III
polysaccharide and isolated a line secreting small
amounts of specific antibody. Baumal et al (1971) used
Epstein-Barr virus to transform human lymphocytes from an
immune donor; this approach led to the production of
several lymphoblastoid cell lines (LCL) secreting large
amounts of antibody, although none was specific for the
immunising antigen. This technique has been greatly
improved in recent years and has been used successfully
to produce many cell lines secreting specific antibody
(see later).
In the meantime progress was being made in attempts to
fuse myeloma cells, these studies being undertaken mainly
to analyse the expression of immunoglobulin genes. In
these experiments Sendai virus induced fusion was largely
unsuccessful, probably because the majority of murine
cells lack a viral receptor.
The low frequency of hybrid formation continued to be
a problem until Davidson and Gerald (1976) reported that
polyethelyne glycol (PEG) promoted fusion of adherent
cells. This method was rapidly adapted for fusing
myeloma and lymphocytes in suspension (Kohler and
Milstein, 1975; Marguilies et al., 1976) and has been the
fusion method of choice ever since.
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Cotton and Milstein (1973) successfully fused a murine
and rat line which continued to secrete both murine heavy
and light chains and rat light chains. At the same time
Schwaber and Cohn (1973) formed hybrids between human
lymphocytes and murine myelomas that continued to secrete
both human and mouse immunoglobulin. These and further
studies led to the establishment of basic principles
concerning the expression of immunoglobulin in hybrid
cells. Hybrids continue to secrete all of the
immunoglobulin chains secreted by both parent lines
(Marguilies et al., 1976; Milstein et al., 1976) unless
the chromosomes are lost due to genetic instability. No
new immunoglobulins are synthesised (Milstein and Kohler
1977) and fusion of an antibody producing cell line with
a non-producing cell does not prevent antibody
production. Detailed studies of the immunoglobulin
produced in these experiments indicated that many were
mixed molecules produced by assembling heavy and light
chains from both parents (Marguilies et al ., 1976)
All of the above developments acquired greater
significance when Kohler and Milstein (1975) reported the
production of cell lines secreting antibodies specific
for sheep red blood cells. These lines were produced by
fusing spleen cells from a previously immunised mouse
with a HAT sensitive MOP-21 myeloma cell line. The
hybridomas as they were known were cloned and were the
first monoclonal antibodies to be produced by deliberate
prior immunisation.
Since then the technology has mushroomed into the vast
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field which exists today. Monoclonal antibodies are
currently being produced against a wide range of epitopes
including viral, bacterial, hormones, enzymes and many
others. The applications and potential applications are
almost as varied, from highly specific assays to
immunoaffinity depletion and purification techniques and
as human and animal therapeutics.
The great majority of monoclonal antibodies reported
to date are of rodent, mainly murine origin. This
reflects the fact that murine tissue culture has been
extensively developed since the very earliest in vitro
studies were undertaken. As a result, murine myelomas
which secrete no antibody are readily available for use
as fusion partners. Because the majority of tissue
culture development has been carried out using murine
cell lines, the culture media etc. are designed to give
maximum growth of murine cells. The myelomas of other
species may require slightly altered conditions for
optimal growth.
Advances in murine tissue culture, in particular in
relation to monoclonal antibody production, have not
always been readily transferred to the human system. The
reasons for this are not entirely clear, but it is
obvious with even the briefest glimpse through the
literature that production of human monoclonal antibodies
has not proceeded as quickly as would have been expected.
The first human monoclonal antibodies produced by cell
fusion were reported almost simultaneously by Croce et al
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(1980) and Olsson and Kaplan (1980) although Steinitz et
al (1977) had previously reported the production of
specific antibodies by Epstein-Barr virus transformed
cells. Since this time relatively few antibodies have
been reported, indicating that severe technical problems
are encountered when attempting to produce human
monoclonal antibodies.
There are several key areas where problems arise,
these will be discussed in detail later in the text.
Briefly the major problems are: 1) identifying a donor
who is immune to a particular antigen of interest;
because of ethical considerations donors must have become
immune via a natural infection or an approved vaccine 2)
obtaining sufficient immune lymphocytes; here it is the
choice of tissue which is important, 3) immortalising
the appropriate cells, and 4) cloning cells to obtain
stable cell lines.
1.2 SOURCE OF IMMUNE LYMPHOCYTES
In the murine system, which has by now become extremely
well developed, the source of immune lymphocytes is
almost exclusively the spleen of hyperimmunised mice.
Generally speaking provided a substance is non-toxic and
immunogenic then an immunisation schedule can be
optimised to ensure sufficient immune cells are available
for fusion. Unfortunately this path cannot be followed
in the development of human monoclonal antibodies. The
main problems are ethical considerations involved when
immunising humans with potentially harmful substances.
For this reason the range of human monoclonal antibodies
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developed to date is limited to antigens for which an
approved vaccine is already available or to those which
have appeared via a natural infection or disease state.
The source of the lymphocytes is usually restricted
for practical purposes to peripheral blood. Spleen,
tonsil, lymph node, tumour infiltrate and bone marrow
have all been used as lymphocyte sources but in most
cases peripheral blood is the most convenient source.
The suitability or otherwise of peripheral blood as
lymphocyte source will be discussed below.
Despite the problems, lymphocytes immune to a wide
range of antigens have been isolated from a variety of
sources. These include donors who have been deliberately
or accidentally exposed to antigen as well as those from
donors with no previous record of exposure to the
immunogen and some with ongoing active disease.
Not surprisingly antibodies to bacteria and viruses
comprise the majority of antibodies produced following
active immunisation. However antibodies to other
antigens have also been obtained using lymphocytes from
actively immunised individuals. These include
monoclonals to colorectal cancer (Haspel et al., 1985)
Rhesus D (Boylston et al.,1980; Crawford et al.,1983;
Doyle et al.,1985; Paire et al.,1986 and Thompson et
al.,1986), HLA antigens (Hulette et al.,1985; Effros et
al.,1986) and haptens (Olsson and Kaplan, 1980). The
great majority of antibodies generated from the
lymphocytes of donors with active disease are directed
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against tumour cell antigens (Wunderlich et al.,1981;
Sikora et al.,1982; Cote et al.,1983; Glassy et al.,1985;
Kan-Mitchell et al.,1986; Strelkauskes et al.,1987) and
various autoantigens (Schoenfield et al.,1982; Massicote
et al.,1984; Saski et al.,1984). Finally lymphocytes
obtained from non-immunised apparently normal donors have
given rise to autoantibodies reacting with a variety of
cell surface and internal antigens (Simpson et al.,1986).
It is assumed that the state of differentiation and
activation of lymphocytes will affect their ability to be
immortalised. The time interval between boosting donors
and harvesting lymphocytes will therefore be a critical
step in successful monoclonal antibody production. For
practical reasons there have been very few studies to
determine the optimum time for harvesting human
lymphocytes for fusion. Where studies have been
performed it would appear that the optimum time for
harvesting peripheral blood is 6-7 days (Bogard et
al.,1985), while for spleen it is 3 days post boosting,
as in the mouse (Schwaber et al.,1984). These schedules
have been successfully employed to produce monoclonal
antibodies against bacterial, red cell and tumour
antigens. It should be noted however that monoclonals
have been produced using lymphocytes isolated 1-3 months
post boosting (Boyd et al.,1984; Tiebout et al.,1984,
1985; Thompson et al.,1986).
The immune state of the donor is obviously of vital
importance in the production of human monoclonal
antibodies; however successful immortalisation is also
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influenced by the state of activation, differentiation
and proliferation of the immune lymphocyte. Although
these processes are beginning to be understood for
Epstein-Barr virus induced immortalisation (see below)
their relevance to fusion still remains to be
established. As stated by Schwaber et al (1984) B cells
fuse at some unidentified stage of differentiation and
activation.
1.3 IN VITRO IMMUNISATION
In an attempt to bypass the problems of obtaining immune
lymphocytes from donors and thereby increase the
potential number of antigens which may be used,
increasing attention is being focused on in vitro methods
of sensitising and amplifying specific B cells. This
approach has already been well studied in the murine
system (Reading, 1982; Borrebaeck, 1986). The studies
carried out on the human system have yielded less
successful results than those previously achieved in
mice. The reason for this is not clear. Borrebaeck
(1986) suggests it could be due in part to the fact that
human studies have used mainly peripheral blood where
there is an unfavourable ratio of T suppressor cells to B
cells. Another possibility is that the circulating B
cells are arrested in a phase in which additional stimuli
are required to induce antigen-specific clonal
activation.
Developments in this area have been slow but progress
is now being made. In vitro immunisation procedures have
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been successfully employed with lymphocytes from
peripheral blood, spleen and tonsils and antibodies have
been produced which react with bacteria, viral, red cell
and other antigens. The few comparative studies carried
out suggest that spleen and tonsil are superior to
peripheral blood as the lymphocyte source (Strike et
al.,1984; Teng et al.,1985).
One interesting point which should be made here is
that all of the successful stimulations reported so far
have used lymphocytes obtained from seropositive donors.
Attempts by Matsumoto et al (1986) to sensitise cells
from seronegative donors being unsuccessful. So it seems
that these in vitro "immunisations" are in fact "re¬
activations" of memory cells.
In an attempt to improve the performance of peripheral
blood lymphocytes, some studies have employed various
fractionation techniques. The majority of in vitro
immunisations are carried out on lymphocytes obtained by
density centrifugation. However several techniques have
been developed to deplete the preparation of T cells or
more specifically T suppressor cells. These include SRBC
rosetting (Teng et al.,1983), separation on nylon wool
(Ho et al.,1985; Garzielli et al.,1984; Yamaura et
al.,1985) or sephadex G10 columns (Hoffman and Hirst,
1985a,b), specific lysis with an anti-suppressor cell
(0KT8) monoclonal (Lagace et al.,1985; Brodeur et
al.,1987) or panning on cimetidine coated plates (Ho et
al.,1985). In some cases the adherent and non-adherent
fractions have been reconstituted to give more favourable
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ratios of T„ cells (Ho et al.,1985). The removal of T„
n S
and the enrichment of is not universally practised and
more comparative studies will be required before it can
be decided whether or not this is a desirable practice
(Borrebaeck, 1986). It should be noted however that
depletion or inactivation of T cytotoxic cells is
advisable especially if subsequent immortalisation is to
be by EBV transformation (Crawford et al1983,1985;
Larrick et al.,1985; Yamaura et al.,1985) Cyclosporin A
has proved extremely useful as a inhibitor and has
been shown to promote spontaneous outgrowth of EBV
induced cell lines (Bird et al.,1981)
Most studies have employed mitogen of some form or
another. Pokeweed mitogen has been most extensively used
while others include LPS, PHA and Staphylococcus aureus
Cowan 1 (a B cell stimulant). The mitogens have been
used either alone or in conjunction with an antigen. In
some cases the mitogen alone has been found to increase
the production of antibody secreting hybrids and to exert
a synergistic effect with antigen (Ichimori et al.,1985).
Growth and differentiation of B cells is obviously
dependent on growth factors in the culture medium. In
most cases these have been elicited in the media by the
mitogens, however, some studies have used external
sources of growth factors. These include unfractionated
lymphocyte conditioned media (Strike et al.,1984; Ho et
al.,1985), T cell growth factor (Brodeur, 1987) and B
cell growth factor ((Matsumoto et al.,1986).It would
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appear that the impure products are of doubtful value (Ho
et al.,1985). The choice of serum used in the culture
medium will also play an important role in the provision
of growth factors. Some authors claim that human serum
is essential, at least in the early stages of in vitro
cultivation (Strike et al.,1984; Ho et al.,1985; Teng et
al 1985b). However in most reports foetal calf serum has
been employed without any apparent disadvantages.
The optimum time in culture varies from author to
author but generally falls around three days (Crawford et
al.,1983; Ichimori et al.,1985; Larrick et al.,1985)
while in others seven days or more are used (Yamaura et
al.,1985; Brodeur et al.,1987)
1.4 IMMORTALISATION PROCEDURES
There are at present two main techniques being used to
immortalise human lymphocytes namely fusion with myeloma
(or lymphoblastoid) partners or transformation with
Epstein-Barr virus. It is also feasible to combine the
two techniques and fuse transformed cells with an
immortal partner. Some other techniques involving
genetic manipulation have also been attempted but are as
yet uncommon.
1. Cell Fusion
The first reports of the production of human
monoclonal antibody secreting cell lines produced by
fusing splenic lymphocytes with myeloma cells came from
Olsson and Kaplan (1980). Since then many papers have
reported success using cell fusion as the method of
immortalisation. There are however several problems
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associated with hybrid formation.
As previously stated the choice of lymphoid tissue
plays a major role in determining the success or
otherwise of a fusion. Several studies have indicated
that spleen or lymph node are superior to peripheral
blood for hybrid formation (Chiorazzi et al.,1982; Glassy
et al.,1983; Cote et al.,1984; Teng et al.,1985).
2.Fusion Partner
A second major factor to be considered is the fusion
partner itself. When murine monoclonals were first
reported the myeloma fusion partners being used gave
relatively satisfactory results, especially when non-
secreting lines became available. This meant that a few
partner lines were rapidly available to most laboratories
and the development of new lines was not necessary. Good
human partner lines have not appeared rapidly and
vigorous attempts to develop the same has led to the
generation of a plethora of fusion partners. In theory
the ideal partner would be a myeloma as these lines have
a phenotype with many polyribosomes, well developed golgi
apparatus and are thus able to secrete large amounts of
antibody (Kozbor et al.,1983, 1985). In reality very few
myeloma lines are in existence (see table 1) and those
which have been successfully cultured have very poor
growth characteristics and perform poorly in fusion
experiments (Kozbor et al.,1983). The vast majority of
fusion partners used to date have been lymphoblastoid
cell lines produced from EBV transformation of
12
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lymphocytes. These cells are generally easier to handle
in culture than myelomas and perform somewhat better in
fusion experiments. They have fewer polyribosomes,
sparse golgi apparatus and as a result secrete relatively
low amounts of immunoglobulin (Kozbor et al.,1983).
Recently several groups have attempted to improve the
antibody production and growth characteristics of their
lymphoblastoid lines by fusing them with either human or
murine myelomas. The rationale behind this approach is
that hybrids of these two cell types may retain much of
the phenotype of the myeloma while still retaining the
division time, ease of handling and rate of hybrid
formation of its lymphoblastoid parent. It is claimed
that the heterohybrids do in fact perform better than
their parents in fusion experiments. Kozbor et al (1984)
have fused the human myeloma RPMI 8226 with their
lymphoblastoid cell line KR4 to produce a heterohybrid
KRl2. This line exhibits a myeloma like phenotype and
shows improved fusion rates over its parents. By fusing
lymphoblastoid lines with murine myelomas several useful
partner lines have been produced (Teng et al.,1983, 1985;
Foung et al.,1985).
Fusion of human lymphocytes directly with murine
myelomas has been successfully attempted by several
groups (Wunderlich et al.,1981; Astaldi et al.,1982; Cote
et al.,1984; Haspel et al.,1985; Hirohashi et al.,1986;
Thompson et al.,1986). It has been known for many years
that heterohybrids preferentially eject human chromosomes
and indeed this fact has been used to assign genes to
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particular chromosomes (Croce et al.,1980; Erikson et
al.,1981). It was therefore naturally assumed that
mouse/human hybrids would expel human chromosomes.
Despite this it would appear that loss of antibody
secretion due to genetic instability is no worse in
heterohybrids than that encountered in murine hybrids and
that these lines can be stabilised by early cloning
(Thompson et al.,1986).
The fusion rates achieved using mouse myelomas as fusion
partners are much higher than those achieved with human
partners in comparative experiments (Cote et al.,1983,
1984, 1986). By using a fusion partner which is itself a
mouse/human hybrid the expulsion of human chromosomes can
be minimised (Kozbor et al.,1984). It has been shown
that hybrids formed when a heteromyeloma is the fusion
partner are more stable than when a murine myeloma is
used (Teng et al.,1985).
Few comparative experiments have been performed which
use more than two available partner lines, however,
Abrams et al (1983) suggest that LINC-LON Hmy2, UC 7296
and HF2 are worth further investigation, although this
study used only seven of the available partner lines.
More recently there have been preliminary reports of a
detailed study with a variety of cell lines including
mouse myelomas, heteromyelomas etc. (Usagawa et
al.,1986). Among the various lines tested KR12, SHM-D33,
3HLA-6 and 3HL3-27 (all heteromyelomas) proved the best.
It is obvious that many more time consuming studies are
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required before any hard and fast conclusions on the best
fusion partners can be reached.
3.Fusion proceedures
Polyethelyne glycol remains the major promoter of cell
fusion although the actual technique used varies from one
group to another. There are many factors which affect
the formation of hybrids by PEG but due to the wide
variations encountered in fusions even when carried out
by the same experimenter, very few comparative
experiments have been undertaken (Kadish and Wenc, 1983;
Lane et al.,1984; Dorfman, 1985; Westerwoudt, 1985). The
PEG itself plays a major role in determining the success
of hybrid formation and any new batch of PEG should be
tested in fusions before it is routinely used. The
studies recommend PEGs of different molecular weight and
source, however, it would appear that if a PEG is
performing satisfactorily in fusion experiments then
there is no reason to change.
The pH of the PEG solution is important in the
formation of hybrids (Lane et al.,1984) and should be
optimised for the particular solution being used. The
method of sterilising the PEG has also been reported to
affect hybridoma formation (Kadish and Wenc, 1983).
Filter sterilisation of the PEG solution is suggested to
produce larger percentages of hybrids than autoclaving.
Time of cell incubation in the PEG is also crucial
(Davidson and Gerald, 1976) and again an optimum should
be sought.
The entire procedure of fusing cells with PEG solution
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is inherently inefficient and dependent to a large extent
on chance contacts between appropriate cells. More
efficient mechanisms of cell fusion are naturally being
sought and these will be discussed later in the text.
1.5 VIRAL TRANSFORMATION
The second method of immortalisation, which
chronologically was the first to be used on human
lymphocytes (Steinitz et al., 1977), is Epstein-Barr
virus induced transformation. The virus used in this
technique is Epstein-Barr virus as described by (Epstein
and Barr, 1964). It is a herpes virus which
preferentially infects the B lymphocytes of humans and
some other primates. The normal source of the virus for
experimental laboratory work is the culture supernatant
of the marmoset cell line B95-8 (Millar and Lipman,
1973). Although the virus has been detected in the cells
of patients with Burkitts lymphoma and is known to be the
causative agent in infectious mononucleosis these are not
used as routine sources of virus. The viral receptor on
B cells has been shown to be the C3d (CR2) complement
receptor which is a 140KDa glycoprotein (Frade et
al.,1985).
There is at present some debate as to which cells
become infected and which are transformed, with several
different theories being given. It would seem that EBV
can bind to and penetrate all B cells which posses the
appropriate receptor yet only a small proportion of these
become transformed. Binding of heat killed EBV induces
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cells to become activated as does antibody directed
against the C3 receptor, suggesting that activation and
transformation are related but separate events (Aman et
al., 1985). Aman et al (1985) suggest that the
responsive population is a small high density resting
population, while Chan et al (1986) claim that the
susceptible population is an activated large cell
population.
• 4*
The activated population are mainly slgM and slgD
and are destined to secrete IgM. The small resting
population on the other hand gives rise to IgG and IgA
secreting populations, the precursors of these being
sIgG+ or sIgA+ and slgD .
It is also interesting to note at this point that Chan
et al (1986) suggest that the susceptibility to
transformation may be more dependent on entry into the
cell cycle than the density of viral receptors. This
suggestion by Chan et al would explain the the bias found
by many workers towards IgM secretion while still
allowing for IgG and IgA secretion by such lines.
A recent report by Roome and Reading (1987) however
tends to support the theory of Aman et al. By
fractionating B lymphocytes on percoll and incubating the
fractions with EBV they showed that higher rates of
transformation were produced in the small resting
population. Further experiments on the fractions showed
that if the resting population was activated by mitogens
or anti-immunoglobulin then the susceptibility to viral
transformation declined. Which ever theory is true the
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transformation of B lymphocytes can be used to produce
antibody secreting cell lines using lymphocytes from most
lymphoid tissues. If the work of Roome and Reading is
substantiated then peripheral blood would seem an ideal
source of lymphocytes as the majority of circulating B
cell are in a resting state. This in turn would suggest
that EBV could become the immortalisation method of
choice because of the ease with which peripheral blood
can be obtained.
As mentioned above EBV not only transforms B
lymphocytes but also acts as a polyclonal activator,
giving transient activation without subsequent
transformation. This phenomenon can be a major problem
when attempting to produce human monoclonal antibodies.
Moreover it appears that there are other problems with
transformed lines, particularly relating to the stability
of antibody secretion. It is not uncommon for cell lines
to grow well secreting specific antibody for 1-2 months
before their antibody titre suddenly declines. This fall
in titre which is often accompanied by a phenotypic
change, may be due at least in part to a defect in the
regulatory, secretory or genetic functions of the cell.
These possibilities will be discussed at a later stage.
Cloning of any cell line is important if monoclonality
is to be established, with EBV transformed lines it is
absolutely critical. The fact that some cells stop
secreting antibody implies that there may be an
overgrowth of secreting cells by non-secretors. Cloning
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cell lines at an early stage is the only way to avoid
this problem. Although early cloning has in some cases
rescued antibody secreting lines (Crawford et al.,1983;
Crawford and Callard, 1983; Doyle et al.,1985) many
potentially useful lines have been lost due to the
extremely poor cloning efficiencies of lymphoblastoid
lines (Evans et al.,1984). Attempts to improve cell
growth at low densities have not proved successful
despite using many feeder cells and supernatants.
Tiebout et al (1987) say that the poor cloning is an
inherent feature of these cell lines.
It should be noted that viral transformations have
occasionally occurred "accidentally" while fusion with an
EBV+ partner cell was being attempted (Boyd et al.,1984;
Strieker et al.,1985). These cell driven transformations
appear uncommon but do give rise to stable lines despite
the fact that the mechanisms underlying this phenomenon
have never been investigated.
1.6 LYMPHOCYTE TRANSFORMATION FOLLOWED BY BACK FUSION
Kozbor et al (1982) successfully combined the techniques
of fusion and transformation to produce a hybridoma
secreting anti-tetanus toxoid antibody. Since then the
method has been widely adopted being used to produce
antibodies against bacterial (Kozbor et al.,1984; Larrick
et al.,1985), viral (Emanuel et al.,1984; Van Meel et
al.,1985), red cell (Foung et al.,1986; Thompson et
al.,1986) and tumour antigens (Cole et al.,1984; Campbell
et al.,1986) among many others (see table 2). By
combining the two techniques it was hoped to profit from
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TABLE NO: 2. HUMAN MONOCLONAL ANTIBODIES PRODUCED BY EPSTEIN-BARR VIRUS
TRANSFORMATION OF HUMAN LYMPHOCYIES FOLLOWED BY FUSION
WITH IMMORTAL PARTNER LINES





Tetanus toxoid PBL Hu KR4 MOO > 7 Kozbor et al. 1982
Tetanus toxoid PBL Hu KR1 2 M >10 Kozbor et al. 1984b
Pseudomonas
aeruginosa SP Hu LTR228 M — Siadak and Lostrom 1985
Pseudomonas
aeruginosa SP Hu/Mo F3B6 M — 'Siadak and Lostrom 1985
Exotoxin PBL Mo SP2/0 M - Larrick et al. 1985
Mycobacterium
leprae PBL Hu KR4 M >12 At law et al. 1985
Gram neqative SP Hu/Mo SHM-033 M Teng et al. 1985a






Hu Org MHHI M + G 2.5-6 Van Meel et al. 1985
Rhesus 0 PBL Hu/Mo SHM-033 G3 (A) > 8 Bron et al. 1984
Rhesus 0 PBL Mo x63-Ag
8.653 M + G3 >14 Thompson et al. 1986
Rhesus G PBL Hu/Mo SBC-H20 G1 - Foung et al. 1985
Blood group A PBL Hu/Mo S8C-H20 — Foung et al. 1985a
Blood group A PBL Mo SP2/0 M - Larrick et al. 1985
HLA PBL Hu GM1500-
6TG-0B
M — Hulette et al. 1985
Lung carcinoma PBL, LN,
ITL
Hu KR4 M >5 Cole et al. 1984
Breast carcinoma PBL Hu KR4 >4 Campbel1 et al. 1986








KR4 M, G+A Haskard et al. 1984
Footnotes for Table No. (transformation +■ fusion).
PBL « peripheral blood lymphocytes
SP ■ splenic lymphocytes
TON » tonsular lymphocytes
LN » lymph node lymphocytes
ITL « intra-tumoral lymphocytes
Hu « human cell lines
Mo • mouse cell lines
the advantages of the two methods while avoiding some of
the problems and to a large extent this has succeeded.
The major advantage of this technique becomes apparent
when peripheral blood is the lymphocyte source. When PBL
are fused directly hybrids are formed with a frequency of
_7
around 20 x 10 , however fusion with EBV transformed
_7
cells increases this to 100 x 10 (Kozbor and Roder,
1984). It has been suggested that the reason why
peripheral blood fails to fuse well is that the cells are
not actively dividing and therefore their nuclei do not
fuse with that of the myeloma partner during mitosis
(Burnett et al.,1985). Since EBV acts as a polyclonal
activator of B lymphocytes, it allows lymphocytes to fuse
more efficiently resulting in a higher yield of hybrids.
Hybrids produced by this method have exactly the same
instability problems as those formed by direct fusion,
but these can be overcome by early and repeated cloning.
Hybrids undoubtedly clone more easily than EBV
transformed cells and so lines which may have been lost
can potentially be rescued. Antibody secretion by
hybrids is generally greater than transformed cells and
lines have been reported which are stable for greater
than 14 months (Thompson et al.,1986). The antibodies
secreted are representative of those being secreted by
the transformed lines at the time of fusion and as a
result IgM is the most common isotype. IgG's are not
uncommon however especially IgG^, so that potentially
useful antibodies could be produced by this method.
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1.7 POTENTIAL USES OF HUMAN MONOCLONAL ANTIBODIES
Despite the many problems associated with the production
of human monoclonal antibodies, many workers remain
optimistic and suggest many potential uses for the
reagents they are hoping to produce (see table 3). It is
hardly surprising that the main thrust of research has
been aimed at producing antibodies which could be used as
prophylactic and therapeutic reagents. Infectious
diseases and cancers have recieved the lions share of
attention in this area. Administration of protective
antibodies is extremely important where the organisms
reponsible are gradually developing resistance to the
drugs currently in use against them. Obvious examples
here are the gram negative bacteremias (Sasawada et
al.,1985; Teng et al.,1985) and Malaria falciparum
(Schmidt-Ullrich et al.,1986)
By producing antibodies which are protective against
infection in vivo the potential exists to use these to
isolate antigen (Schmidt -Ullrich et al.,1986) and hence
develop protective vaccines from either a recombinant or a
natural source. The monoclonals themselves may even
prove useful as anti-idiotype vaccines (Atlaw et
al.,1985; Matsushita et al.,1986; Schmidt-Ullrich et
al.,1986). More recently there has been interest in
using monoclonals to target drugs to microrganisms.
Many of the above applications also apply to tumour
specific antibodies, especialy as regards to drug
targeting either drug conjugates (Glassy et al.,1983;
Sikora et al.,1983; Cole et al.,1984; Haspel et al.,1985;
TABLE NO: 3. PROPOSED USES OF HUMAN MONOCLONAL ANTIBODIES
Example
A - DIAGNOSTIC AND MONITORING:
1. Viral infections e.g. cyto¬
megalovirus, HTLV-1
2. Other infections e.g. chlamydia
3. Malignancies e.g. leukaemia,
colorectal carcinoma,
melanoma, etc.
4. Red cell typing e.g.
Rhesus incompatibility
5. Tissue typing e.g. HLA
antigens
6. Immunopathology e.g. anti¬
bodies to pathological
and normal cell components
B. PROPHYLACTIC AND THERAPEUTIC:
1. General comment on value as
prophylactic and therapeutic
2. Treatment of infectious diseases:
a) identifying immunogenic epi¬
topes for use in vaccines
b) purifying immunogenic
peptides for use in vaccines
c) investigating regions of
genome coding immunogenic
peptides
d) as anti-idiotype vaccines




f) passives enhancement of
response
Reference
Emanuel et al. 1986
Rosen et al. 1983
Glassy et al. 1983; Cole et al. 1984
Haspel et al. 1985a,b; Matsushita et
1985 ; Andreasen et al. 1986; Olsson
et al. 1984; Kan-Mitchel1 et al.
1986; Smith et al. 1987;
Strelkauskas 1987a
Crawford et al. 1983a; Bron et al.
1984
Steinitz et al. 1977; Hulette et al.
1985; Effros et al. 1986
Haspel et al. 1985a,b; Imam et al.
1986; Simpson et al. 1986;
Kan Mitchell et a!. 1986
Gigliotti and Insel 1982; Glassy et
al . 1983; Ichimori et al. 1985;
Koizumi et al. 1986; Larrick and
Bourla 1986
Atlaw et al. 1985; Schmidt-Ullrich
et al. 1986; Matsushita et al. 1986
Schmidt-Ullrich et al. 1986
Schmidt-Ullrich et al. 1986
Atlaw et al. 1985; Schmidt Ullrich
et al. 1986; Matsushita et al . 1986
Hunter et al . 1982; Emanuel et al.
1984
At!aw et al. 1985
Table No. 3 (Cont'd.)
Example Reference
3. Treatment of malignancies:
a) identifying immunogenic
peptides for vaccines
b) as anti-idiotype vaccines
c) as therapeutic agents
(either alone or drug
conjugates)
Kan-Mitchell et al. 1986
Gaffar et al. 1986a
Glassy et a 1. 1983; Sikora et al.
1983; Cole et al. 1984; Haspel et
al. 1985a,b; Matsushita et al. T9"85;
Andreasen et al. 1987; Borup-
Christensen et al. 1986; Sikora et
al. 11987; Smith and Teng 1987;
Strelkauskas 1987a
d) imaging or localisation
of tumours
Sikora 1983; Glassy et al. 1985;
Borup-Christensen et al. T986;
Burnett et al. 1987; Sikora et al
1987; Strelkauskas et al. 1987a
4. General application as immuno-
modulators e.g. antibodies to
suppressor cells, interleukins,
anti-idiotypes
5. Therapy of autoimmune diseases
Dorfman et al. 1985
Sasaki et al. 1984
Croce et al. 1980; Sasaki et al.
1984; Chiorazzi 1986
6. Management of transplant patients
e.g. antibodies to histocom¬
patibility antigens
Hulette et al. 1985; Effros et al
1986 ~
7. Prevention of Rhesus incom¬
patibility
8. In contraception:
a) as contraceptive per se
b) in identifying immunogenic
peptides for use in contra¬
ceptive vaccines
Crawford et al. 1983a; Bron et al
1984 ~~
Kyurkchiev et al. 1986
C. INVESTIGATING THE IMMUNE SYSTEM IN
HEAL IH AND DISEASE:
1. Studying the normal B cell Winger et al . 1983; Glassy et al
repertoire in health and 1983; Cote et al. 1985,1986
disease
2. Examining the specificity/ Winger et al. 1983; Watson et al
activity of B cells in micro 1983; Glassy et al. 1983
environments e.g. tumour,
synovial cavity
Table No. 3 (Cont'd.)
Example Reference
3. Analysing the relevance of humoral
immunity in situations of clinical
importance:
a) infection Matsushita et
et al. 1986
al. 1986: Redmond
b) malignancy Paulie et al. 1984; Cote et al.
1986; Kan-Mitchel1 et al . 1986;
Andreasen et al. 1986; Glassy et
al . 1985,1987; Watson et al . l¥S"3;





4. Characterising and isolating
antigens of clinical relevance:




d) red cell antigens
Eisenbarth et al. 1982; Shoenfield
et al. 1982; Glassy et al. 1983;
Satoh et al. 1983; Sasaki et al.
1984; Chiorazzi 1986
Chiorazzi 1986
Smith and Teng 1987
Satoh et al. 1983
Bron et a 1. 1984
5. Studying the molecular biology
of the immunoglobulin locus
Carrol et al. 1986
Matsushita et al.,1986; Borup-Christensen et al.,1986;
Andreasen and Ollson, 1987; Sikora et al.,1987; Smith and
Teng, 1987; Strelkauskas 1987) or direct imaging of
tumours (Sikora, 1983; Glassy et al.,1985; Borup-
Christensen et al.,1986; Burnett et al.,1987; Sikora et
al.,1987; Strelkauskas et al.,1987).
Another exremely important therapeutic application is
the use of monoclonal antibodies as modulators of the
immune reponse ( Sasaki et al.,1984). Of particular
interest in this context are antibodies against human
lymphocyte subsets, antigens of the major
histocompatability complex and any soluble mediators of
the immune reponse such as the interleukins which might
be used to reverse graft rejection (Hulette et al.,1985;
Effros et al.,1986) or treat autoimmune diseases (Croce
et al.,1980; Sasaki et al.,1984; Chiorazzi, 1986).
While the main interest in research so far has been to
produce potential therapeutic reagents perhaps the
largest benefits will arise from the information gained
about the immune system itself. Our understanding of the
B cell repertoire in health and disease has been advanced
considerably by immortalising human B cells (Glassy et
al.,1983, 1987; Winger et al.,1983; Cote and Houghton,
1985; Cote et al.,1986). While the investigations
carried out into the growth requirements and control
events on B cells has led to detailed knowledge of the
humoral immune response and provided further insight into
autoimmunity and tolerance (Eisenbarth et al.,1982;
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Shoenfield et al.,1982; Glassy et al.,1983; Satoh et
al.,1983; Sasaki et al.,1984; Chiorazzi et al.,1986).
Although the studies performed to date have resulted in
considerable advances in knowledge, it is readily
apparent that further studies will both increase our
under standing of the basic components of the immune
system and provide valuable therapeutic reagents.
1.8 OUTLINE OF THE PROJECT
This project was commenced at a point where relatively
few human monoclonal antibodies had been reported.
Kozbor et al (1983) had recently published their data on
back fusing EBV transformed cells with the lymphoblastoid
cell line KR4. Within the Department of Surgery an anti¬
tetanus toxoid secreting cell line ES12 had been produced
by Dr. J Boyd. This cell line had been fairly well
characterised and its growth characteristics studied. It
was decided to use ES12 as a model line to investigate
the possibilities of fusion with several partner lines
available in the laboratory.
Hybrids produced in the initial experiments were
studied extensively for their growth characteristics,
antibody secretion and general stability. All three of
the hybrids chosen proved to be stable and showed
increased immunoglobulin secretion over the parent line
ESI 2 .
The methods learnt in handling the anti-tetanus lines
were applied in attempts to produce an antibody which
bound Hepatitis B surface antigen (HBs). It was assumed
that the production of a cell line by EBV transformation
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would be a relatively simple process, however this proved
not to be the case. Problems were encountered with the
stability of antibody production and providing antibody
secreting cells in sufficient numbers for fusion.
After many attempts using various combinations of in
vitro stimulation, EBV transformation and cell fusion,
two cell lines were produced which secreted specific
antibody. The first (GF41/27) was derived from the
fusion of an EBV transformed line with the human partner
Hmy2. The second HBl arose from a spontaneous
transformation during an in vitro immunisation
experiment. Both of these lines have proved difficult to
clone effectively especially the transformed line. The
hybrid even though it can be cloned does not produce
stable clones. The parent hybrid is also unstable with
antibody secretion stopping at around 12 weeks after
fusion. As both of these lines appeared relatively late
in the course of experimental work neither have been
particularly well characterised.
The success achieved with the anti-tetanus was not
repeated in the anti-Hepatitis experiments. Why this
should be will be discussed in more detail within the
text. The line produced most recently (HBl) has
characteristics very similar to ES12 and may react in a
similar manner in fusions. If this is the case then it
should be possible to develop a panel of hybrids from the






During the course of this project several cell lines have
been either used or produced. The lines were supplied by-
various laboratories as stated in table (4). The precise
details of their pedigree and growth requirements can be
found by referring to the papers quoted in the table.
Lymphoblastoid cell lines and myelomas were used as
fusion partners in experiments with either Epstein-Barr
virus transformed or untreated B-lymphocytes. The
marmoset cell line B95-8 (Miller and Lippman, 1973) was
used as the routine source of Epstein-Barr virus for
transformation of lymphocytes. Other lines were
produced by fusing various partner lines with antibody
secreting cells.
2.2 MEDIA
The basic complete media used in most experiments, was
RPMI 1640 containing 20 mM HEPES, 2 mM L-glutamine, 1 mM
sodium pyruvate, lOOlU/ml penicillin, lOOug/ml strepto¬
mycin, (Gibco Biocult, Paisley) 100 ug/ml kanamycin and 5
-5
x 10 M 2-mercaptoethanol. Preselected foetal calf
serum ( Flow Labs , batch number 29015111) was added at
either 10% or 20% (volume/volume). Complete media was
prepared and sterility tested by adding 3ml of media to
3ml of nutrient broth and incubating for 1 week at 37°C.
Media was stored at -20°C until required; once thawed
media was stored at 4°C and any media which had not been
used after 4 weeks at 4°C was discarded.
Selective media was prepared by adding HAT solution
-4
(Gibco Biocult) to give a final concentration of 10 M
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TABLE NO: 4. CELL LINES USED IN EXPERIMENTS
Line Cell Type Drug Markers Ig Secreted Reference
NSO Murine myeloma 8-A6
KR4 Human/LCL 6-TG,0UA











IgG2 (K) Kozbor et al. 1982





Edwards et al. 1982
Glassy et al. 1983
Mi 11er & Lipman 1973
TABLE NO: 4. CELL LINES PRODUCED DURING EXPERIMENTS









Hepatitis B surface AG.
Hepatitis B surface AG.
-5 . -5
hypoxanthine, 10 M aminoptenn, 1.6 x 10 M thymidine.
When Epstein-Barr virus transformed lymphocytes were
being fused, ouabain was also included at a concentration
of 5 x 10~6M.
2.3 SERUM FREE MEDIA
When trying to adapt cells to growth in serum free media,
four different media supplements were used. The source
and description of each supplement is given in table (5).
Complete serum free media was prepared and sterility
tested as normal complete media. Aliquots of 3ml were
incubated in 3ml of nutrient broth for 1 week at 37°C.
In these particular experiments media was always used
within 4 weeks therefore it was not necessary to freeze
media.
2.4 FREEZING MEDIA
In initial experiments, freezing medium was prepared with
50% foetal calf serum, 10% dimethylsulphoxide (DMSO) and
40% RPMI 1640. This preparation was later modified to
90% FCS + 10%DMSO as this was shown to give higher
viability on recovery from cryopreservation. After
preparation freezing media was sterility tested by
incubating 3ml media with 3ml nutrient broth for 1 week
at 37°C. The medium was stored frozen at -20°C in
aliquots of 20ml until required.
2.5 FOETAL CALF SERUM
Six batches of foetal calf serum from different suppliers
were tested for their ability to support the growth of
human cells at cloning dilutions. The serum which gave
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TABLE 5_










Supplied as a complete liquid
medium requiring only anti¬
biotics and L-glutamine.
Supplied as liquid medium
plus liquid supplement of
defined composition.
Supplied as in serum like
batches, reputed to have
batch to batch consistancy.
Added to RPMI 1640 instead of
serum.
Ultroser-G LKB Supplied as lyophilised
powder. Reconstituted with
water and added to RPMI 1640
instead of serum
N.B. Northumbria Biologicals Ltd.
NEN NEN Research Products
C.R. Collaborative Research Inc.
LKB LKB Instruments Ltd.
the best growth rates (see experiments in section 3.6)
was ordered and used exclusively in all experiments
requiring foetal calf serum. The serum which was
supplied sterile and heat inactivated was stored at -20°C
until required.
2.6 CRYOPRESERVATION OF CELL LINES
Cells taken either from culture, from fresh tissue or
from blood samples were prepared for freezing by washing
3 times in Dulbecco A solution. After washing, the
pellet with supernatant, was placed on ice for several
minutes to cool. The supernatant was decanted and the
pellet loosened by tapping gently. Freezing medium was
7
added such that the final cell concentration was 10
cells/ml and 0.5ml aliquots were dispensed into NUNC
freezing vials. The vials were placed inside polystyrene
containers in a -70°C freezer overnight before transfer
to the vapour phase of a liquid nitrogen vessel.
2.7 RECOVERY FROM CRYOPRESERVATION
Vials removed from liquid nitrogen were warmed in a 37°C
water bath as quickly as possible. As soon as the ice in
the vial had completely melted the cell suspension was
removed to a sterile universal and 10ml of prewarmed
complete medium was added. Cells were allowed to stand
for 5-10 min at room temperature before being centrifuged
for 10 min at 1500rpm. The pellet was then resuspended
in fresh, complete medium and the cells were incubated
in a humidified incubator with 5% C02 at 37°C.
2.8 PREPARATION OF VIRUS SUPERNATANT
Epstein-Barr virus was routinely used to transform human
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lymphocytes. The normal source of virus was the
supernatant of the marmoset cell line B95-8 (Miller and
Lippman, 1973). Cells were grown for 3-4 days to allow
complete recovery from cryopreservation then seeded at
3 x 10^ cells/ml in complete RPMI 1640 with 10% FCS.
Cultures were incubated for 7 days before cells were
removed by centrifugation for 10 min at 1500rpm. Cell
debris was removed by filtering the supernatant through
0.45um filter (Gelman Sciences). Viral supernatant was
aliquoted to 1ml vials and stored at -196°C in liquid
nitrogen.
2.9 PREPARATION OF FEEDER SUPERNATANTS
(1). Mixed Thymocyte Medium (MTM)
Thymus from two 4-5 week' old rats, one Sprague-Dawley,
the other Wistar, were homogenized and the cells washed 3
times in Dulbecco A solution. Cells were seeded at a
density of 5 x 10^ per ml in complete RPMI 1640 with 10%
FCS. Cultures were incubated for 48h, incubation for
periods longer than this can result in the production of
inhibitory factors in the supernatant (Dr L Micklem,
personal communication). The cells were removed by
centrifugation for 10 min at 1500rpm and the supernatants
were filter sterilised. Aliquots of 15ml were stored
frozen at -20°C until required.
(2). Human Mixed Thymocyte Medium (HMTM)
Human thymus or frozen thymus cells were kindly supplied
by Dr E. Dewar, Department of Pathology, Edinburgh
University. To prepare medium, thymus cells were isolated
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by homogenising tissue and washing 3 times in Dulbecco A
g
solution. Cells were incubated at 5 x 10 per ml in
complete RPMI 1640 containing 10% FCS for 48h. Cells
were removed by centrifugation for 10 min at 1500rpm and
the supernatant was filter sterilised. HMTM was stored
frozen at -20°C in 15ml aliquots until required.
(3). Human Endothelial Cell Supernatant (HECS).
HECS was prepared by Mr. N. Hunter at Scottish National
Blood Transfusion Service Headquarters Laboratory,Forrest
g
Road, Edinburgh. A subconfluent layer (5-7x10 ) of the
endothelial cell line H40PS was fed fresh growth medium
(Medium 199, 20% pooled human serum, 2.5ug/ml fungizone,
150ug/ml endothelial cell growth supplement) and
incubated for 3 days at 37°C in a humidified 5% CC>2
incubator. The supernatant was filter sterilised and
stored at -20°C until required.
2.10 EBV NEGATIVE LEUCOCYTES USED AS FEEDER CELLS
Leucocytes were obtained previously by Dr. J. Boyd from a
leocopheresis donor at Edinburgh and Southeast Scotland
Blood Transfusion Service Donor Suite, Lauriston Place
Edinburgh. The cells were supplied as the leukocyte
fraction from a blood separation. Cells were irradiated
7
(4000 rads) before cryopreservation in aliquots of 10
cells.
2.11 ISOLATION OF MURINE PERITONEAL MACROPHAGES
Balb/c mice were killed by exposure to ether fumes and
then their bodies soaked in Savlon solution for 2 min.
The skin was removed around the abdomen and 3-4 ml of
Dulbecco A solution injected into the peritoneal cavity;
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the abdomen was then gently massaged and the fluid
withdrawn, this process being repeated several times.
The cell suspension obtained was placed in a siliconised
glass universal and the cells were washed 3 times with
Dulbecco A solution. After the washes cells were
resuspended in complete RPMI 1640 + 10% FCS and incubated
overnight to ensure that the cells had remained sterile.
The macrophages were counted by staining with nigrosin
and cells were plated with PEG treated cells at a final
3
concentration of 10 cells per well.
2.12 ISOLATION OF LYMPHOCYTES FROM BLOOD
Whole blood samples (50ml) were collected fresh from
informed, consenting plasmapheresis donors at Edinburgh
and Southeast Scotland Blood Transfusion Service donor
suit, Lauriston Place, Edinburgh. EDTA (0.03% final
concentration) was added as anti-coaggulant. Blood was
layered onto Ficoll (Flow Labs) and spun at 1800 rpm for
25 min. Lymphocytes were collected from the interface
and washed 3 times in Ca and Mg free Hanks balanced salt
solution (HBSS). Cells were resuspended in RPMI 1640 and
viability was estimated by counting in nigrosin dye.
cell concentration was adjusted and lymphocytes were used
according to which experimental procedure was being
followed.
2.13 PREPARATION OF LYMPHOCYTES FROM SPLEEN
Spleen samples were kindly supplied by Dr. E. Dewar,
Department of Pathology, Edinburgh University and
Edinburgh Royal Infirmary. In all three spleens were
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used, 2 from patients with lymphoma the third from an HIV
positive patient. Because of the extremely high numbers
of lymphocytes present in the spleen only a small piece
3
of tissue approximately 8 cm was used from any single
spleen. The tissue was supplied in a sterile container
and always maintained under sterile conditions. Small
pieces of tissue were macerated either in a glass
homogeniser or by pushing through a sterile tea strainer.
The cells were suspended at this point in a small volume
of Hanks BSS. The homogenising was continued until
approximately 10-20 ml of cell suspension was collected,
any connective tissue or larger pieces of undisrupted
tissue were allowed to settle out. The cell suspension
obtained was layered onto Ficoll and after centrifugation
for 25 min at 1800 rpm the cells were washed three times
in Hanks BSS before counting. If at all possible spleen
cells were used fresh as recovery from cryopreservation
was extremely poor. The viability of recovered cells
could be greatly improved by adding 0.03% EDTA to the
freezing medium. The EDTA seemed to prevent the cells
from clumping as they did in its absence, presumably as a
result of fibrin formation.
2.14 AET-TREATMENT OF RED BLOOD CELLS FOR E ROSETTES
Sheep red blood cells in 50% Alsevers solution obtained
from the Scottish Antibody Production Unit (SAPU),
Glasgow and West of Scotland Blood Transfusion Service,
Law Hospital, Carluke, were washed three times in
Dulbecco A and spun at 2000 rpm for 10 min. A solution
was prepared by dissolving 402 mg of 2-aminoethylisothio-
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uronium bromide hydrobromide (AET) in 10ml of distilled
water and adjusting the pH to 9.0 with 4N NaOH. The
solution was filter sterilised through a 0.2um filter and
4ml of AET solution was added to 1ml packed sheep red
cells. After incubation for 30 min at 37°C with gentle
mixing, the treated cells were washed 3 times in ice cold
Dulbecco A and once in RPMI 1640 before finally being
resuspended in 9ml of cold RPMI 1640 + 10% FCS.
2.15 REMOVAL OF E+ ROSETTING LYMPHOCYTES
The lymphocyte preparation from the Ficoll spin was made
g
up to approximately 100 x 10 cells in 2.5ml and 2.5ml of
AET-SRBC added. Cells were incubated for 15 min at 37°C
with gentle mixing every 5 min, then spun to a loose
pellet (500 rpm for 5 min) and further incubated on ice
for lh. The pellet was then disrupted by shaking gently
and the cells were layered onto cold Ficoll, a small
sample (10-2(^/ul) being retained for counting rosettes.
After spinning for 25 min at 1800 rpm the E cells were
removed from the interface and washed three times in
Hanks BSS. The cells were then used as a B cell
population.
2.16 VIRAL TRANSFORMATION
The E rosetting population (B cells) was washed three
times in Hanks BSS. After the final wash the
supernatant was decanted and the cell pellet resuspended
in the residual volume by tapping the container firmly on
the bench. Supernatant from B95-8 cells was added such
7
that the concentration was approximately 10 cells/ml
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with a minimum volume of 0.5ml of supernatant. The
lymphocytes were incubated at 37°C for lh before the
suspension was topped up with RPMI 1640 and the cells
spun to a pellet. Supernatant containing live virus was
soaked in a Savlon solution overnight before being
discarded. The cell pellet was disrupted and resuspended
in RPMI 1640 containing 20% FCS. The concentration was
4
adjusted and cells were plated at either 10 cells/well
in 96 well, round bottomed microtitre plates (100jul/well)
or 105 cells/well in 24 well plates (lml/well) or 105
2
cell/ml in 25 cm tissue culture flasks. Peripheral
blood leucocytes obtained previously by Dr. J. Boyd from
an EBV negative donor were added as feeders at a
4
concentration of 10 cells per microtitre well or
equivalent. Wells were fed by adding 150/11 of RPMI 1640
+ 20% FCS after 7 days incubation. Growth was normally
visible by day 14 and the cultures were assayed for
specific antibody between days 14 and 28 depending on the
size of the colonies growing. Any positive wells were
expanded into 1ml of RPMI 1640 + 20% FCS in 24 well
2
plates then via 2xlml wells to a 25 cm tissue culture
flask. It was important at this stage to keep the cell
density fairly high, as diluting the culture with too
much fresh medium tended to cause cells to stop growing.
If cultures remained positive at this stage several
vials of cells were cryopreserved.
2.17 CELL FUSION
The fusion technique used was based on that of Cole et al
1984. Cells to be fused were washed three times in serum
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free RPMI 1640 and counted. The two cell types were then
mixed together in a 1:1 ratio and spun for 10 min. The
supernatant was completely removed and using a 1.0ml
pipette, 0.5ml of warm (37°C) PEG solution was added over
a 1 min period with the pipette tip resting on the bottom
of the tube and stirring gently. After the addition of
PEG, mixing was continued for 1 min then 10 ml of
prewarmed RPMI 1640 was added over the next 7 min. To
ensure consistent technique this was done at a set rate
of 1 drop/5 sec for 2 min, 2 drops/5 sec for 2 min, 3
drops/ 5 sec for 2 min, and the remainder over a further
1 min. The suspension was then placed in a 37°C water
bath for 40-60 min, after which cells were centrifuged at
1800 rpm for 10 min and washed once in RPMI 1640.
The PEG treated cells were finally resuspended in the
appropriate selective media (ie. RPMI 1640 + 20% FCS +
HAT for lymphocytes or RPMI 1640 + 20% FCS + HAT + OUA
for transformed lymphocytes) at 10^ cells/ml and plated
into the centre wells of 96 well microtitre plates
(lOOjul/well) . MTM diluted 1 in 3 in the selective media
was added to each well (lOOjul). In later experiments the
selective media was added 24h after fusion and for some
partner lines this seemed to improve the yield of
hybrids.
Wells were fed 3-4 days after fusion with selective
media, then fed as required every 3-5 days, the selective
media being stopped after 2-3 weeks. Hybrids could be
observed microscopically within 14 days and wells
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were assayed when cells covered approximately 25% of the
base of the well. Positive cultures were expanded via
2
lml wells to 25cm tissue culture flasks, and cloned as
early as possible. Any positive hybrids were
cryopreserved for later study.
2.18 CLONING OF CELL LINES
Hybrid cells and EBV transformed cells were cloned by
limiting dilution. Cells were counted using the vital
stain nigrosin, dilution prepared in RPMI 1640 +20% FCS
and 100.pl aliquots plated into 96 well u-bottomed plates
at 1 and 10 cells per well. Occasionally if cells were
extremely difficult to grow, initial densities would be
raised to 25 and 50 cells per well. The cultures were
then incubated at 37°C in a humidified C02 incubator
until growth was visible. When growing colonies were 1-
2mm in diameter, the supernatants were assayed for
specific antibody production. If no growth was visible
after 4 weeks cultures were discarded.
2.19 ELISA TO MEASURE HUMAN IMMUNOGLOBULINS
Goat anti-human immunoglobulins (Sigma) were diluted to
lOjug/ml protein in coating buffer ( see appendix B) and
100jul of this solution was dispensed into each well of
Titertek 96 well microtitre plates. The plates were
incubated overnight at 4°C to allow wells to become
completely coated. The wells were washed 3 times using
ELISA wash buffer and a Titertek plate washer. Non¬
specific binding was blocked by incubation for lh at 37°C
with 150pl/well of a 1% Bovine serum albumin solution
(PBS-BSA). Standard (Hoescht, IgM and IgG) and test
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solutions (100jil/well) were added to appropriate wells
and incubated at 37°C for lh. Plates were washed 3 times
as before, then lOOjul of alkaline phosphatase conjugated
anti-human IgG (or IgM as appropriate) was added to test
wells and the plates again incubated for lh at 37°C.
Conjugate solution was washed off and lOOjul of
substrate was added to each well (p-nitrophenyl
phosphate, Sigma, dissolved at a concentration of Img/ml
in substrate buffer as described in appendix B). Plates
were incubated at 37°C for 30 min to allow colour
development. Plates were read at 410 nm on a Titertek
plate reader. The standard solutions used were prepared
by diluting the neat solutions in PBS-1%BSA to
concentrations of lOjug/ml in doubling dilutions to
0.3jig/ml human immunoglobulin.
2.20 ELISA TO MEASURE ANTI-TETANUS TOXOID
Wellcome Tetanus vaccine (containing 40Lf/ml) was
dialysed against PBS overnight at 4°C. The toxoid was
then diluted to 17 jug/ml in 0.9% NaCl and lOOul aliquots
of the diluted solution were placed in the centre wells
of 96 well microtitre plates (Dynatech). After
incubation for 3h at 37°C then overnight at 4°C, the
wells were emptied and blotted dry. Plates were sealed
with clingfilm and stored at 4°C until required (plates
have been shown to be stable for up to 6 months Farzad et
al (1986) .
Plates were removed from storage and washed 3 times
with washing buffer using the Titertek plate washer.
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Unbound sites in the wells were reblocked by incubation
with 150jul of PBS-1 %BSA for lh at 37°C. Plates were
washed 3 times before the addition of lOOjul of sample or
standard solution to appropriate wells; the plates were
then incubated for lh at 37°C. After washing 3 times,
lOOjul of alkaline phosphatase conjugated goat anti-human
IgG (Sigma, diluted 1/1000 in PBS-1%BSA) was added and
incubation continued for a further lh at 37°C. Plates
were again washed 3 times before the addition of lOOjal of
p-nitropheny1 phosphate (lmg/ml) dissolved in substrate
buffer ( see appendix B) to each well. After a final
incubation period of lh at 37°C plates were read at 410nm
on a Titertek multiscan plate reader.
The standard anti-tetanus toxoid used in this case was
a preparation obtained from Protein Fractionation Centre
(Scottish National Blood Transfusion Service, Edinburgh).
In the assay doubling dilutions from 1/3200 to 1/102400
were prepared in PBS-1%BSA, these being equivalent to
0.0768-0.0024 IU/ml of anti-tetanus toxoid activity.
2.21 ANTI-HEPATITIS B SURFACE ANTIGEN DETECTION
To detect anti-Hepatitis B surface antigen activity in
the culture supernatant a commercial hemagglutination
assay was used (Serodia-anti-HBs, Diamed Diagnostics
LTD). This kit consisted of four major parts, positive
control serum, diluting fluid (also used as a negative
control) and two sets of lyophilised chicken red blood
cells, the first antigen sensitised, the second control
cells.
The assay was performed with slight variations from
the manufacturers recommendations. Briefly each vial of
lyophilised red cells was reconstituted in 1500jul of
diluting fluid. Sample supernatants (25ail) were placed
into duplicate wells in a 96 well U-bottomed microtitre
plate and 25jul of sensitised or control chiken red cells
were added; positive and negative controls were included
on every plate. After 1 min agitation plates were
allowed to stand at room temperature for 30-60 min before
agglutination was assessed.
2.22 IMMUNOFLUORESCENT STAINING OF CELLS FOR
FLOWCYTOMETRY
Lymphocytes or hybrid cells were washed three times in
Dulbecco A solution, counted and aliquots of 0.5-
g
1x10 cells added to test tubes. Cells were pelleted by
spinning for 10 min at 1800rpm, the supernatant decanted
and the pellet disrupted by tapping the tube firmly. The
first antibody was added to the residual volume (normally
a mouse monoclonal directed against a specific lymphocyte
subset) diluted 1:1 in human serum albumin and incubated
for 30 min on ice. Cells were washed once in Dulbecco A
then second antibody (5jul anti-mouse FITC conjugated
FAB-) was added and incubated for a further 30 min on
ice. After two washes in Dulbecco A solution cells were
analysed on the EPICS C cell sorter.
2.23 KARYOTYPING OF CELLS
Cells were karyotyped with the help of Dr S Szymaniec.
Hybrid cells were harvested after 2-3 days incubation in
RPMI 1640 + 10% FCS, washed three times and incubated in
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fresh RPMI 1640 + 10% FCS containing 0.4ug/ml colchicine
for 4h. Cells were spun to a pellet at 1500 rpm, 0.8%
sodium citrate was added dropwise to a volume of 5-10ml,
the cells being maintained at 37°C in a water bath. The
the cells were spun gently again (700 rpm) and the
supernatant was removed. Cold fresh fixative (3:1
methanol:acetic acid) was added dropwise to a volume of
5ml. The cells were spun again and the fixation process
repeated. Fixed cells were dropped onto clean cold
slides from a height of 5-10cm and allowed to dry.
2.24 STAINING OF CELLS FOR CELL CYCLE ANALYSIS
An aliqot of 10^ cells was pelleted and washed three
times in Dulbecco A solution to remove any serum. Cells
-2
were then resuspended in 1ml of 10 M Tris pH 7.0
containing 5mM MgCL2 and 50 jjg/ml propidium iodide.
After incubation for 10 min at room temperature cells
were washed again and resuspended in Dulbecco A solution
and analysed on the EPICS C.
When stimulated with laser light of wavelength 488nm
propidium iodide stained DNA fluoresces red, with the
intensity of fluorescence directly proportional to the
amount of DNA present within the cell (Larsen et al.,
1986). By examining the profiles of various cell lines
and comparing them to normal peripheral blood lymphocytes
it is possible to determine if cells have a normal
diploid karyotype or if they are carrying extra
chromosomes and are therefore hybrids (Larsen et al.,
1986) .
In an actively dividing population cells will be
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present in all stages of the cell cycle. Cells on the
G2-M boundary will appear as tetraploid and so will
appear as a small secondary peak on the screen. The
particular program used to analyse the data obtained uses
the ratio of the two peaks to calculate the number of
cells at any particular stage in the cell cycle. It is
possible therefore to measure how actively dividing a
cell population is at any point in time.
2.25 IMMUNOCYTOCHEMISTRY
(1). Preparation of slides
Cells which had been maintained in culture were
centrifuged and washed once with Dulbecco A solution.
Cells were counted and resuspended at a concentration of
5
5 x 10 cells/ml in Dulbecco A. The cell suspension was
loaded onto a Shandon-Elliot cytospin with 200xil of cells
being spun onto each slide. After spinning for 15 min at
1500rpm the slides were air dried under a hairdrier.
Cytospins were fixed by immersion for 10 min in acetone
and air dried again. Slides were stored wrapped in
tinfoil at -20°C until required.
(2) . Staining of slides
Slides were removed from -20°C and allowed to stand at
room temperature for a few minutes to defrost. An
indirect immunoperoxidase stain was used as follows. The
cytospun cells were overlaid with normal rabbit serum
diluted 1 in 4 in tris buffered saline (see appendix B)
for 10 min to block non-specific binding of protein.
After incubation the slides were washed in tris buffered
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saline for 5 min. The cells were then overlaid with
mouse anti-human immunoglobulin M or mouse anti-human
immunoglobulin G (Unipath). After incubation for 30
minutes in a moist chamber, the antibody solution was
washed off by submersion in 2 changes of tris buffered
saline for 5 min each.
The sections were overlaid with peroxidase conjugated
rabbit anti-mouse antibody (Dako) containing normal human
serum diluted 1:50 in tris buffered saline. Slides were
incubated for 30 minutes followed again by washing in 2
changes of tris buffered saline.
The final colour reaction was achieved by incubating
the smears for 5-8 min in 0.01% H2®2 anc^ 0.05%
diaminobenzidine (BDH) freshly prepared in tris buffered
saline. The reaction was terminated by rinsing the
slides in tap water. To enhance and increase the
intensity of staining, the slides were incubated in 2%
CuSO^ in distilled water for 4 min and washed in tap
water. The smears were counter stained in Mayer's
haematoxylin for 30-60 seconds and mounted in Apathy's
aqueous mounting medium.
(3) . Control slides
The object of these experiments was to determine if human
immunoglobulin was present in any of the test cells. To
ensure that the procedure was working properly, positive
and negative controls were always used. Negative control
slides were prepared using the murine myeloma NSO. It
was assumed that this line did not secrete any human
immunoglobulin. For a positive control the anti-tetanus
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toxoid secreting line GF4/1.1 was chosen as this line





All of the experiments carried out in this section were
based on the cell line ES12 (Boyd et al.,1984). This
line is an EBV transformed line produced in the
Department of Surgery (Edinburgh University) by Dr J.
Boyd. ES12 is somewhat unusual in that it was created by
a "cell driven" transformation. During a fusion between
peripheral blood from an anti-tetanus toxoid producing
donor and an EBV+ partner cell, the lymphocytes became
infected with virus and were transformed.
Initially it had been assumed that the line was a
hybrid as it had grown in the selective medium.
Subsequent karyotyping proved the line was in fact an EBV
transformed line. ES12 behaves in a manner typical of
lymphoblastoid cell lines, in that it produces relatively
low levels of immunoglobulin and is extremely difficult
to clone. Growth at larger volumes is however relatively
simple and the line appears to be quite stable, so large
numbers of cells were available for experimental
purposes.
ES12 seemed a good model to attempt fusions with both
human and mouse partners. Large numbers of cells were
readily available as was a good reliable assay. At the
time of these experiments there had been very few reports
on back fusions published in the literature, especially
using murine myelomas as the fusion partner. It was
known that human/murine hybridomas expelled human
chromosomes, therefore it was assumed that the
heterohybrids would be unstable. The fact that the
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murine cells were much easier to handle in culture and
secreted greater amounts of immunoglobulin made a
human/mouse fusion a desirable experiment. As the
results below indicate the experiments were very
successful and have subsequently been supported by other
work published since the experiments were carried out.
As well as fusing ES12 with murine cells it was
successfully fused with two human partner lines KR4 and
Hmy2. The reason for fusing with human lines as well as
murine was to ensure that any immunoglobulin produced was
processed entirely by human cells and so any
glycosylation etc. would be in the correct position. It
was also thought at the time that the human/mouse hybrids
would be unstable.
The results described below are for fusion experiments
where ES12 is the antibody producing parent. A flow
chart (fig 1) shows at a glance how each of the lines
described in this section was derived.
3.2 FUSION OF ES12 WITH MURINE PARTNERS
In the first experiments ES12 was fused with the murine
myeloma line NSO in four separate fusion experiments.
Only two of these experiments were fully cloned (GF3
and GF4) and the resulting lines studied in any detail.
The other experiment GF6 was expanded through 1ml wells
and the cells cryopreserved as uncloned lines for later
study. Results of the NSO fusions are shown on table 6.
When hybrids were screened by ELISA, very few gave no
anti-tetanus activity and in fact only 17 hybrids from
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TABLE 6








no of specific (%)
hybrids
GF3 60 60 57 (95)
GF4 75 16 10 (63)
GF6 360 360 357 (99)
GF9 360 54 7 (13)
(%) is calculated as percentage of hybrids present which
secrete specific antibody
FIGURE 1
FLOW CHART SHOWING FUSIONS CARRIED OUT WITH ESI2 CELL LINE
ESI 2
cultures grown to provide
high cell numbers.
Fusion experiments carried out
partner line
NSO KR4 Hmy2








436 tested were negative. This result may at first seem
to be very high, but it should be noted that the EBV
transformed cells are already a relatively pure, actively
dividing and antibody secreting cell population. All of
these factors are thought to be an advantage when fusions
are being attempted.
In experiment GF3, 57 of 60 wells seeded on a
microtitre plate contained actively growing cells between
2 and 3 weeks after fusion. The supernatants from these
wells were tested by ELISA for activity against tetanus
toxoid and all gave positive results (ie. OD405 > 0-1/
negative control was < 0.01). Three of the wells
containing the highest antibody titres were cloned by
limiting dilution at 10, 5 and 3 cells per well. Of the
three lines cloned only GF3/8 produced clones giving
positive readings in the ELISA.
The second NSO/ES12 fusion GF4 produced only 16
hybrids, 5 of which showed anti-tetanus toxoid activity.
The well with the highest antibody titres GF4/1 was
cloned immediately at 10, 5 and 1 cell per well while
other hybrids were expanded and cryopreserved for
possible future study.
Two clones GF3/8.4 and GF4/1.1 were chosen for further
investigation because of their high antibody titre and
good growth characteristics.
3.3 FUSION OF ES12 WITH HUMAN PARTNERS
Fusion GF5 involved hybridising ES12 with the human
lymphoblastoid line KR4. It was known from previous
experiments by Dr J. Boyd that the fusion efficiency of
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KR4 was much lower than that achieved by NSO. A large
number of wells (360) were seeded for this fusion. As
expected the fusion rate proved to be much lower with
fewer than 5% of the wells seeded containing growing
hybrids. These hybrids also grew at a much slower rate
than those formed by NSO, taking 3-4 weeks to grow large
enough for testing. The hybrid giving the highest titres
of anti-tetanus activity was GF5/9. This line was cloned
immediately at 10, 5 and 1 cell per well. From the
cloning 15 wells gave growth , 9 were positive for
antibody secretion. The best line GF5/9.13 was selected
for further study, others were expanded and
cryopreserved.
The lymphoblastoid cell line LINC-LON-Hmy2 (Hmy2) was
used as the fusion partner in experiment GF7. From 360
5
wells seeded at 10 cells/well 264 contained growing
hybrids, all of which were positive for anti-tetanus when
assayed by ELISA. Five hybrids were chosen for their
high anti-tetanus activity and cloned by limiting
dilution at 10, 5 and 1 cell per well. Three positive
clones from each plate were cryopreserved and GF7/3.2 was
chosen for further study.
3.4 THE EFFECT OF FEEDER CELLS ON HYBRID PRODUCTION
Balb/c peritoneal exudate cells were used as feeders in
the three fusions which produced anti-tetanus secreting
lines. It is not clear if the feeders made any
significant difference to the number of hybrids produced.
Several mechanisms have been described which would
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suggest that this could be the case. It is possible that
the PEC's produce a growth factor which is released into
the supernatant (see section 6.4) or that cell contact is
important. When the hybrids were growing in the wells it
was not clear whether they normally grew beside PEC's,
but this could have been the case. The only visible
difference when PEC's were used as feeders as opposed to
supernatants was that the wells contained much less
debris. This suggests that the macrophages "cleaned up"
any cells which were killed in the selective medium, so
leaving growing hybrids with more room.
In other fusions where MTM has been used as the
feeder, hybrids have been formed very successfully
especially when the fusion partner was Hmy2 (see section
4.6). Various feeder systems have been claimed to
increase hybridoma formation (table 7) but the results
obtained here failed to show any increase in either
hybrid growth or cloning efficiency with any of the
systems tested.
3.5 CHOICE OF POLYETHYLENE GLYCOL FOR FUSION
Several different polyethelyne glycol (PEG) preparations
were available as fusogens. In order to decide which PEG
would give the best results they were compared for their
ability to fuse ES12 and KR4. Three different PEG
solutions were prepared, each at pH 7.0 and pH 9.0 and
used in fusion experiments with ES12 and KR4. In each
5
case 60 wells were plated with 10 cells per well and the
results are shown on table 8. These results demonstrate
the low fusion rates achieved with KR4 as the fusion
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Sasaki et al. 1984; Melamed et al. 1985
Winger et al. 1983; Garzelli et al. 1984
Bischoff et al. 1982; Olsson et al. 1983
Melamed et al. 1985; Andreasen & Olsson
1986
Kozbor & Roder 1981; Astaldi et al. 1982;
Irie et al. 1982; Crawford et al. 1983;
Paulie et al. 1984; Tiebout et al. 1984;
Ho et al. 1985; Garzelli et al. 1986;
Schmidt-Ullrich et al. 1986













Zurawskiet al. 1978; Emanuel 1984;
Siadak & Lostrom 1985
Strike et al. 1984
Raubitchek et al. 1985; Van Meel et al.
1985
Steinitz et al. 1979
Kozbor & Roder 1981; Satoh et al. 1983;
Watson et al. 1983; Rosen et al. 1983
Zurawski et al. 1978
Evans et al. 1984
Zurawski et al. 1978
Astaldi et al. 1982




Nowinski 1980; 01sson et al. 1983; Teng
et al. 1985a
Kozbor et al. 1981,1982,1984; Cole et al.
1984; Atlaw et al. 1985
Kozbor et al. 1982; Satoh et al. 1983;
Cote et al. 1983,1985; Cole et al. 1984;
Gigliotti et al. 1982,1984; Haskard et al
1984; Doyle et al .1985; Melamed et al.
1985; Borup-Christensen 1986; Carroll et
al. 1986; Matsuho et al. 1986; Thompson
et al. 1986; Brodeur et al. 1987
TABLE NO: 8. SHOWING NUMBER OF POSITIVE HYBRIDS FORMED WHEN FUSING
ESI2 to KR4 USING VARIOUS PEG1 s UNDER VARYING CONDITIONS
PEG Molec. Wt. pH Wells with % Positive
of PEG Hybrids(a) Wells
Si gma 1500 7.0 0 0 0
Si gma 1500 9.0 3 5 1
BDH (biochem grade) 4000 7.0 5 8 3
BDH (biochem grade) 4000 9.0 1 2 1
BDH 4000 7.0 3 5 1
BDH 4000 9.0 4 7 4
(a) In each case 60 wells were seeded.
partner. The rates were never significantly increased no
matter what fusion conditions were used.
The Sigma PEG gave very poor hybrid production in
this experiment, although it had been used successfully
in murine fusions on many previous occasions (personal
communication Dr. J. Boyd). Of the two PEGs obtained
from BDH, the biochemical grade when used at pH 7.0 gave
the best yield of hybrids. When the number of positive
hybrids was measured then the ordinary grade BDH PEG used
at pH 9.0 gave the best results. This PEG was used in
all subsequent fusions. It should be noted that the rate
of hybrid formation achieved when Hmy2 or NSO are the
fusion partners is very much higher than the rates
achieved by KR4.
3.6 CHOICE OF FOETAL CALF SERUM
The foetal calf serum used for culturing cells obviously
has a great influence on the condition and growth of any
hybrids produced. In order to ensure continuity
throughout all of the experiments described, only one
batch of foetal calf serum was used throughout the entire
project. To decide which foetal calf serum should be
used, several batches were obtained from commercial
sources and used to clone four different cell lines.
The cell lines chosen represented the four major cell
types grown in the Department of Surgery, a human EBV
transformed line, a fusion of the EBV line and NSO and a
fusion of the EBV line to KR4 as well as a murine
hybridoma line. This group covered all of the cell types
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used in this study ie. an EBV transformed line, a
human/human hybrid and a human/murine hybrid. The murine
hybrid was included for a comparison of the relative
cloning efficiencies of the cell types.
In each case the four cell lines were cloned by
limiting dilution to 1 cell/well in medium containing 20%
of the appropriate foetal calf serum. The results are
shown on table 9, the most immediate and striking
observation is the vast difference in the cloning ability
between the human and mouse cells. Fusion of human cells
to mouse cells greatly enhances the number of clones
growing to the extent that they perform as well as murine
hybrids. Overall the Flowlabs sera was by far the best
with over 95% growth in GF4/1.1 and J15/123. It also
achieved almost 10% growth of the human/human hybrid
GF5/9.13 this being almost twice as great as the next
best serum.
Growth of cells in 95% of the wells may appear high,
indicating that the counting of viable cells was not as
accurate as it should have been. The relative growth
within a given cell line should not have been affected by
this as cells were counted in serum free medium and
dispensed to the various complete media from a single
stock. As as result of this experiment the Flow labs
serum batch number 29015111 was reserved and used in the
preparation of all subsequent media.
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TABLENO:9.NUMB ROFWELLSITHGROWINGC ONIESFACHC LLTYPEINCOMPLETEMEDIAAUSINGDIFFERENTFO ALCALFS RA CellLine FCSSourceESI2(%)GF5/9( )GF4 1.1(%)JT5/123( ) Flow29015111( )28(9.7)275(95.5)283(9 .3) Northumbria BiologicalsS10523( )(5. )219(76)250(8 .8) Northumbria Biologicals32414(0.7)1(0.3)169(58.7)6(47.2) Gibco20Q0940R1(0.3)(163(5 .6)100( 4.7) 288wellsofeachcelltypewereplat dinachs rum.
3.7 IMPROVING THE CLONING OF CELL LINES
Various supplements have been suggested to improve the
growth of human cells in vitro (Astaldi et al.,1981; Mao
and France, 1984; Sugasawara et al.,1985). In an attempt
to improve the cloning of human hybrids, some of these
supplements were used in two separate experiments. In
the first experiment cells were cloned in the presence of
each supplement and the results tabulated as the number
of wells containing growing colonies (table 10). This
measure was thought to be subject to too much variation
due to inaccurate counting and other chance factors. To
obtain a more accurate and objective measure of cell
3 . .
growth in these supplements, the uptake of H-thymidine
was measured. In order to do this cells were seeded at a
4
density of 10 cells per well in the appropriate media
and incubated for 3 days. The cultures were pulsed
3
overnight with H-thymidine and the radioactive uptake of
each group of cells measured. The results of the
experiments are tabulated (table 11); they show that none
of the feeder supernatants gave a significant increase in
3
growth as measured by either H-thymidine uptake or
3
cloning. The only supernatant which gave any boost in H
uptake was a control ie. the medium used to culture the
human endothelial cells. Normal human serum which was a
pooled AB serum supplied by the Edinburgh and Southeast
of Scotland Blood Transfusion Service gave an increase in
cloning in one experiment, but this could not be repeated
in further experiments.
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(a)Thesupplementss dw re EC1-10%endothelialce lsupernatant. HEC-10%endothelialce lsup rnatant. MTM-10%mixedthy ocyteedium. HMTM-10%humanixedthy ocyteedium. NHS-2%pooledn rmalhumanABse um.
(b)Platesscoredfogr wthft r14-16d ys. (c)Wellswithgrowthereassayed. (d)Notdone.
TABLE NO: 11. COUNTS PER MINUTE FOR CELLS AFTER OVERNIGHT
INCUBATION WITH 3H-THYMIDINE CULTURED IN
VARIOUS FEEDER SUPCRNATANTS
Experiment 1 Experiment 2
10% 50% 10% 50%
R20 ND ND 36,172 ND
RIO ND 31,549 ND 30,637
MTM ND 27,140 44,708 33,609
HMTM ND 42,813 38,993 28,098
HECS ND 1,096 762 283
HEC-cont ND 66,086 54,176 42,961
NHS ND 32,344 49,115 27,453
NO - Not done
MTM - Mixed thymocyte medium (rat thymus)
HMTM - Human mixed thymocyte medium
HECS - Human endothelial cell supernatant
HEC-cont - The medium used for culturing the endothelial cells
NHS - Normal human serum
From these experiments no firm conclusion are
possible. It appears that the cells derive no
significant advantage from any of the feeder supernatants
used. It must be stressed that in these experiments only
supernatants were used in order to reduce any background
3
uptake of H-thymidine. It is possible that using feeder
cells such as irradiated peripheral blood leukocytes or
PEC may have had a greater effect, but these were not
tested.
3.8 GROWTH CHARACTERISTICS OF THE CELL LINES
The hybrids produced in these experiments all have
different growth characteristics. GF4/1.1 which is a
human/mouse hybrid, tends to grow in a manner very
similar to NSO (plate 1). The cells are large, round and
tend to adhere to the sides of the plastic culture
vessels. The adherence is firm but cells can be removed
easily by washing the cell monolayer with a 0.02% EDTA
solution, stronger measures such as trypsin are not
required. In static culture cells remain almost 100%
viable until the cell layer becomes confluent; at this
point some cells begin to detach from the plastic and
grow in suspension. Cell viability declines steadily as
the culture becomes more acidic (as indicated by the
supernatant turning yellow).
The KR4 hybrid GF5/9.13 tends to grow in tightly
packed clumps (plate 2). On microscopic examination
cells of this hybrid seem to have a definite polarity,
pointed at one end and rounded at the other. The clumps
form with the rounded ends inwards and the points
PLATE 1: Wet film preparation of GF4/1.1 cells in culture.
Phase contrast microscope, note the cells are
uniform in size and shape. cells in culture grow
as an adherent monolayer.
PLATE] 2: Wet film preparation of GF5/9.13 in culture. Phase
contrast microscopy. Note the clumps are tightly
packed and the cells have "villi" like processes.
sticking out, giving the colonies a star shaped
appearance with many small spikes on the surface
to ES12, plate4) . The colonies tend to form
within 24 hours of cells being seeded into fresh flasks
and in order that the cells grow to a reasonable density
they must be regularly disrupted. If the colonies are
not disrupted they grow to around 1mm in diameter then
growth stops. The viability of a culture will remain
high ( >90%) for several days until the pH begins to fall
at which point the viability also begins to decline.
GF7/3.2 is a hybrid of ES12 and Hmy2 and grows in
suspension as large, mainly single cells (plate 3).
Occasionally the cells will form clumps but these are
much looser aggregations than those formed by GF5/9.13.
This hybrid grows to much higher densities than either of
the others, because it's growth is not inhibited by a
lack of surface area or by the formation of clumps. Even
6
in populations with cell densities of greater than 10
cells/ml (which is greater than those found in the other
hybrids) viability remains relatively high ( >95%) .
In order to compare the antibody secretion of the
various lines, clones of each line were grown by a
standard technique. GF4/1.1 and the GF7 clones were
4
seeded at a cell density of 5 x 10 cells/ml, GF4/1.1 was
seeded in 10 ml and GF7 was seeded in 20 ml. The other
hybrid GF5/9 was seeded at 10 cells/ml as this proved
to give better initial growth. The cultures were
incubated until they had reached the point where the
(similar
52
si <»° ° <s> Oofe
m ■>
° <§3 ooo°




PLATE 3: Wet film preparation of GF7/3.2 cells in culture.
Phase contrast microscopy. Note although the
cells are growing in clumps they are not so
tightly packed, also many more cells are growing
free in the medium.
PLATE 4: Wet film preparation of ES12 cells in culture.
Phase contrast microscopy. Note here the cells
are again tightly clumped (the free cells here
were mainly a result of disruption during
preparation of the slide).
viability was about to decline. In the case of GF4/1.1
this was 3 days, for GF5/9 it was seven days and for GF7
clones it was 4 days. At the appropriate time the
cultures were harvested, the cells counted and the
supernatants assayed for anti-tetanus toxoid activity.
The results are shown on table 12. Cultures were
harvested while the viability was high so that the amount
of antibody being produced per cell per day could be
calculated.
The results show some interesting features of each
cell line. The amount of antibody being produced per
cell per day for an individual line remains fairly
constant, especially within the GF4/1.1 subclones. The
GF7 hybrids show more variation, but that is not
surprising as they are derived from different wells in a
single fusion experiment rather than being derived from a
single hybrid.
As calculated by this method GF5/9.13 and the other
GF5/9 clones produce the most antibody per cell. The
best line produces almost four times as much antibody as
the parent line ESI2. The GF4/1.1 clones produce twice
as much antibody as ES12 while the GF7 hybrids range from
less than ESI2 to almost two times as much.
Although the antibody production by GF5/9.13 is much
higher than that of GF4/1.1 the growth characteristics
make GF4/1.1 a much easier line to handle. Cloning is
possible and relatively simple, whereas with GF5/9.13 it
is extremely difficult. For these reasons most of the
detailed studies and growth of cells at larger volumes
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have been carried out with GF4/1.1.
3.9 GROWTH OF CELL LINES IN SERUM FREE MEDIA
Attempts were made to adapt ESI2, GF4/1.1, GF5/9.13 and
GF7/3.2 to growth in serum free medium. Four different
defined media or media supplements were used ( see
section 2.3). The media chosen were HB104 and SF-1,
both formulated media which did not require serum and
UltroserG and NU-SER which were used as supplements
instead of serum.
In initial experiments cells were transferred directly
from their normal media to the serum free media. In all
cases cells failed to adapt to the new conditions
indicating that a gradual removal of serum would be
2
required. Cells were seeded into 25 cm flasks at 5 x
4
10 cells/ml in media consisting of 25% serum free media
and 75% (RPMI 1640 + 10% FCS). After 2 passages in this
medium (approximately one week) the cells were reseeded
4
at 5 x 10 cells/ml in media consisting of a 50:50
mixture of serum free and normal media. Cells were again
passed twice before increasing the percentage of serum
free media to 60%. In this way cells were grown in
continually decreasing percentages of serum (10%
reductions from a ratio of 50:50 to 90:10). None of the
cell lines would grow in completely serum free medium
even after several passages at 90% serum free medium to
10% RPMI 1640 + 10% FCS (a final concentration of FCS of
1%)
The cells showed phenotypic changes as the percentage
54
of FCS was reduced. GF5/9.13 which normally grows as
tight clumps began to grow as larger more refractile
cells which although they still tended to form clumps did
so in much looser aggregations. GF7/3.2 stopped forming
clumps and grew as single cells spread evenly across the
surface of the flask. GF4/1.1 which grows as single
round adherent cells began to change so that the cells
were different sizes where previously they were more
uniform. Some cells were almost twice as large as
others.
The doubling time of all of the lines was affected as
the serum concentration was reduced. The doubling times
were not actually measured but were deduced from the time
taken from seeding to reach confluence; this was
generally longer in cultures which contained lower
concentrations of FCS. When cells were transferred to
completely serum free medium they survived for several
days without undergoing any appreciable increase in cell
numbers, then the viability began to decline. Cells
which were growing in 90% serum free media were
cryopreserved and may be used in future studies on cell
growth. The cells growing in 90% serum free media
produced measurable amounts of anti-tetanus toxoid
antibody as measured by ELISA. No comparisons were made
between serum free and complete medium because the
incubation time and the cell numbers varied between
cultures.
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3.10 GROWTH AT HIGHER VOLUMES
If human cell lines are to be of any commercial value
then they must have the ability to be grown easily at
higher volumes. In order to show that GF4/1.1 could
adapt to growth in larger volumes several different
culture techniques were employed.
Cells were grown in static culture in RPMI 1640 + 10%
FCS simply by passing confluent logarithmically growing
cultures into increasing volumes in larger culture flasks
2
until a volume of 200 ml was reached in a 150 cm flask.
At this point the cultures were left to grow until most
of the cells appeared dead on microscopic examination.
Cultures were harvested and assayed for anti-tetanus
toxoid activity.
GF4/1.1 cells were also grown on a roller bottle
system to a final volume of 300 ml. Cells were seeded
2
from confluent static 75 cm flasks into 100 ml of RPMI
1640 + 10% FCS in a roller bottle. The roller system was
housed in a 37°C room with no gas control. As the cells
4
were seeded at a relatively high density (5 x 10 ) in
medium containing 20mM HEPES, the flasks did not require
gassing.
The cells grew as a monolayer surrounding the inside
of the roller bottle. After 7-8 days the layer began to
disintegrate and on sampling most of the cells were found
to be dead. The culture was harvested and the
supernatant assayed for anti-tetanus toxoid activity. A
static and roller culture were seeded from the same flask
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and grown to death. The supernatants from each culture
were then assayed for anti-tetanus activity and the
results which are shown on table 13 are directly
comparable.
The Celligen bioreactor (New Brunswick Scientific LTD)
was available in the department and was used as a third
bulk culture method. The apparatus consists of a 11
culture vessel with entry and exit ports, dissolved
oxygen (^02) ' PH anc^ temperature probes (see fig 2) .
The probes are connected to a control unit which adjusts
pH and d02 by sparging the medium with a varying mixture
of C>2, N2, CC>2 and air. Gasses are passed into the
medium behind a mesh which excludes cells, this prevents
cell damage by bubbles and also helps to avoid foaming.
The temperature is maintained by an electrically heated
jacket surrounding the vessel and the medium is mixed by
a constantly rotating central rotor.
The entire vessel complete with pH and dC>2 probes was
sterilised by autoclaving. Medium was poured into the
vessel by means of a sterile glass funnel inserted into
the entry port, the entire procedure being carried out in
a laminar flow hood. No sterility problems were
encountered using this method of loading.
The C>2 concentration was increased until the medium
was saturated, the control unit was set as 100% and the
dC>2 was subsequently controlled to 30% of this level. The
pH was controlled to 7.2 while the medium was stirred at
30 rpm and the temperature maintained at 37°C. Once the
reactor had reached equilibrium, it was left overnight to
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TABLE 13
Antibody Titres In GF4/1.1 Supernatant Produced By
Three Bulk culture Methods
Method of Final [Ab] Total time Total volume




flask 1.84 14 200
Roller
culture 1.52 8 300
Celligen
Bioreactor 1.42 12 1000
IM
CELLIGEN BOREACTOR
ensure that the medium was sterile. Cells were seeded at
a final density of 104 cells/ml by injection through a
septum in one of the ports. Daily samples of 5-10 ml
were withdrawn and the viability and cell concentration
determined. The supernatants were stored and assayed for
anti-tetanus activity in one assay at the end of the run.
Results of growth and antibody production are shown on
graph /I.
Despite the fact that these cells normally grow as a
monolayer, they adapt well to growth in a stirred
reactor. The viability remained high until the cell
5
numbers reached 1.6 x 10 cells/ml on day 7 then declined
sharply. The controlled factors ie. pH, ^0^, and
temperature did not alter appreciably, therefore it must
be assumed that at this point some nutrient in the medium
became limiting and this lead to cell death.
Assay of the daily samples shows that the antibody
titre rises along with the cell numbers during the log
phase of growth, then plateaus as the cell number begin
to decline. It is interesting to note that antibody
titres in the bioreactor did not rise as high as those in
a static culture seeded at the same time from the same
stock. There are several possible explanations for this
observation, the most likely is that the cells were
growing more quickly in the bioreactor and that the
nutrient limit was reached before the antibody titre had
a chance to reach those in the static flask.
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Graph 1: Cell Concentration and Antibody Concentration with
Time for GF4/1.1 Growing in Celligen Bioreactor
3.11 DNA ANALYSIS AND KARYOTYPING OF CELL LINES
Cultures of the cell lines ES12, GF4/1.1, GF5/9.13,
GF7/3.2, NSO, KR4 and Hmy2 were grown in RPMI 1640 + 10%
FCS. Aliquots containing 10^ cells of each cell line
were centrifuged in 10 ml centrifuge tubes and washed
three times in Dulbecco A solution. To the cell pellet
_2
in each tube, 1 ml of 50yug/ml propidium iodide in 10 M
tris pH 7.0 containing 5mM MgCL2 was added. After 10 min
incubation at room temperature, cells were centrifuged
and resuspended in Dulbecco A solution. Analysis was
carried out on an EPICS C cell sorter and the positions
of the peaks on the red fluorescence noted. Propidium
iodide stains DNA and causes it to fluoresce in the red
wavelengths of the spectrum. Since the amount of DNA
present within a cell is directly proportional to it's
fluorescence, the position of the peak on the EPIC's can
be used to compare the amount of DNA present in the cell
line tested with that of normal peripheral blood
lymphocytes.
The results not shown here indicated that ES12, Hmy2
and KR4 all have profiles similar to normal lymphocytes.
The profiles show that the cells are dividing much more
than lymphocytes as would be expected but appear to have
the same amount of DNA ie. they are diploid. Cell lines
GF5/9.13 and GF7/3.2 contain twice as much DNA as
peripheral blood lymphocytes confirming that they are in
fact hybridomas. The mouse line NSO contains more DNA
than the human cell and the mouse human hybrid GF4/1.1
also contains more than a normal human cell. GF4/1.1
does not however contain enough DNA to accommodate a
complete set of chromosomes from both the parent cells.
This is consistent with the idea that some chromosomes
are lost during the period immediately after fusion.
The hybrid cell lines GF4/1.1, GF5/9.13 and GF7/3.2
were all karyotyped by Dr Szymaniec in the Department of
Surgery. The results showed that GF5/9.13 had 86 chromo¬
somes, GF7/3.2 had 88 chromosomes and GF4/1.1 had 138.
The human/mouse hybrid contained a mixture of human and
murine chromosomes indicating that it is a hybrid. The
karyotypes obtained were not clear enough for Dr
Szymaniec to say exactly how many chromosomes were human
and how many murine. The general impression gained was
that more murine than human chromosomes were present,
this would correspond with the theory that huamn
chromosomes are expelled.
3.12 DISCUSSION
The results achieved in this section were extremely
encouraging. The cell line ES12 originally secreted
small amounts of immunoglobulin and grew quite slowly in
culture. By fusing ES12 with each of the three available
partner lines as described in section 3.2 the properties
of the cell line were improved. The use of a murine
fusion partner had previously been described (Wunderlich
et al., 1981, Astaldi et al., 1982, Gigliotti et al.,
1982). In all of these reports human lymphocytes were
fused directly to murine myelomas without prior viral
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stimulation. By adapting the method of Kozbor et al
(1983) and fusing EBV transformed lymphocytes with murine
myelomas, large numbers of hybrids could be easily
produced.
When the human partner lines KR4 or Hmy2 were used,
although fewer hybrids were produced, specific antibody
secreting lines were derived extremely easily. This fact
is reflected in the number of fusions described in this
section. From only 9 fusions 3 high secreting lines were
chosen and many others were cryopreserved as reserves.
It is possible that the lines chosen were not in fact the
highest secreting hybrids. With the relatively high
number of positive hybrids produced, especially with the
murine partners, positive lines were chosen almost at
random. It was only at the cloning stage that titrations
were carried out to determine which clones secreted the
largest amounts of antibody.
It has been suggested that murine/human hybrids
preferentially eject human chromosomes and are thus
unstable (Croce et al., 1980, Erikson et al., 1981).
Work carried out with the two human/murine hybrids chosen
in these experiments does not confirm these findings.
Since the two hybrids were chosen at random from 63
positive wells in 2 fusion experiments there seems no
reason to suppose that they are not representative of the
hybrid population in general.
After the initial cloning procedures GF4/1.1 was
maintained in culture continuously for 6 months without
any apparent decline in antibody titre. During this time
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flasks were split 1-2 times per week by detaching the
cell monolayer with a 0.02% EDTA solution and the cells
poured off. Complete RPMI 1640 + 10% FCS was added to the
residual volume and incubation at 37°C resumed. Every 2-
4 weeks a flask was allowed to grow until nearly all of
the cells were dead. Supernatants from these flasks were
assayed for anti-tetanus toxoid activity by ELISA. In
the six month period there was very little variation in
the titres of antibody produced indicating that GF4/1.1
is stable.
The two human hybrids produced were treated in a
similar manner, except that stability studies extended
for only 4-5 months. Again there was no noticable fall
in antibody titres up to this point. This must imply
that all of the hybrids investigated are genetically
stable in long term culture.
Since the human/mouse hybrid GF4/1.1 has proved to be
the easiest of the cell lines to work with, most of the
studies have been carried out on this line. This fact
alone suggests that heterohybrids are desirable lines to
produce.
GF4/1.1 has been sent to Damon Biotech who have
attempted to clone the immunoglobulin genes from this
line. Briefly the approach taken was to wash GF4/1.1
cells in PBS before extraction with guanidine
isothiocyanate. The RNA was pelleted through a CsCl
cushion and poly(A)+ RNA was then selected on an oligo
(dT)-cellulose column. The purity and integrity of the
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mRNA was verified by agarose gel electrophoresis.
Poly(A)+ RNA was then used as a template for first-
strand cDNA synthesis using reverse transcriptase and an
oligo (dT) primer. The second strand was then copied
using RNAse H and E coli DNA polymerase. By filtering
over a Sephadex G-50 column the cDNA was purified and the
ends were linkered. After electropheresis in a native
acrylamide gel, two fractions were recovered: 850-1200bp
(kappa) and 1400-2200bp (gamma). The size fractionated
cDNAs were then ligated into bacteriophage lambda gtlO
and these were in turn packaged with lambda proteins to
form infective particles.
Bacteriophage were plated onto lawns of E coli host
cells and plaque lifts were taken onto nitrocellulose
paper. By hybridising specific probes (for kappa or
gamma) onto the filter paper it was possible to isolate
phage colonies expressing the appropriate gene. At the
time of writing the positive phage are being plaque
purified and readied for further analysis. Details of
experimental procedures and results were kindly supplied
by Dr. Reilly, Damon Biotech, Boston, USA. The
techniques described above open up a whole new area for
future study, this will be discussed in more detail later
in the text.
In conclusion this section has shown that when starting
with an EBV transformed line it is possible to produce a
series of hybrids with different fusion partners. The
antibody secreted by these hybrids is the same as that
produced by ES12. Levels of antibody secretion measured
63
in an ELISA are higher in hybrids than in the parent
line. Growth characteristics of these hybrids are as
favourable if not better than ESI2 and the hybrids are
stable in long term culture. If experiments along these
lines could be repeated for other antigens then human






Following the success in producing anti-tetanus toxoid
secreting cell lines, it was decided that experiments
should be carried out with another antigen. The antigen
chosen was Hepatitis B surface antigen (HBs). This
target was chosen for several reasons; a source of highly
immune donors was easily available, a convenient assay
system was present, the antigen was already well defined
and finally any antibodies produced would be potentially
useful as a therapeutic reagent.
In the previous chapter dealing with anti-tetanus, an
EBV transformed line was already present in the
department. In the case of anti-HBs the first step was
to attempt to produce an antibody secreting line.
Initial experiments were aimed at EBV transforming
peripheral blood lymphocytes of immune donors. When
these failed to give satisfactory results, other methods
were attempted. Eventually two anti-HBs secreting cell
lines were derived. Very little biochemical analvsis has
been carried out on these lines because they were
produced very late in the project.
4.2 DONORS
Plasmapheresis donors at Edinburgh Blood Transfusion
Service, who were donating plasma for anti-HBs were used
as the lymphocyte source. All of these donors had high
titres of antibody as measured by the technique used by
the regional transfusion centre. Donors normally donated
two 450ml packs for plasma separation and between these
packs samples were withdrawn for routine screening. It
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was at this point that an additional 50ml of whole blood
was withdrawn for lymphocyte isolation. Alternatively
the first blood donation was spun at 500 rpm for 10 min
and a buffy coat removed into a separate pack.
Lymphocytes were isolated according to the materials and
methods section 2.12.
4.3 TRANSFORMATION OF PERIPHERAL BLOOD LYMPHOCYTES
Lymphocytes isolated either from whole blood or a buffy
coat preparation were passed through lvmphocvte
separation medium (Flow) to remove red cells and
platelets followed by three washes in Hanks BSS.
Rosettes were formed with AET-treated sheep red cells and
non-rosetting cells were separated by a further pass
through lymphocyte separation medium. The non rosetting
cells were assumed to be mainly B cells (Dr. J Boyd
personal communication) and were used as the B cell
population in subsequent experiments.
The B cell population was incubated for lh at 37°C
4
with B95-8 supernatant and the cells were plated at 10
cells per well with irradiated EBV leukocytes as
feeders. In general growth was visible within 14 days
and supernatants were ready for testing between 21 and 28
after viral infection. Colonies were tested when they
were clearly visible to the naked eye ie. approximately
l-2mm in diameter.
Cells which were positive on the first test
were transferred to 1ml culture wells and fed with 0.5ml
of fresh RPMI 1640 + 20% FCS. The cells were examined
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daily and when cell growth had covered most of the well
floor the cells were tested again. After this time cell
supernatants were tested regularly every 3-4 days to
ensure that cells were still secreting antibody.
Cultures were split into 2 x 1 ml culture wells and
2
subsequently into small 25cm flasks. If the lines were
still positive at this stage they were either
cryopreserved or hybridised with one of the available
fusion partners.
4
In all cases 100% of the wells seeded at 10 cells per
well gave growth by 4 weeks. When these were assayed by
a haemagglutination assay all experiments gave some
positive wells, but the actual number varied
considerably. Table 14 shows a summary of all of the
results from transformation experiments. The number of
wells which gave positive results always began to decline
as soon as the cultures were expanded to 1 ml wells.
When a graph is plotted of the number of positive
cultures versus time as in graph 2 the fall off in
antibody secretion is most noticable.
The disappearance of specific antibody from a culture
was often accompanied by a phenotypic change in the
cells. Lymphoblastoid cells normally have a tightly
clumped appearance with the cells being irregularly
shaped however when antibody secretion ceases the cells
tend to become rounder and appear dissociated in culture.
The fall off in antibody secreting lines usually begins
around 20 days after exposure to the virus when cells are
fed fresh medium. The process continues gradually until
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TABLE NO: 14. TRANSFORMATION EXPERIMENTS ASSAYED FOR ANTI-HBs
Wells % Growth Wells Lines
Experiment Seeded Positive % Cryopreserved
GT4 672 100 35 (5.2) 16
GF32 768 100 59 (7.6) 3
GF38 768 100 75 (9.7) 17
GF54 470 100 17 (3.6) 0
GF56 384 100 7 (1.8) 0
GF59 768 100 9 (1.1) 0
Graph2:NumberofEBVTransformedLin sSec tingpecif cA tibodyv r usTi ef r TransformationGF32. DaysinCulture
at 70 days no positive cultures remain. The lines which
have ceased antibody secretion normally continue to
divide and grow. Occasionally growth stops completely
and cells simply remain viable in culture without
dividing.
4.4 CLONING OF EBV TRANSFORMED CELL LINES
It was known from previous experiments on anti-tetanus
toxoid lines that cloning EBV transformed lines was
extremely difficult. However as it was obvious that by
4
seeding wells with 10 cells, growth was almost certainly
polyclonal, then the lines had to be cloned. Cells were
cloned initially at 25 and 10 cells per well into 96
well, U-well plates each containing 200ul of RPMI 1640 +
4
20% FCS. To each well 10 EBV leukocytes were added as
feeders. Plates were incubated at 37°C in a humidified
5% CO2 incubator for up to 4 weeks. Growth was normally
visible .microscopically within 14 days and the colonies
were tested when they reached l-2mm in diameter.
Table 15 shows the results of the cloning of the 35 HBs
positive lines obtained from transformation experiment
GT4. As can be seen the outgrowth of colonies from both
25 and 10 cells per well was extremely poor, resulting in
11% and 4.5% respectively of the wells seeded. the
positive wells were expanded into 1ml wells and assayed
after 3-4 days, however at this point all of the wells
had ceased antibody production and were abandoned.
In subsequent experiments similar results were
obtained, with any positive clones produced being as
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TABLE 15
NUMBER OF WELLS CONTAINING GROWTH FOR EBV
TRANSFORMED CELLS SEEDED AT TWO DENSITIES
Cell line wells growing at wells growing at












GT 4/12 1 2
GT4/13 3 3
GT4/14 3 0
GT4/15 11 (1 + ) 1
GT4/16 11 6
GT4/17 5 3
GT4/18 10 (1 + ) 3
GT4/19 3 1
GT4/20 12 5







GT4/28 10 (1+) 3
GT4/29 6 4







total number of clones at
total number of clones at
total number of positive
1680
25 cell/well 185 (11%)
10 cell/well 76 (4.5%)
lones 6 (0.4%)
unstable as the parent line. Clonings have also been
carried out in medium containing mixed thymocyte medium
(MTM). No increase in the number of clones produced has
been observed using this medium instead of feeder cells.
4.5 DIRECT FUSION OF PERIPHERAL BLOOD LYMPHOCYTES TO
FUSION PARTNERS.
A total of 9 fusions were carried out where peripheral
blood lymphocytes (PBL) were fused directly to
lymphoblastoid or murine fusion partners. Table 16 shows
the results obtained from these fusions and it is
immediately obvious that the rate of hybrid formation is
extremely low. Although not all of the fusions can be
compared directly it appears that none of the variables
noted had any great effect on hybrid formation. Fusion
numbers GF50 and GF51 used lymphocytes from the same
donor treated in an identical fashion except that in
fusion GF50 the cells were prestimulated. The AET
population was incubated for 72h prior to fusion with 100
jug/ml of PHA and 100 ng/ml of HBs. This preincubation
led to the production of hybrids in 12.2% of wells as
opposed to 1.7% in GF50 where no incubation occurred.
These results are highly suggestive that prestimulation
of lymphocytes leads to an increase in hybrid formation.
None of the hybrids produced were secreting specific
antibody so that the possibility exists that an
inappropriate cell population was stimulated by mitogen.
It should be noted that so far no firm evidence has been
published to support this theory.
By comparing fusions 51 and 53 or 63 it can be seen
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13 Whole UC7296 - 300 0 0
21 Whole Hmy2 - 720 9 1 .3
29 Whole UC7296 - 300 0 0
50 aet" NSO - 240 4 1.7
51 aet" NSO + 107 13 12.2
53 Whole NSO + 86 3 3.5
55 Whole NSO + 720 0 0
63 Whol e NSO + 600 20 3.5
70 aet" UC7296 + 120 0 0
58 Whol e NSO + 600 64 10.6
that by fractionating whole blood and using the AET
population for fusion, again the rate of hybridisation is
markedly increased. Although these fusions are not
directly comparable as the lymphocytes were donated by
different individuals, the results obtained in fusions 53
and 63 are sufficiently similar to suggest that the
effect observed is real.
4.6 FUSION OF EBV TRANSFORMED LYMPHOCYTES
Because of the instability problems encountered with the
EBV transformed lines, it was decided to attempt to
hybridise antibody secreting lines with lymphoblastoid or
myeloma partners. The particular fusion partner chosen
were Hmy2 and NSO as these had produced satisfactory
numbers of hybrids in previous experiments (see previous
chapter).
As described above the EBV transformed lines secreted
specific immunoglobulin only up to a maxiirium of 70
days after exposure to virus. Cells had to be subject to
fusion before this end point was reached.
As large a number of cells as possible are required
for fusion as this increases the number of hybrids
formed. By increasing the total number of hybrids formed
it is assumed that the chances of isolating a positive
hybrid will also be increased. However, this had to be
balanced against the fact that frequently antibody
production stopped abruptly and therefore a compromise
had to be reached. The optimum time would be where the
maximum number of cells were available and the antibody
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production is still at its peak.
In early experiments the EBV transformed cells were
expanded from 96 well plates through 1ml wells to 10ml in
2
a 25cm tissue culture flask. Lines still producing
specific antibody at this stage were fused with one of
the partner lines. This point normally came between 4
and 6 weeks after exposure to the virus, a point midway
down the decay curve on graph 2. Many lines became
negative before they reached this point and so could not
be used in fusions.
In later experiments lines were fused when cell
numbers were much lower, with the result that the total
number of hybrids produced in these experiments was
lower. Fusions were carried out at an earlier stage
because it was reasoned that if overgrowth by non-
secreting lines was responsible for the loss of antibody
secretion then at an earlier stage the proportion of
antibody secreting cells would be greater. The chances
of obtaining a specific hybrid would be correspondingly
increased. The results obtained did not lend support to
this theory as very few specific hybrids were produced in
any of the experiments carried out.
Positive hybrids were treated as described in
materials and methods section 2.17, being expanded
2
through 1ml wells to 25cm flasks. Instability of
antibody secretion was a problem encountered in hybrids
as well as with transformed cells All of the hybrids
produced except one stopped secreting antibody while
growing in 1ml wells. The cause of loss of antibody
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secretion in hybrids is generally accepted to be genetic
instability immediately after fusion. Early cloning
however failed to produce any stable lines. The results
from all fusions are contained in appendix C, the results
of one transformation experiment and its subsequent
fusions will be described in detail. The procedures
described and the results obtained are generally similar
to those of other transformation experiments.
4.7 RESULTS OF TRANSFORMATION GF32 AND SUBSEQUENT FUSIONS
Cells were obtained from a female donor who had high
levels of anti-HBs in her plasma. She had not received
vaccine in the previous six months. Lymphocytes were
isolated, AET+ rosetting cells were removed and the
remaining population was infected with EBV and plated at
10^ cells/well in 200.nl of RPMI 1640 + 20% FCS in 96 well
plates (see fig. 3).
When growth was visible after approximately 21 days,
all wells were tested and those positive for anti-HBs
were transferred to 1ml wells. Cells were maintained in
lml wells until growth was confluent, at which point they
were transferred to flasks and then fused.
On initial assay 59 of 768 wells contained anti-HBs
activity and were transferred to lml wells. Six of these
lines were cloned immediately at 25 and 10 cells/well and
three other lines were cloned at a later stage. No
positive lines were derived from these clones. When the
lml wells were assayed four days after transfer from the
96 well plates, 35 of the original 59 lines had stopped
72
FIGURE 3




GF3 2 •no positive clones
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all negative all negative
41/27 positive hybrid
.1 .2 .3 .4 .5 .6 positive clones
subsequently all negative
secreting specific antibody.
Lines were expended as required and fused when
confluence was reached in 10ml of medium. By the time
cells reached this stage only 10 lines remained
positive and were subsequently fused. The results from
these fusions (numbers 34-45) are shown on table 17. In
these particular fusions the fusion partner was the human
cell line Hmy2, however, in other experiments the murine
myeloma NSO has been used quite successfully to produce
hybrids (see appendix C).
From all of these fusions only one well GF41/27
assayed positive for anti-HBs by hemagglutination. This
2
line was expanded through 1ml wells to 25 cm flasks and
aliquots were stored in liquid nitrogen. The line was
immediately cloned at 25 and 10 cells per well, but no
positive clones grew from this experiment. GF41/27 was
expanded in volume up to 200ml so that sufficient
supernatant to fully characterise the antibody would be
available. However the titre of the antibody in the
supernatant was almost negligible as the lined had ceased
antibody production.
Subsequent experiments with frozen samples showed that
the cells continued to secrete antibody until eight to
ten weeks after fusion at which point the titre declined.
After several further cloning experiments positive clones
were produced at 25 and 10 cells/well. These were
immediately recloned and the original clones expanded.
The clone GF41/27.1-GF41/27.6 stopped secreting specific













17. RESULTS OF FUSIONS USING GF32 TRANSFORMED CELLS AS PARENTS
Parents Partner Wells Seeded Hybs. % No. Positive
32/6 Hmy2 60 44 73 0
32/18 Hmy2 60 41 68 0
32/51 Hmy2 60 10 16 0
32/4 Hmy2 60 37 61 0
32/1 Hmy2 24 18 75 0
32/16 Hmy2 35 35 100 1
32/45 Hmy2 40 36 90 0
32/28 Hmy2 43 33 77 0
32/36 Hmy2 20 1 5 0
32/43 Hmy2 43 27 82 0
from which they were cloned did. So far, the line has
never been successfully stabilised as regards antibody
secretion.
When assayed by ELISA the supernatant contains both IgG
and IgM confirming that the line is not monoclonal. It
is not known which isotype is specific for HBs, but as
Hmy2 is known to secrete IgG^ and the majority of EBV
transformed lines secrete IgM the chances are high that
the IgM is specific for HBs.
4 . 8 ;IN VITRO IMMUNISATION
After carrying out six transformation experiments it had
become apparent that there was a very real problem
with stability which was not going to be easily solved.
Fusion of transformed lines had produced only one semi-
stable hybrid from some 1200 hybrids tested and so a
different approach was tried.
Previous experiments (section 4.5) had shown that by
stimulating peripheral blood lymphocytes with mitogen
prior to fusion, the number of hybrid obtained could be
increased. It was decided to- stimulate so that anti-
HBs cells would be specifically stimulated. To
accomplish this a series of experiments were designed
which used various combinations of antigen, mitogen and
adjuvant peptide. Lymphocytes for these experiments were
isolated from buffy coat preparations (see section 2.12)
obtained from informed, consenting plasmapheresis donors.
In several cases donors who had been used in
transformation experiments were also used in the in vitro
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stimulation studies.
The mitogen chosen was pokeweed mitogen (PWM) as this
was routinely used in the laboratory by other workers.
PWM also has the advantage that it stimulates T cells as
well as B cells , so that any essential T cell derived
growth factors will also be produced in the culture. The
concentration of PWM was fixed at 2.5jug/ml final strength
as this had been shown to cause blast formation in other
experiments (results not shown). MDP was used at a
concentration of 20jag/ml as recommended by Boss (1984).
Cells were plated into 1ml wells in a final volume of
500jj1. Three different concentrations of antigen plus a
control were used in each experiment. In all cases the
final concentration of antigen was 10 ng/ml, 100 ng/ml
and 1000 ng/ml.
Fig 4 shows the typical layout of an in vitro
immunisation experiment. This design covered as many
variables as possible while still allowing each set of
results to be present in triplicate. In all six
experiments were carried out and table 18 shows the
combinations of antigen and mitogen used in each case.
In all of the experiments wells were tested after 3-4
days then again after 14 days. The medium was replaced
as much as possible after the first test to remove any
free antigen which may have been absorbing antibody from
the medium. Only one well from experiment 6 gave any
anti-HBs activity. The conditions in this well were 100
ng/ml of HBs with 10% pooled human AB serum as
supplement. The lymphocytes had been fractionated by
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TABLE NO: 18. CONDITIONS FOR IN VITRO IMMUNISATION
No. Donor Sex Cell Time since3 Cell Positive
Cone./ml. last boost Population Assays
1 A.C. 2 x 106 4 Whole lymph. 0
2 D.P. 2 x 106 3 Whole lymph. 0
3 E.D. 2 x 10^ 7 Whole lymph. 0
4 I.G. 4 x 106 4 Whole lymph. 0
5 E.L. 2 x 106 4 AET" 0
6 M.M. 2 x 106 3 AET" 2
TABLE NO: 18. CONDITIONS FOR IN VITRO IMMUNISATION
Combinations of two factors used as in Fig.
a Time in months
b MDP - 20 ug/ml.
c PWM - 2.5 ug/ml.
d PHA - dilution
e AB Serum - 10% v/v
FIGURE 4













20ug/ml MDP 2.5ug/ml PWM
20ug/ml MDP
Cells plated at 10 cells/well
Final well volume 500ul
Basic medium is complete RMPI 1640 + 10% FCS
AET-sheep red cell rosetting and wells were plated.
Unfortunately in this particular experiment only single
wells were plated because there were relatively few cells
available. It is unclear whether the observations were
real or merely due to a chance event.
As only one well had been observed positive in all of
the experiments carried out, it was decided that the
conditions in this well should be replicated on a larger
scale and immortalisation procedures attempted. A buffy
coat preparation from the same donor was obtained on her
next visit to the donor suite. Lymphocytes were isolated
and fractionated by the AET-SRBC rosetting technique.
The AET population was incubated for 48h in RPMI 1640 +
10% FCS with 100 ng/ml HBs vaccine (Wellcome) and 10%
pooled AB serum. After 48h the cells were washed twice
and divided into 3 parts; the first part was fused with
NSO, the second was transformed with EBV, and the third
was returned to culture with fresh RPMI 1640 + 10% FCS.
The fusion and transformation were treated as normal (see
materials and methods section 2.16 + 2.17) The cultured
stimulated lymphocytes were kept to determine if any
anti-HBs activity could be detected.
The fusion yielded very disappointing results with few
hybrids being formed (10 hybrids in 240 wells). The
hybrids formed grew very slowly and none secreted
specific antibody. The transformation produced 6
positive wells from 600 wells plated, again very low
compared to other transformation experiments. The
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positive wells were expanded but became negative
approximately 5 weeks after initial infection with virus.
The flask with untreated lymphocytes was maintained at
37°C in a humidified 5% CC>2 incubator for 2 weeks. When
examined microscopicaly at this point it was noticed that
although most of the lymphocytes had died a small
proportion remained viable. The culture was fed fresh
RPMI 1640 + 10% FCS and incubated for a further 2 weeks.
At this point it was obvious that a cell line had
developed from the lymphocytes.
The line (HBl) was maintained at first merely out of
interest, however when supernatant was assayed it was
positive for anti-HBs at a titre of 1:16. Cells were
grown up and cryopreserved. Fourteen weeks after the
initial experiment began supernatant from a confluent
flask had a titre of 1:1024. This titre was stronger
than any measured in previous experiments.
The cell line HBl was fused with NSO in a single
5
fusion experiment. PEG treated cells were plated at 10
cells/well in 96 well plates. The fusion efficiency
achieved in this experiment was satisfactory with 130
wells from 180 seeded containing growing hybrids. All of
the hybrids tested showed anti-HBs activity, 12 were
transferred to 1ml wells for further study. Of the 12,
six were cloned immediately at 10, 5 and 0.5 cells/well.
All of the lines produced growing clones but none showed
any anti-HBs activity. The 1ml wells were negative for
anti-HBs activity when they were confluent around 1 week
after transfer from 96 well plates. In retrospect it
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seems likely that the positive results obtained with the
hybrids were due to antibody secretion by unfused HBl
cells before they were killed in the selective medium.
No further fusions were carried out with this line as
time did not permit, however, it is anticipated that if
more fusions were undertaken then HBl would behave in
a manner very similar to ES12.
4.9 DISCUSSION
The second part of this project proved to be much more
difficult than the first. The initial attempts to
produce an anti-HBs secreting cell line by EBV
transformation were quite successful. Around 10% of the
wells tested were producing anti-HBs antibodies and
initially it was thought that at least one cell line
would be derived quickly from these experiments. The
stability problems which were encountered, however, were
extremely severe.
In the first experiment all of the lines were lost in
a short space of time and as this was completely
unexpected very few lines had been cryopreserved. The
large number of cloning experiments carried out on
transformation GT4 were undertaken as a counter measure
against what at the time was suspected to be overgrowth
by non-secreting lines. The number of clones growing was
low, but this was not entirely unexpected, what was
surprising was that so few of the clones were actively
secreting antibody. Positive clones sv/itched off
antibody production almost as soon as they were
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transferred from small wells to larger 1ml wells. The
instability of antibody production has been one of the
few predictable results in all of the transformation
experiments carried out.
The mechanism and cause of the loss of antibody
secretion has not as yet been elucidated however there
are several possibilities. The most obvious cause is
overgrowth by non-secreting cells which gradually dilute
out specific cells. This problem is particularly
relevant in the experiments described here, as the lines
in question were almost certainly derived from wells
containing several EBV activated precursors and are
consequently polyclonal. Early cloning would provide a
simple solution but as stated in section 4.4 cloning in
these experiments was not successful.
A second possible cause of the loss of antibody
secretion is the loss of the heavy and/or light chain
genes. This is more relevant to hybrids than
transformed lines but the possibility of gene loss in
these lines must be considered. Other areas which should
be investigated are a shortage of exogenous or endogenous
growth factors or equally important growth factor
receptors. Further possibilities include defects in
translation/transcription of DNA via mRNA to protein or
even faults in the secretory mechanisms of the cells.
It seems unlikely that a loss of genetic material is
responsible for the inability to produce immunoglobulin.
This statement is based on the the results of two fusion
experiments between EBV transformed cells and normal
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peripheral blood lymphocytes. Cells from an anti-HBs+
donor were transformed with virus and expanded as
described previously. When one particular line under
investigation stopped producing antibody, it was
maintained in culture until sufficient cells were
available for a fusion
The cells were fused with peripheral blood lymphocytes
isolated from a donor showing no anti-HBs activity in
their plasma. The cells were plated into 96 well plates
as described in methods section 2.12. In this case
no selective mechanism was available so hybrids could not
be differentiated from unfused lymphoblastoid cells.
Cells grew quickly in all wells as would be expected and
so wells were assayed at 14 days instead of 21-28 days as
would be the case in a normal fusion. Of the 384 wells
assayed, 4 gave anti-HBs activity. No attempts were made
to clone or expand these wells as it was considered at
that time that the chances of success were too low.
These results clearly indicate that even although the EBV
transformed lines stopped secreting antibody they retain
the genetic material which allows re-expression of
antibody under appropriate conditions.
It was obvious from very early in these experiments
that a line such as ES12 was not going to be easily
derived from EBV transformed lymphocytes. Fusion of an
antibody secreting population seemed to be the obvious
next step. Satisfactory numbers of hybrids were
produced in most of the experiments carried out, but
again the number of positives was disappointingly low.
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Hybrids were being produced regularly and reproducibly
with both Hmy2 and NSO but relatively few hybrids
secreting anti-HBs were detected.
In experiments where anti-HBs was found, the hybrids were
both cloned and transferred to 1ml wells. Unfortunately
no positive clones were produced and of all of the
positive hybrids only 1 maintained antibody secretion for
any significant time. This hybrid, derived from a fusion
with Hmy2, also proved to be ultimately unstable in
culture and eventually stopped secreting antibody.
Since fusion of EBV transformed lines had not produced
satisfactory results it was decided to change the
approach once again. From previous experiments it was
known that prestimulation of peripheral blood lymphocytes
with mitogen increased the number of hybrids produced
when this population was subsequently fused with one of
the partner lines. In order to produce a specific
stimulation and so hopefully produce specific hybrids,
cells were incubated with mitogens and antigen in various
combinations. Only one combination gave positive results
for anti-HBs secretion in these particular experiments.
In previous stimulations, for example fusion GF51,
antibody could be detected in the medium after 3 days, no
explanation can be given for these results. The only
common factor between fusion GF51 and in vitro
immunisation 6 was that in both cases the cells were AET-
rosetted prior to incubation with antigen. It is
possible that the removal of some AET+ rosetting cells is
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important in the stimulation of B-lymphocytes to secrete
antibody.
The transformation and fusion experiments subsequently
carried out on lymphocytes from the same donor as in
IVI.6 and incubated in a similar manner did not give many
positive lines. In the transformation experiment only 6
positive wells were detected from 600 which were growing
and these stopped secreting antibody within 1 month. No
positive hybrids appeared and overall the number of
hybrids produced was low.
The cell line which appeared in the flask stimulated
by HBs and 10% human AB serum was completely unexpected.
The fact that specific antibody was being produced was a
bonus, but with the previous experience of EBV
transformed lines was not expected to last very long.
However at the time of writing, the line is still
secreting antibody 3 months after the start of the
experiment and the titre is still rising.
The only reasonable explanation for the appearance of
this line was that it was produced by a spontaneous
transformation of B lymphocytes. Such spontaneous
transformations have been previously reported (Bird et
al., 1981) when cyclosporin A is added to the culture
medium. Since cyclosporin A acts by inhibiting T cells
it is not unreasonable to assume that by removing T cells
a similar phenomena could be produced. When the
supernatant was assayed for immunoglobulin content it was
found to contain both IgM and IgG in roughly equal
amounts. This indicates that the transformation seems to
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have been polyclonal thus producing a mixed population.
So far cloning experiments have yielded very few clones
none of which have been positive.
This line has been fused with NSO in one fusion
experiment and the rate of hybrid formation achieved was
5
high (133 wells with hybrids from 180 wells seeded at 10
cells/well). Initially it seemed that positive hybrids
were present in the fusion but later testing showed that
they had most likely been due to carry over of unfused
EBV transformed cells.
The spontaneous appearance of HBl has meant that in
one sense the project has come full circle. A stable
antibody producing cell line has been produced by an
unknown mechanism. It seems likely that antibody
secreting hybrids will be derived from this line as they
were from ES12. Between times much has been learned
about the characteristics and production of. both hybrids
and transformed cell lines. It must be considered
extremely doubtful whether a similar experiment would





5 . 1 INTRODUCTION
The experiments which will be descrabe<i in this section
do not fall readily into a single catagory. They do
however provide additional information essential to this
thesis as a whole. Many of the statements made in the
discussion later in the text are based on a combination
of results from the previous two chapters and this one.
The Chapter is divided into several sections which stand
on their own and do not neccessarily bear any relation to
each other.
5.2 FUSION OF SPLEEN CELLS WITH MURINE MYELOMA
Reports in the literature had indicated that the fusion
rates achieved using splenic or lymph node lymphocytes
were much higher than those achieved with peripheral
blood lymphocytes (Chiorazzi et al.,1982; Schwaber et
al.,1984; Teng et al.,1985; Koizumi et al.,1986; Bibier
and Teng, 1987). These conclusions were reached on the
basis of our own study (James and Bell, 1987) and table
19 shows the results published in this paper. It was
decided therefore that some fusion experiments should be
carried out using splenic lymphocytes to determine
whether or not this was true.
Two spleens were supplied by Dr E Dewar, Department of
Pathology, Edinburgh University. Lymphocytes were
isolated from tissue samples as described in section 2.13
and the cells were prepared for fusion. In both cases
NSO was chosen as the fusion partner because in most
experiments this had yielded higher numbers of hybrids
than any of the other available partners. In experiment
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TABLENO:19.
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GF65 spleen cells from donor W.B. were fused with another
murine myeloma P653. This experiment was carried out to
discover if the fusion rate would be similar in both of
these murine lines.
Cells were fused with a 50% PEG Mwt 4000 solution
containing 10% dimethylsulphoxide, the solvent for this
mixture being RPMI 1640 containing 20mM HEPES buffer.
PEG treated cells were incubated in 96 well microtitre
plates and fed as described in section 2.17. When
growing hybrids covered 25% of the well surface, 150ul
samples were removed for assay.
In all, three experiments were carried out in this
section (numbers GF64, GF65 and GF68). The first two
experiments used lymphocytes derived from donor W.B.
This donor was found to possess an alio anti-kell
antibody in his serum. This antibody was of interest to
the Blood Transfusion Service and it was decided that any
hybrids should be screened by Mr C. Green at the
Edinburgh and South East of Scotland Blood Transfusion
Service. Samples were passed to Mr Green and the results
returned within 24h enabling any positive samples to be
identified rapidly and cloned.
The donor in experiment GF68 (D.R.) was female and was
shown to have serum antibody reactive with cytomegalo¬
virus. This antibody was of interest to Dr M. McCann of
the Protein Fractionation Centre, Edinburgh and
consequently supernatants from this experiment were
passed on for assay against CMV by ELISA.
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The results from these experiments are shown in table
20 and as can be seen, none of the hybrids tested
secreted specific antibody. No conclusions can be drawn
either as to whether or not P653 forms as many hybrids as
NSO. The range produced in these experiments was much
too wide and shows again the vast variation in hybrid
formation encountered when carrying out fusions.
When the results from this section are compared to
those where fusion was direct to unstimulated peripheral
blood lymphocytes, it can be seen that more hybrids are
produced when splenic lymphocytes are used. The reasons
for this are not clear. It is possible that lymphocytes
fuse more easily when they are activated. To prove this
it should be possible to measure the state of activation
in relationship to fusion frequency. The number of cells
in any particular stage of the cell cycle can be assessed
using the EPICS C cell sorter and correlation between
cell state and fusion efficiency could be measured.
The spleen cells in question were derived from a
patients with B cell lymphoma. Although it was not
measured at the time it, it could be assumed that a
higher than normal proportion of the cells was actively
cycling at the time of fusion. A better comparison of the
relative efficiencies of peripheral blood and splenic
lymphocytes would undoubtedly have been obtained with
matched fusions of both types of lymphocytes from the
same donor. Unfortunately the opportunity to carry out
such an experiment never arose.
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TABLE NO: 20. RESULTS OF FUSIONS USING SPLEEN AS LYMPHOCYTE SOURCE
Fusion Donor Partner Wells No. Hybrids Assay No. Positive
Seeded
64 W.B. NSO 130 104 anti-Kell 0
65 W.B. P653 94 24 anti-Kell 0
68 D.R. NSO 300 43 anti CMV 0
5.3 ATTEMPTS TO PRODUCE ANTI-HIV MONOCLONAL ANTIBODIES
A patient at the Royal Infirmary Edinburgh presented with
thrombocytopenia which was not being controlled by
conventional therapies. It was decided that the patient
should be splenectomised in an attempt to improve his
condition. Previous blood tests had shown that the
patient was seropositive for anti-HIV. Since it was
known that splenic lymphocytes fused better than
peripheral blood lymphocytes and anti-HIV would be a
particularly interesting antibody to produce the decision
was taken to attempt a fusion with the spleen cells. In
order to maximise the chances of isolating a positive
line transformation experiments were also undertaken.
The spleen in question was assumed to have a highly
unfavourable ratio of T„:T_, reflecting the counts
n b
carried out on peripheral blood. Since it is well
documented that Tg have a deleterious effect on
transformed cells, T-cells were removed prior to viral
transformation. Since no such effects have been shown on
hybrids and in the murine system T-cells do not seem to
have any effect, the whole population was used in fusion
experiments.
Initially fusion was favoured for several reasons.
Removal of T-cells requires extra incubation and washing
steps and since all of this work had to be carried out in
a class 1 hood in the Department of Bacteriology, it was
considered that fewer steps and less time occupying the
hood was to be preferred. The first experiment carried
out was a fusion and the second a transformation.
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Finally a second fusion was carried out. The methods
followed and the results produced are summarised in fig
5 and table 21.
Briefly for the fusion, cells were removed from liquid
nitrogen and cultured overnight before fusing with Hmy2
and NSO. Cells were plated into 96 well microtitre
5
plates at 10 cells per well. For transformation
lymphocytes were cultured for 2h on flasks coated with
goat anti-human Ig (SAPU). Non-adherent cells were
washed off and viral supernatant was placed directly onto
the adherent population in the flask. Cells were
incubated in this supernatant for 48h after which they
were washed and placed in fresh RPMI 1640 + 10% FCS.
After 2 weeks growth was apparent and cells were plated
into 16 x 1ml wells which were then assayed when growth
became confluent. In all experiments supernatants were
tested for anti-HIV activity in the Department of
Bacteriology using the DU-PONT direct binding ELISA.
The first two fusion experiments carried out were
unfortunately lost due to the incubator in the
containment laboratory being allowed to run dry. Half of
the wells seeded were lost before the condition could be
rectified and no hybrids grew in any of the other wells.
The volume of liquid present in each well each well had
been reduced by half so increasing the salt concentration
correspondingly. It is not surprising that hybrids did
not grow after being stressed in this manner.
In the final fusion experiment HIV 3, the fusion
88
TABLE NO: 21. RESULTS OF EXPERIMENTS TRYING TO PRODUCE HUMAN ANTI-HIV
MONOCLONAL ANTIBODIES
Expt. Method of Wells Wells Wells with
Immortalisation Seeded Growing Anti-HIV
1 Fusion 480 Dried out
2 Transformation 16 16 0
3 Fusion 240 12 0
FIGURE 5
FLOW DIAGRAM OF EXPERIMENTS CARRIED OUT ON HIV- SPLEEN
Splenic lymphocytes isolated
Expt2
T cells removed by
panning on to anti-Ig
coated flasks
adherent cells incubated
for 48h with B95-8 sn.
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partner was Hmy2. In all 240 wells were seeded at
10^ cells per well. Growing colonies were present in 12
wells but when assayed they contained no anti-HIV
activity. Several of the wells in this experiment
contained colonies which grew as tightly packed clumps,
more like EBV transformed cells than typical Hmy2
hybrids. The cells in these wells also grew much more
slowly than Hmy2 hybrids produced in previous
experiments. It may be that the cells observed in fact
been transformed in a manner similar to that previously
reported by Boyd et al (1984). It is also possible that
unusual state of the hybrids produced simply reflected
the poor state of the immune system as a whole.
The transformation experiment, although initially slow
to grow, soon took on the growth characteristics of other
EBV transformed cell lines ie. growing in tight clumps
and doubling every 24h or so. When the 1ml wells were
assayed after approximately 4 weeks in culture none of
showed any anti-HIV activity and were discarded.
Disappointingly no specific antibody activity was
detected in any of the assays carried out on
supernatants. However these experiments have shown the
feasibility of carrying out fusions and transformations
under the strict containment conditions required for
growing HIV infected lymphocytes. More lymphocytes are
stored in liquid nitrogen and are available for future
experiments if the facilities are available. Because of
the potential uses for a human anti-HIV monoclonal
antibody, these experiments are well worth repeating.
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5.4 PRODUCTION OF ANTI-BRAIN ANTIBODIES
Previous work in this department (Simpson et al 1986) has
shown that patients with Alzheimers disease have
antibodies which bind to structures in brain sections.
Antibodies were produced which bind to plaques and
tangles, diagnostic features of the disease. Age matched
controls were also shown to possess antibodies which
could bind these features.
In order to investigate whether these antibodies are
present in younger donors or are characteristic of older
patients, a transformation experiment was carried out.
The donor was a 30 year old female who donated 50ml of
peripheral blood. The method transformation is described
previously (section 2.16). Samples were taken from the
96 well plates 14-21 days after seeding and assayed by Dr
J. Simpson (MRC Brain Metabolism Unit, Department of
Pharmacology, Edinburgh University). The assay consisted
of layering the test supernatant onto frozen sections of
brain from Alzheimers patients or normal control. After
incubation and washing, a conjugated secondary antibody
was added, followed by substrate. Slides were examined
for evidence of staining and scored for intensity and
specificity.
In all more than 80 samples were tested, 37 of which
bound to one or more structures in both Alzheimers and
control brain. Table 22 shows the specificity of the
strongest samples ie. >3 on the intensity scale (the
scale was judged from 1-5). The staining patterns of
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TABLE 22
REACTIVITIES OF SOME EBV TRANSFORMED CELL SUPERNATANTS
WITH NORMAL AND ALZHEIMER HUMAN BRAIN








34 U> 1 *
35 3-4*
Samples stained by the immunoperoxidase technique.
Intensity of staining scored from 0-5* by Dr. J. Simpson
MRC Brain Metabolism Unit
some of the transformed lines are shown in plates 5-10.
It was surprising to find that a donor with no history of
disease and who was young possessed these antibodies.
It is possible that these antibodies play some role in
the mechanism of clearing cell debris from the blood
stream, much work remains to be done to fully
characterise and explain the presence of such antibodies.
Since these experiments were carried out, brain binding
murine antibodies have been raised from unimmunised mice
of various ages from neonates to 12 months (Simpson et al
1987). These monoclonals which are at present being fully
characterised show that the reaction is not species
specific and is likely to be against some internal or
membrane structure exposed by cell damage. The
monoclonals have not as yet been used to stain other
tissues although this may prove an extremely interesting
experiment.
The human cell lines were not expanded or cloned as
the lines had shown signs of dropping titres and it was
felt that the chances of success were too low compared to
the time involved. The experiment was however considered
a success as it has shown that antibodies of the required
specificity were present in the blood. Transformation
experiments of this type can be used to investigate in
detail the immune response of an individual to any
antigen, indeed Logtenberg et al (1987) used a similar
approach with fusions to investigate the production of
auto-antibodies. Even where no permanent cell lines are
produced in the end, valuable information can be gained
PLATE 5: Immunoperoxidase staining of Alzheimer brain
section with human antibody as primary antibody.
Low power (X50) field showing typical Alzheimers
tangle.
«
PLATE 6: Immunoperoxidase staining of Alzheimers brain
section with human antibody as primary antibody.
High power (xlOO) oil immersion field showing
typical Alzheimers tangle.
PLATE 7: Immunoperoxidase staining of Alzheimers brain
section using human antibody as first antibody.
Low power (X50) field showing stained astrocytes.
PLATE 8: Immunoperoxidase staining of Alzheimers brain
section using human antibody as primary
antibody. High power (xlOO) oil immersion
field showing astrocytes.
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PLATE 9: Immunoperoxidase staining of normal brain
section using human antibody as primary
antibody. Low power field (X 2 5) showing
staining of nuclei.
PLATE 10: Immunoperoxidase staining of normal brain
section using human antibody as primary
antibody. High power (X100) oil immersion
field showing staining of nuclei
about the immune system.
5.5 IMMUNOCYTOCHEMICAL STAINING OF CELLS FOR
IMMUNOGLOBULIN CONTENT
As stated in previous sections there was an extreme
problem with stability of antibody secretion. There are
many possible causes for this (table 23) one of which is
that cells have a defect in their secretory mechanism.
In order to test if cells produced immunoglobulin but
were unable to secrete it, cells were stained for IgG and
IgM as described in section 2.25.
The studies described in this section were carried
out on the hybrid line GF41/27. This hybrid had not been
cloned and secreted both IGM and IgG. Cells stopped
secreting antibody some 12-14 weeks after the initial
fusion. Aliquots of cells frozen in liquid nitrogen were
recovered and grown in RPMI 1640 + 10% FCS. At regular
intervals cells were removed and spun onto washed
microscope slides. The cells were air dried, fixed and
stored at -20°C until required.
Slides from sequential samples were stained for IgG
and IgM by the method previously described (section 2.25)
The plates (11 to 17) show the staining patterns which
were produced. It is obvious that the percentage of
cells which stain for IgG falls off at the same time as
the titre of specific antibody ( see table 24). The
number of cells staining for IgM does not alter
dramatically.
In order to show that the IgG is the active
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PLATE 11: Immunoperoxidase staining of cytocentrifuge
smear of GF41/27 cells harvested on 30.4.87.
Cells stained with anti-human IgG.
Immunoperoxidase staining of cytocentrifuge
smear of GF41/27 cells harvested on 1.5.87.
Cells stained with anti-human IgG.
PLATE 13: Immunoperoxidase staining of cytocentrifuge
smear of GF41/27 cells harvested on 21.5.87.
Cells stained with anti-human IgG.
PLATE 14: Immunoperoxidase staining of cytocentrifuge
smear of GF41/27 cells harvested on 1.5.87.
Cells stained with anti-human IgM.
PLATE 15: Immunoperoxidase staining of cytocentrifuge
smear of GF41/27 cells harvested on 21.5.87.
Cells stained with anti-human IgM.
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PLATE 16: Immunoperoxidase staining of NSO cells stained
with anti-human IgG. Note this is a negative
control and no non-specific staining occurs.
PLATE 17: Immunoperoxidase staining of NSO cells stained
with anti-human IgM. Note this is a negative
control and no non-specific staining occurs.
TABLE 23
POSSIBLE REASONS FOR LOW OR ABSENT IMMUNOGLOBULIN SYNTHESIS BY HUMAN
MONOCLONAL CELL LINES.
SUGGESTED DEFECT REFERENCES
Inhibitory effect of mycoplasma
or other microorganisms
Overgrowth of secreting cells
by non secretors




receptors for growth and
differentiation factors
Van Meel et al. 1985
Zurawski et al. 1978
Winger et al 1983
Melamed et al. 1985
• Loss or inappropriate incor¬
poration of structural genes
for immunoglobulin H and L
chain
• Insufficient copies of
structural (and regulatory
genes)
• Inappropriate H and L chain
combination resulting in
hybrid molecules
t Failure/Loss of relevant
regulatory genes or other
defects in regulation
Schwaber et al. 1984; Teng et al. 1985b
Schwaber et al. 1984; Sahagan et al. 1986
Raison et al. 1982; Kozbor and Croce 1985a;
Schwaber et al. 1984




• Defects in the secretory
machinery of the cell
Sikoraet al. 1983; Kozbor and Croce 1985a;
Teng et UTT 1985b
Kozbor and Croce 1985a; Teng et al . 1985;
Gaffar et al. 1986b
TABLE 24
Percentage of GF41/27 Cells Staining With Anti-IgG or
Anti-IgM in Immunocytochemistry
Date IgM+ IgG+ Negative Specific Ab.
(a) (b)
30.4 NA 11.9*C) NA +
1.5 62.2 10.7 27.1 +
21.5 76.1 0.7 23.3
(a) negative cells
positive cells
were deduced by totaling IgM and IgG
and subtracting the total from 100.
(b) as assayed by hemagglutination.
(c) In each case 1000 cells were counted.
NA no result available.
immunoglobulin species, supernatant from a GF41/27
culture was concentrated by a factor of 10 and mixed with
a human serum known to be negative for anti-HBs. This
mixture was passed through a sephadex G200 column and the
samples were collected. The profile shown in figure 6
was obtained by measuring the absorption of individual
samples at 280nm. The pattern obtained is typical of
serum and the contents of each peak are well known. Peak
1 contains IgM and 2 macroglobulins, peak 2 is mainly
IgG with IgA and peak 3 consists of a mixture of albumin
and other small molecules.
When the peak samples for peaks 1-3 were assayed for
anti-HBs, only peak 2 contained specific antibody. When
the number of IgG containing cells declined then the
specific antibody titre also declined. It seems fair
therefore to assume that the IgG is the active
immunoglobulin species in this particular case.
The cause of decline in antibody titre cannot be
concluded directly from this experiment, however, it is
apparent that in this case the secretory mechanism of the
cell is not at fault. Since the experiments carried out
here were performed on an uncloned cell line, a strong
argument could be put forward that in this case the
specific cells are being overgrown. The results achieved
in other experiments would dispute this. For example in
cloning experiments, positive clones were produced by
this line, but when they were expanded they stopped
secreting antibody. This would indicate that even in a
homogeneous cell population the switch off event is
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occurring.
The mechanism of loss of antibody secretion by these
hybrids may not be the same as that in transformed cells.
Preliminary experiments are underway where EBV
transformed lines are treated in a similar manner,
sampled and stained at regular intervals. The time taken
for EBV transformed cells to switch off seems to be very
short. That is when cultures are fed fresh medium every
2-3 days and reseeded at the same cell density each time,
specific antibody titre will decline within one three day
y
culture. The speed with which this occurs would tend to
argue against overgrowth by non-secreting cells. The
supernatant from these cell lines however still contain
non-specific immunoglobulin indicating that some cell
populations retain the ability to secrete antibody.
The whole picture is further confused in virus
transformed lines because all of the lines tested are
oligoclonal. In the case of hybrid GF41/27 it was
apparent that only three and at most four separate
hybrids were present in the original culture well, with
the transformed lines however this could have been as
high as ten or eleven. This higher number makes it more
difficult to interpret the data from the staining
experiments. However it would appear that in most cases
the number of IgG secreting cells is falling at around
the same point that specific antibody titre drops.
It would be interesting to label some HBs and stain
the cells directly for anti-HBs activity. This would
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show conclusively whether or not the specific cells
declined slowly (as in overgrowth) or quickly (due to
active switch off or genetically controlled events).
Many more experiments will be required to show that
in other lines IgG antibodies are specific and that there
is in fact some correlation between loss of specific
antibody and the observed reduction of IgG secreting
cells. It seems strange that some populations, mainly
IgM, retain their antibody secretion while others lose
theirs. It is possible that IgM and IgG secreting lines
are derived from different areas of the B cell activation
pathway and therefore have different growth factor
requirements. This could explain why one species of





The results produced in the preparation of this thesis
are generally encouraging. Despite the problems
encountered with stability of antibody secretion, several
specific antibody producing cell lines have been
produced. Investigations were carried out into the
characteristics of cell fusion and of hybrid growth, and
also into the growth of EBV transformed cell lines.
Finally preliminary attempts were made to expand the
antibody specific B cell population by in vitro
immunisation.
The most successful technique in the experiments
described in this thesis was the fusion of EBV
transformed lymphocytes to murine myeloma cells. The
technique was first advocated by Kozbor et al (1982) and
has since been employed by many other workers with
varying degrees of success (table 2). The original work
was carried out with a human rather than a murine fusion
partner, but since this time various workers have
successfully used murine partners (Cote et al., 1983,
1984, 1985, 1986; Thompson et al., 1986; Larrick et al.,
1985; Yamaura et al., 1985; Macdonald et al.,1987).
It would appear that the instability problems
anticipated in human/mouse hybrids have not arisen. It
is untrue to suggest that all human/mouse hybrids are
stable and it is likely that human chromosomes are
preferentialy segregated from hybrids (Kozbor and Croce,
1985; Teng et al., 1985) however the vast problems which
were anticipated do not seem to have arisen. Published
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work (Cote et al., 1983; Burnett et al.f 1985; Sugano et
al., 1987; Masuho et al., 1987) supports the results
obtained here using murine cells as fusion partners.
Thompson et al (1986) state that loss of antibody
secretion due to chromosomal instability is no more
significant in heterohybrids than in human/human or
indeed entirely murine hybrids.
Murine myelomas undoubtedly give higher fusion rates
than any of the currently available human fusion partners
when comparative experiments are carried out (Abrams et
al., 1983; Cote et al., 1983, 1984, 1986; Usagawa et al.,
1986). There is also the advantage that lines are
available which do not secrete any immunoglobulin,
until recently this was not the case for human myelomas
(Jernberg et al., 1987). Therefore by using non
secreting murine partners the possibility of producing
mixed antibody molecules is negated. It is possible that
for various reasons the products of human/mouse hybrids
will not be acceptable as therapeutic grade reagents, the
reasons for this will be discussed in more detail below.
The production of antibody secreting lines by EBV
transformation was not particularly successful in
experiments described here. Despite the fact that many
transformation experiments were carried out, only one
cell line was derived and that was of doubtful origin.
The difficulty faced was not one of detecting or
isolating specific antibody secreting cells, but rather
with the stability of antibody secretion. The pattern of
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secretion was almost identical in each experiment with
initially quite large numbers of positive cells being
detected. Over a period of several weeks the number of
positive wells slowly declined until at 8 weeks none
remained. Cloning of these cells failed to isolate any
useful lines.
There are many possible causes for the loss of
antibody secretion and these have been discussed
previously. A great deal of work is required into the
basic cell biology of EBV transformed lines before any
firm conclusions can be drawn as to the mechanism of loss
of antibody secretion. The preliminary experiments
described in section 5.5 tend to suggest that the
secretory mechanisms of the cells are not at fault and
that the switch off event is occurring at the gene level.
This event could be due to an active "switch off" message
or lack of a "switch on" message. further experiments
will hopefully identify which if either of these
hypotheses are correct.
The second major problem encountered in these
experiments was the poor performance of the human lines
under cloning conditions. This statement refers
especially to EBV transformed cell lines. Even when the
lines were stable and well established such as ES12 or
latterly HBl, cloning was extremely difficult. In the
experiments described in section 3.7 the effects of
various feeder supernatants on clone growth were
examined. From these particular experiments no firm
conclusions can be drawn. The problem of cloning EBV
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cells has also been encountered by others (Tiebout et
al., 1987). The impression gained by these investigators
is that EBV transformed cells are inherently difficult to
clone.
This fact brings up another interesting point and that
is the lack of soluble factors. Because of the
difficulty in cloning mentioned above, many types of
feeder cells and supernatants have been employed. These
fall into two distinct groups, cells of the lymphocyte
and mononuclear phagocyte lineage of human or murine
origin and human cells of embryonic origin or fibroblasts
(see table 7). Some groups believe they greatly enhance
the isolation of antibody producing lines (Crawford et
al., 1983, 1985; Rosen et al., 1983; Tiebout et al.,
1984; Teng et al.,1985a). While others feel they are of
limited value (Cote et al., 1983, 1985; Strike et al.,
1984; Schmidt-Ullrich et al., 1986).Experiments performed
here support the later view. It must be pointed out that
in these experiments, it was the ability of the feeder
supernatants to support growth at lower cell densities
which was assessed and not the ability to increase the
outgrowth of specific antibody producing cells.
It has been suggested that the abnormal growth of
some cancer cells may result from the self perpetuating
mitogenic response to autogenous growth factor (Kaplan et
al., 1982). The activation of this autocrine loop has
also been implicated in the continued growth of other
cell lines such as T-lymphomas and EBV transformed lines
99
(Gootenberg et al.,1981; Gorden et al., 1984). Scala et
al (1987) have recently shown that an EBV transformed
line ROHA-9 produces an Il-l like substance which acts as
an autocrine growth factor. Other EBV transformed lines
have also been shown to produce similar growth factors
(Oppenheim et al., 1984). Since the major source of Il-l
is normally monocytes, it may be considered that cells of
this lineage are the most appropriate feeder cells.
It is possible that the EBV transformed cell lines
produced here are dependent on an autocrine growth
factor. When cells were passaged into fresh medium it
was normal practise to transfer 2-3ml of spent medium.
This practise was performed due to an empirical
observation that cells tended to grow better when this
was done. When actively growing cells split into fresh
medium but still maintained at a fairly high density (say
4
5 x 10 cells/ml) it could be imagined that the
concentration of the autocrine factor would begin to rise
fairly rapidly. While this may result in a lag phase
before exponential growth begins, it would never leave
the cells completely without growth factor. On the other
hand when cells were seeded at cloning densities (1-10
cells/lOOpil) , even if cells were secreting growth factor
immediately after cloning the concentration is not likely
to rise quickly. The lack of growth factor could then
in turn cause its' own production to cease and so cells
would not grow at all.
One way to avoid this would be to clone cells using
supernatant from their own culture as a feeder. This
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would then raise problems when assaying for specific
antibody at a later stage. If all of the EBV transformed
lines were dependent on the same growth factor then it
should be possible to clone using supernatants from well
established lines as feeder. Unfortunately these
experiments were not carried out and so the discussion is
purely speculative; it would however be interesting to
try. It is also possible that growth factors other than
IL-1 or indeed a series of factors is involved, if this
is the case cloning in media conditioned by other EBV
transformed lines is unlikely to have much effect.
6.2 LIMITATIONS OF THE EXPERIMENTS CARRIED OUT
It is not always easy to know in advance what is going to
happen in any particular experiment. Hindsight however
reveals many faults and limitations in the design of
almost all scientific experiments. In most cases where a
completely unforeseen result is obtained the problem is
that the appropriate controls have not been used. Thus
extrapolations made from any one experiment must then be
considered speculative rather than being based on sound
scientific evidence.
Many of the experiments carried out here suffer from
such faults. Experiments tended to overlap due to the
period of time taken from isolating lymphocytes from a
donor through to testing cloned EBV transformed lines or
their hybrids. for example transformation GF38 was
started while transformation GF32 was being cloned and
fused. This overlap of experiments meant that any
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alteration suggested by the results of one particular
experiment took time to filter through the system.
Again because of the time involved changes had to be
made to the system constantly in order to test as many
variables as possible. All of these changes meant that
when the results are reviewed as a complete work, very
few can be compared directly. The final decision as to
when changes should be made and the reasoning behind them
was taken with the ultimate aim of trying to produce a
stable cell line rather than on systematically testing
all of the variables. In reviewing the results it would
seem that this was perhaps not the best approach to
adopt. In many experiments the control systems are not
as stringent as would be liked, but this lack again only
became apparent with hindsight.
The system itself is basically a biological one which
is inherently variable. The donors chosen for anti-HBs,
had varying antibody titres and had been boosted at
various times prior to bleeding. From this point it is
likely that each donor would react differently to EBV
transformation. Perhaps it would have been advisable to
to carryout some identical test on all of of the donors
to establish a base line or starting point in each case.
Possible parameters to measure include the state of
activation of the B cells, AET rosettes, antigen specific
cells and antibody titre. In each case any variation in
positive cultures could then be ascribed to a poorly
reactive individual or a suboptimal step in the
experimental procedure.
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The antibody titre in the plasma are known for each
donor. These titres however indicate only that actively
antibody secreting cells are present at some point within
the individual and not necessarily circulating in the
blood. Since only peripheral blood lymphocytes were used
in these experiments, high circulating antibody level is
not necessarily the best indicator of an appropriate
donor, it was however the only marker available.
The binding of EBV is basically a chance event. This
can however be optimised by varying the concentration of
cells, virus etc. In the transformation experiments
carried out here, growth always appeared in 100% of the
wells seeded. Experiments were performed previously
where wells were seeded with fewer cells. Results
indicated that the number of wells with growing colonies
quickly dropped as the seeding density was reduced. Not
only did the number of colonies decline but so did the
total number of wells secreting specific antibody. It
was decided to sacrifice the possibilities of isolating
the progeny of a single clone in the initial culture well
in order to achieve an as high as possible number of
positive cultures. This was done in the knowledge that
cloning would then be vital, but it was decided that
producing more lines would increase the chances of
finally isolating a positive line.
This approach may again have been the wrong choice as
it leaves open the question of whether or not the loss of
antibody secretion was due to overgrowth by non-specific
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lines. Here the failure to produce reasonable numbers of
clones has had a particularly bad effect on the project
as a whole. The failure to clone effectively reduces the
chances of producing a monoclonal line by this method to
zero.
Fusion of EBV transformed lines was carried out for
two reasons. Firstly it was known that transformed cells
had a tendency to stop antibody secretion. Secondly it
had been shown that hybrids would clone where transformed
cells would not. By fusing transformed cells it was
hoped that antibody secretion would be "stabilised" and
that from these hybrids the specific antibody secreting
cells could be cloned.
The fusion technique used was standarised so that the
actual technique varied as little as possible.
Incubations and the addition of media were carefully
timed so that they were reproducible. The polyethylene
glycol used was always from the same source (the same
container), and it had been shown in early experiments to
produce reasonable rates of hybridisation (see for
example GF3 and GF4).
Despite all of these steps the numbers of hybrids
produced during any particular fusion varied
considerably. For example, if a single EBV transformed
line and a fusion partner were prepared for fusion and
then divided into two aliquots, the number of hybrids
produced in the two aliquots varies tremendously. This
large variation makes direct comparison between fusions
almost pointless. It is possible however to distinguish
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trends; for example in a fusion experiment EBV
transformed cells will almost certainly produce more
hybrids than an identical fusion using non-transformed
peripheral blood lymphocytes. However even such general
statements do not always hold firm and there are some EBV
transformed lines which fuse very poorly.
In order to avoid these problems a great deal more
research is required into the physiology and mechanism of
cellular hybridisation. It has been stated that cells
fuse at some unknown point in their differentiation
activation pathway (Schwaber et al.,1984) and the
definition of this point should take a high priority in
future research. The point in the cell cycle may also
prove important and experiments could easily be designed
to see if any correlation exists between these parameters
and the efficiency of hybrid production.
6.3 THE FUTURE OF HUMAN MONOCLONAL ANTIBODY PRODUCTION
From the previous discussion it should be obvious that
the production of human monoclonals is still very much a
chance affair. There are several key areas which require
further investigation if the efforts spent so far are not
to be wasted. These areas are listed in table 25 and
will be discussed in more detail below.
6.3a SUPPLY OF IMMUNE LYMPHOCYTES
The isolation of immune lymphocytes in an appropriate
state of differentiation remains a major problem in human
monoclonal antibody production. Improvements in this
area could be affected by optimising immunisation
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Alternative cloning techniques e.g.
micromanipulation, fluorescence acti
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Use of recombinant growth and differ¬
entiation factors
Regulation of B cell growth
Growth factor effects




Expression of immunoglobulin structural
genes
Role of regulatory genes
Human antibody molecules
Production by recombinant Hybrid antibody molecules
techniques Mixed antibody protein molecules
Site-directed antibody mutants
techniques either in vivo where appropriate or more
especially in vitro. Selection procedures also require
more research in order to maximise the isolation of
specific B cells.
In situations where active immunisation is feasible we
need to optimise injection and bleeding protocols. This
will undoubtedly require a better understanding of the
factors influencing the activation, proliferation,
differentiation and circulation of committed B cell
precursors. Where possible it would be interesting to
discover whether adjuvants such as BCG can be used to
increase the circulating pool of committed B cell
precursors or their activated progeny as has been
previously suggested (James and Bell, 1987).
No matter how much in vivo immunisation advances it is
clear that ethics allow a limited number of antigens to
be introduced in this manner. The future of human
monoclonal antibody production will therefore depend to a
large extent on the use of in vitro immunisation
(Dorfmann, 1985; Borrebaeck, 1986). Initial advances in
this field have shown that this approach permits the
specific expansion of B cell precursors and the
development of antigens against immunogens which cannot
be safely administered in vivo (see for example Wasserman
et al.,1986; Ho et al., 1987).
Of particular importance in the out come of both in
vitro immunisation and immortalisation steps is the
cellular composition of the lymphocyte suspension used.
This in turn depends on the choice of tissue. As
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previously described, lymph node and spleen have been
shown to provide a better starting material than
peripheral blood. The non B cell content is of
particular importance for in vitro immunisation, with
close cell-cell interactions having a major role in B
cell activation. Viral transformation is also impaired
by cytotoxic T cells and NK cells (James and Ritchie
1984; Kuwano et al.,1986). Further studies on the
effects of removal or enrichment of specific cell
phenotypes (such as Tc and NK) should lead to
improvements in both in vitro immunisation and
immortalisation techniques.
The use of cell sorters will greatly enhance the
isolation of B cells of defined phenotype and may also be
used to remove T^ and NK cells. Several methods have
already been suggested (Casal et al.,1986, 1987) these
involve mainly staining specific phenotypes with
fluorescent monoclonal antibodies and then sorting the
positively stained cells either to be used or to be
discarded.
6.3b IMMORTALISATION PROCEDURES
The most widely used techniques of cellular
immortalisation are EBV transformation an PEG facilitated
cell fusion. In the immediate future this is almost
certain to continue. Many refinements are possible in
both techniques but much basic research is still
required. There is still some debate as to which subset
of B cells is immortalised by EBV. According to Chan et
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al (1984) it is the large cycling population while Aman
et al (1984) claim it is the small high density resting
population, Roome and Reading (1987) provide evidence in
support of Aman et al. It is vitally important that this
question be resolved quickly as the optimal choice of
tissue may vary depending on which cell population
transforms most effectively.
The cell driven viral transformation described by
Siadak and Lostrom (1985) also requires further
evaluation. This technique which involves co-cultivation
of normal peripheral blood lymphocytes with a HAT
sensitive EBV transformed B cell line is reputed to be
simple, reproducible and more efficient than conventional
transformation and fusion and has been used by others to
produce cell lines (Nugent et al., 1987). It was this
type of reaction which was believed to have been
responsible for the production of ES12 (Boyd et al,
1984) .
The anti-HBs secreting cell line HBl appears to have
arisen through a similar type of spontaneous
transformation. In previous experiments workers have
shown that removal or inhibition of the T cells with
cyclosporin A leads to the production of transformed
lines. To establish if HBl is indeed a transformed line
it would be necessary to show that the EBV associated
antigen was present within the cell. This could be done
by a simple staining technique. It would also be
preferable to produce a karyotype to assess which
chromosomes were present.
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As far as the fusion process is concerned, the most
obvious limitation is the lack of a suitable non-
secreting partner line. While much effort has been spent
in developing new partners, none have so far been
produced which can compare with the murine lines. What
is encouraging is the success achieved so far with the
mouse and particularly with the human/mouse fusion
partners. As stressed earlier a number of investigators
find that these lines fuse more efficiently than human
partners. The resultant hybrids also clone more easily,
secrete more antibody and have proved to be relatively
stable.
One exciting prospect which has not been fully
exploited as yet is the use of electrofusion as described
by Zimmerman and Vienkin (1982) and Bischoff et al
(1982). This technique is reputed to be 100,000 times
more efficient than the PEG method (Dorfmann,1985) and
has been used for the production of T-cell hybridomas
(Gravekamp et al.,1985) as well as B-cell hybridomas.
The possibility exists of using this technique for the
specific fusion of extremely small numbers of cells.
A further enhancement of this technique is possible
with the development of the avidin-biotin techniques for
linking specific antibody forming B cells and myeloma
cells prior to electrofusion (Lo et al.,1984; Wojchowski
and Sytkowski 1986). The avidin-biotin linking has also
been used to increase the yield of specific hybrids from
a PEG induced fusion (Reason et al., 1987). It is
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conceivable that in the near future procedures will be
developed involving the fusion of single cells, followed
by the expansion of the hybrid in carefully formulated
media containing growth and differentiation factors
produced by recombinant techniques. This procedure could
take advantage of the sophisticated single cell
procedures developed by Nossal and his colleagues (Nossal
and Pike 1983; Pike et al.,1984).
With current immortalisation procedures cloning will
remain a major problem. Transformed cells undoubtedly
clone less well than hybrid cells and human hybrids less
efficiently than their murine counterparts. If as
suspected growth factors are limiting, then new supplies
of highly purified growth factors and knowledge of their
mode of action should be of enormous benefit.
In the meantime alternative cloning techniques other
than limiting dilution and soft agar cloning are
available. These include the micromanipulation of single
cells (Thompson et al.,1986) and the use of fluorescent
activated cell sorter based techniques (Shay 1985) .
These of course will remain of limited value so long as
adequate growth media are lacking.
6.3c IMPROVING STABILITY AND ANTIBODY SECRETION
At the present time one of the major limiting factors in
human monoclonal antibody production is the stability of
antibody secretion by cell lines. The problems arise in
transformed cells, hybrids and heterohybrids and are
generally attributed to either overgrowth by non-
secreting lymphocyte contaminants or the loss of
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structural genes coding for immunoglobulin. Overgrowth
is perhaps the most appropriate explanation in the case
of transformed lines where lymphocytes are polyclonaly
activated and cloning in most hands is difficult.
Experiences here however, tend to support the view that
the explanation is more complex than simple overgrowth.
Loss of regulatory genes is believed to be
particularly relevant to heterohybrids which are regarded
as being chromosomally unstable, preferentially
segregating human chromosomes (Kozbor and Croce, 1985;
Teng et al.,1985). In most cases the reason for the
decline in antibody titre has not been investigated but
merely noted and the lines abandoned. The synthesis of
immunoglobulin is nearly always measured by assaying the
supernatant for either specific or total immunoglobulin.
These techniques totally ignore the possibility that
there is a defect in the secretory mechanism of the cell.
The literature suggests that the apparent loss of
immunoglobulin secretion observed with most cell lines
together with the low levels secreted initially, can be
attributed to a number of factors (see table 27). These
include the chromosomal deletions mentioned above,
shortages of growth factors or their receptors as well as
faults in the synthetic and secretory machinery of the
cell. Possible growth factor problems suggested include
a lack of endogenous (Scala et al.,1987) or exogenous
growth and differentiation factors (Winger et al.,1983)
or their receptors (Melamed et al.,1985).
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It should be noted that the problem with many human
cell lines lies with antibody secretion and not with cell
proliferation, so that some of the suggested growth
factor problems may not be relevant. Furthermore
attempts to improve antibody secretion by co-cultivation
with HLA-DR matched specific T helper cells or antibody
to HLA-DR, which is believed to substitute for T cell
help, have not been successful (Crawford, 1985) .
The problems of cell secretion and synthetic
capability are believed to be largely related to cell
phenotype. In particular changes within the cell such
that they are deficient in rough endoplasmic reticulum,
polyribosomes and golgi apparatus (Kozbor et al.,1983;
Sikora et al.,1983; Kozbor and Croce, 1985).
Considerable efforts will be required to improve the
levels of antibody secreted by human cell lines and to
ensure that these levels are maintained over long
periods. Improvements in immunisation, selection and
immortalisation procedures may help to some extent, but
it is likely that new methods will have to be developed.
The most obvious approach is to frequently enrich
specific antibody secreting lines and to pursue a
rigorous cloning policy. The former has been
successfully applied to lines secreting anti-red cell
antibodies (Crawford et al.,1985; Doyle et al.,1985).
In view of the observations by Schwaber et al (1984)
that cell lines which have stopped secreting
immunoglobulin can be reactivated by fusion with normal
peripheral blood lymphocytes or by stimulation with LPS
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(Raison et al.,1982), it may be that other approaches are
more appropriate. These observations which have been
largely overlooked suggest that the failure of
immunoglobulin secretion may be a consequence of
defective regulatory genes or mechanisms concerned with
synthesis and secretion of immunoglobulin.
Techniques which can enhance gene expression may now
warrant further investigation. This may involve back
fusion with peripheral blood lymphocytes as suggested
above, stimulation with LPS or treatment with phorbol
esters. The last approach has been shown to enhance
receptor expression and immunoglobulin secretion by B
cells (Polke et al.,1986) and is of considerable
importance in view of recent suggestions that senescence
in human antibody-secreting cell lines might be
associated with a decline in receptor expression (Melamed
et al.,1985). More sophisticated approaches could
involve transfecting cells with specific enhancer
sequences (Teng et al.,1985) or gene silencing techniques
involving dimethylation of the genome (Ollson and B.rams,
1985).
Whichever approach is adopted, a better understanding
of the basic cause of senescence of antibody secretion is
required. Once the cause has been identified, the
appropriate corrective measures can more easily be
adopted.
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6.4 B CELL ACTIVATION
As previously implied, it is thought that the state of
activation of B cells is a crucial factor in the success
of immortalisation procedures. It is known for example
that in the case of EBV transformation, small resting B
cells are infected at a higher rate than large activated
B cells (Roome and Reading, 1987) . It seems that a
better understanding of the B cell pathway is required
before human monoclonal antibody production can progress
much further.
A massive amount of research has been carried out into
the control systems of B cell activation, differentiation
and proliferation. This area has been reviewed by
Hamaoka and Ono (1986), Melchers and Andersson (1986) and
Paul and O'Hara (1987). The basis of the humoral (or
antibody producing) immune response to antigen is the
activation, proliferation and maturation of antigen
specific B lymphocytes (Burnet, 1957) . Basically antigen
selects specific B cells from a pool of resting B cells.
Once stimulated either in vitro or in vivo, the cells
begin to divide and mature. It is the cell contacts and
the soluble factors controlling this process which are
vital.
Three cell types are involved in the production of a B
cell response, these being Accessory cells (A cells), T
cells and of course B cells. One of the early events
after antigen is added to the system is its uptake by
cells of the reticulo-endothelial system. These cells
endocytose, digest and present antigen on their cell
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surface in association with MHC class II antigens. The
antigen MHC complex is recognised by T cells of the
helper/enducer subset. Many cell types can act as A cells
for T cells, all of which express MHC class II on their
surface and have the ability to "process" antigen.
Macrophage process and present any antigen to T„ cells
n
while B cells use their antigen receptors to present
"specific" antigen to T„ cells. As a result of this,
II
4
antigen specific B cells require much lower ( up to 10
times) concentrations of antigen for presentation ( Rock
et al.,1984; Lanzavecchia 1985; Tony and Parker, 1985).
One result of the interaction of A cells and T cells
is the production of lymphokines that act on T and B
cells to stimulate proliferation and maturation. Media
conditioned by these interactions can serve to stimulate
antigen specific B cell responses in vitro. Since this
occurs even in T cell depleted B cell populations the
factors have been termed T cell replacing factors (Dutton
et al.,1971; Schimpl and Wecker, 1972). Considerable
confusion exists as to which lymphokines are active on B
cells and which cells produce which lymphokines.
It appears that the lymphokines can be broken into
several groups, <X factors, fh factors and maturation
factors (Melchers and Lernhardt, 1985). The factors
are generally detected using one of three assay systems;
the proliferation of J558 plasmacytoma cells that require
oc factors (Corbel and Melchers, 1984), the proliferation
of A cell depleted B cell blasts (Melchers and Lernhardt,
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1985) and the activation of A cells depleted resting B
cells into the cell cycle (Corbel and Melchers, 1983).
When B cells are activated by c< factors, polyclonal
activators such as LPS are required to complete the cell
cycle.
It has been shown that ex factors control the entry onto S
phase at a restriction point some 4-6h after mitosis in
the phase within the 20h cell cycle (Melchers and
Lernhardt, 1985) . The effect of ex. factors can be
inhibited by the soluble complement component C3d
(Melchers et al.,1985). However, C3b or C3d either
aggregated or sepharose bound, replaces the effects of
factors in the B cell cycle (Erdei et al.,1985; Melchers
et al.,1985).
The finding that soluble C3d is inhibitory while
aggregated C3, C3b or C3d is stimulatory raises the
question why soluble factors are stimulatory if they
are in fact complement components. It has been suggested
(Melchers and Andersson, 1986) that the microaggregation
of CR2 receptors could be achieved by C3b interacting
with other complement components such as C4b and C2a thus
providing a positive signal for B cells.
It is interesting to note at this point that EBV,
which stimulates resting but not activated B cells (Roome
and Reading, 1987) enters the human B cell via the CR2
receptor (Aman et al.,1984; Nadler et al.,1985). This
route of entry may provide a clue as to how B cells are
activated by EBV. The factor stimulated entry of the B
cells into S phase provides the DNA synthetic activity
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which would be required for the incorporation of viral
DNA into the genome. It is not known however whether
this is also a requirement for subsequent
immortalisation.
Many growth factors are produced by T cells in
response to stimulation by antigen in association with
MHC. One well characterised factor is BSF-1 (Howard et
al.,1982) recently designated IL-4. This growth factor
has been shown to be different from IL-1, IL-2 and IL-3
(O'Hara et al.,1985; Takatou et al.,1985). Many other T
cell derived growth factors have been described which
stimulate proliferation and/or maturation of B cells.
These include BCGF-II, TRF, BCDF and IL-2 (Melchers and
Lernhardt, 1985). These factors appear to act on B cells
at a point late in the cell cycle in the phase at a
restriction point 2-4h before mitosis (Melchers and
Lernhardt, 1985).
It seems therefore that several stimuli are required
for any particular round of cell division in the normal B
cell. Fig 7 shows the points at which the various
factors have their effect. There are three restriction
points controlled by Ig specific antibodies; ck factors
(from macrophages) and & factors (from T„ cells). It is
n
likely that cells immortalised either by viral
transformation or cell fusion will still require some
growth factors. Much work is still required to define
which factors are required by hybrids and transformed
cells and at what point they can most usefully be
117
FIGURE 7
The 20h cell cycle of activated murine B lymphocytes,
divided into 8h of Gl-phase, followed by 8h of S-phase,
then by 4h of G2-phase and finally by mitosis (M). In
this cycle are placed the three restriction points
controlled by Ig-specific antibodies (anti-Ig) ; factors
( a ); and 3 factors ( b)• Indicates the point of
influence of macrophages, /3 that of helper T lymphocytes
and anti-Ig that of antigen in immune responses of B
cells. Reproduced from Melchers and Andersson, 1986.
employed. It is hoped that in the near future pure
growth factors will be made available from recombinant
sources. These ultra pure reagents should greatly aid
research in this particular area of cell biology.
6.5 THE EXPANSION OF HUMAN MONOCLONAL CELL LINES
If human monoclonal antibodies are to be used on a
commercial basis, then large volumes must be grown. The
approaches used have generally followed those used in
murine monoclonals. They include a variety of in vitro
culture procedures together with growth in
immunodeficient mice or rats. Where relatively small
amounts of antibody are required then growth in static
culture is perfectly adequate and routinely used. Cell
lines have been successfully expanded using spinner
flasks (Hunter et al.,1982; Thompson et al.,1986) and
roller bottles (Wunderlich et al.,1981; Sikora et
al.,1983; Thompson et al.,1986). Others have grown human
cell lines in immobilised form (Haspel et al.,1985a,b).
In most cases if larger volumes are required then air
lift reactors and immobilised cell techniques are the
methods of choice. These procedures have been reviewed
recently (Birch et al.,1985; Duff, 1985; Altschuler et
al.,1986).
The production of large volumes of cell supernatant
inevitably involves the investment of large amounts of
cash, especially if FCS is to be used as a supplement.
To try to avoid this cost several defined serum-free
media have been developed specifically for the culture of
human and mouse cell lines. While experience with these
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media are as yet limited, it is interesting to note that
there are reports which suggest that cell lines will
produce at least as much antibody when grown in serum
free medium as they do in high concentrations of FCS
(Cole et al.,1985b; Glassy et al.,1985; Teng et
al.,1985; Shacter et al., 1987). This has lead to
suggestions that FCS may contain factors which impair
immunoglobulin production (Glassy et al.,1985). It
should be noted at this point that none of the cell lines
produced during the course of this project would adapt to
growth in serum free medium. Growth was apparent at 1-2%
FCS but complete removal effectively stopped cell
division.
There are several reports of attempts to grow human
monoclonals in nude mice. From these it is apparent that
human/human hybridomas do not grow readily in nude mice
in spite of their T cell deficiency. This is perhaps not
surprising in view of the fact that such mice are capable
of reacting xenogeneic cells by NK and macrophage
mediated mechanisms. A higher success rate of ascites
production can be obtained by irradiating (350-400 rad)
the nude mice prior to innoculation (Bogard et al.,1985;
Kozbor et al.,1985), by adapting the cells to in vivo
growth (Kozbor et al.,1985) or by mixing the cells with
human skin fibroblasts prior to innoculation (Ollson and
Brams, 1985). Even with these procedures the take may be
as low as 50% (Bogard et al.,1985; Kozbor et al.,1985) or
depend on the route of injection (Ollson and Brams,
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1985) .
Heterohybrids appear to grow more easily in mice,
several reports suggest such cells will grow without
prior adaptation (Bron et al.,1984; Insel et al.,1984;
Burnet et al., 1985; Tiebout et al., 1985; Yamoura et
al.,1985). This observation is perhaps not surprising in
the light of previous observations that human/mouse B
cell hybrids express the H-2 haplotype of the murine
parent but fail to express the human HLA antigen which
would evoke an immune rejection (Raison et al.,1982).
There have been conflicting reports on the amount of
antibody produced in the ascites. According to Kozbor et
al (1985) cells which were adapted for growth in nude
mice by in vivo passage showed an increase in both
tumorigenicity and immunoglobulin production. These
properties were associated with a change in cell
morphology. Return to in vitro culture showed that this
change was transient and reversible. The differentiation
observed was attributed to growth factors released during
the inflammatory process induced by pristane treatment.
In contrast others have observed that hybridomas adapted
for growth in ascites do not secrete large amounts of
immunoglobulin (Ollson and Brams, 1985).
When the monoclonal antibodies in question are
required for prophylactic, therapeutic and diagnostic
purposes (such as imaging), it is highly unlikely that
production via ascitic fluid will be considered
appropriate. Since the mice used may harbour unknown
viral infections it would seem prudent not to use ascitic
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fluid (or antibodies derived from it) for in vivo
therapies. It is almost inevitable therefore that the
majority of human monoclonal antibody production will
depend on bulk culture either in air lift fermenters or
immobilised cell systems.
6.6 MOLECULAR BIOLOGY AND MONOCLONAL ANTIBODY PRODUCTION
So far all of the discussion has concentrated on
conventional methods of monoclonal antibody production.
There are however other approaches which are being
investigated, namely those involving genetic engineering
techniques. It should be stressed that these techniques
have already been successfully applied to the cloning of
the immunoglobulin genes themselves. Although there are
still some problems to be overcome, the achievements to
date are extremely encouraging and worthy of discussion
for they open up a the way to establishing stable cell
lines secreting antibodies with unique properties (Aguila
et al.,1986).
To date complete immunoglobulin molecules have been
produced by expressing mouse H and L chains in E coli
(Boss et al.,1984), yeast (Wood et al.,1985) and myeloma
lines (Neuberger, 1985) using conventional recombinant
procedures.
A less sophisticated approach has been to either
transfect antibody secreting cells with calcium-
precipitated DNA from a permanent cell line (Jonak et
al.,1984) or alternatively, permanent cell lines with
similar preparations from antibody producing cell lines
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(Srelkauskas et al.,1987).
There are also reports on the cloning and expression
of genes coding for hybrid molecules containing mouse
variable and human constant region domains. This
approach, which has recently been reviewed by Oi and
Morrison (1986), enables the production of "humanised"
monoclonals against immunogens which cannot be injected
into humans or which fail to produce a good immune
response either in vitro or in vivo.
The genes for these hybrid immunoglobulins have been
introduced into myeloma cells by both spheroplast fusion
(Jones et al.,1986; Sharon et al.,1986) and
electroporation techniques (Sahagon et al.,1986). The
immunoglobulin produced by these recombinants retains the
specificity of the original mouse antibody. With the
human heavy chain domains however, it will be
intrinsically less immunogenic in man than the original
mouse antibody. Using this approach chimeric antibodies
have been produced against haptens (Boulianne et
al.,1984), tumour antigens (Sahagan et al.,1986) and
other antigens (Takeda et al.,1985).
More recently the potential of the technology has been
further advanced with Jones et al (1986) replacing the
genes coding for the hypervariable region of the the H
chain with genes coding for the hypervariable region of a
murine monoclonal heavy chain. The product of this
procedure is an almost entirely human immunoglobulin
molecule containing the specific binding regions of a
murine antibody. Exploitation of this type of approach
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should lead to hybrid molecules of even weaker
immunogenicity in humans.
Sharon et al (1986) have shown that site directed
mutagenesis can be used to alter the specificity and
idiotype expression of murine monoclonals. This approach
involves the insertion of specific oligonucleotide
sequences into heavy chain variable region genes and
could enable the development of antibodies with novel
specificities.
The potential of this technique for the production of
antibodies with novel effector functions should not be
overlooked. Thus Neuberger and his colleagues (Neuberger
et al.,1984; Neuberger, 1985) have expressed in myeloma
cells genes coding for the Ffab^ region of mouse
immunoglobulin linked to genes for either enzymes or
c-myc antigenic determinants. Human constructs of this
type could prove extremely useful in diagnosis, targeting
and imaging.
Fig 8 shows a flow chart of how a molecular biology
approach could be used to produce a human monoclonal
antibody of desired specificity. This approach combines
the conventional murine monoclonal production with
genetic manipulation. Murine monoclonals are relatively
easy to produce so several clones could be tested and one
with appropriate properties selected. Human cell lines
secreting non-specific immunoglobulin are also relatively
simple to produce and so would be available as the source
of the "human" part of the molecule.
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FIGURE 8
FLOW DIAGRAM SHOWING POSSIBLE MOLECULAR BIOLOGICAL APPROACH
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murine hypervariable region
express in myeloma cell line
screen products for antibodies
of desired isotype and specificity
6.7 REGULATORY CONSIDERATIONS FOR HUMAN MONOCLONAL
ANTIBODY USE IN THERAPY AND DIAGNOSTICS
Work is proceeding at a great pace developing both human
and murine monoclonal antibodies and novel suggestions as
to how they may be used are regularly proposed. In the
rush to produce new therapeutic and diagnostic tools
however, many workers fail to mention the strict
regulations controlling the purity and specificity of any
new pharmaceutical reagent. Some of these conditions
will be discussed briefly below.
Monoclonal antibodies are derived from growing cells
which are in turn derived from immune individuals. They
can therefore be regarded as "natural" products, which
might imply some degree of safety from side effects.
One of the major arguments for producing human
monoclonal antibodies as opposed to murine is that when
used for prophylactic purposes they would be less likely
to be antigenic and so would avoid problems of
sensitisation. This fact has yet to be shown in vivo and
as humans are not in bred in the same way as the murine
models used to establish these theories, there remains
the slight chance that sensitisation may occur. Serum
products however, are already widely used and it seems
unlikely that monoclonals would fail any tests on these
grounds.
In most cases in vivo use is envisaged mainly for life
threatening diseases. These patients are normally
already immunocompromised to some extent and are
therefore highly susceptible to any viral particles which
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may be present within the final antibody preparation. It
should be remembered that all human monoclonal antibodies
from either transformed lines or hybridomas are produced
by cells which are in fact tumours. There is a
possibility that a tumorigenic agent may be present in
the culture supernatant. It would be necessary to show
that the final product was free of any genetic material.
Other possible viral contaminants which are already
defined such as HTLV-1, HIV and HB would also be required
to be removed during processing.
Even for in vitro diagnostic use where the
requirements of safety are not as harsh, the efficacy
would need to be shown. These evaluation tests are based
on considerations of specificity, sensitivity, stability,
reproducability and clinical correlation. It is
important to determine the role of clinical factors such
as age, sex, genetics, nutrition, geography and
concomitant medications (Schauf, 1987) .
When a new product is licensed, it is not only the
final product which is assessed, but the entire process.
The cell line producing the antibody and any fusion
partners and possibly the lymphocyte donor may require
testing for harmful viruses. The purification process
would be required to show its efficiency by removing a
standard amount of virus deliberately added to the raw
material. The final packaged material would need to show
stability and continued sterility.
All of the above tests take a great deal of time and
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are extremely expensive. It seems most likely therefore
that only large companies with the resources and
experience of running clinical trials will be able to
produce an end product for the market. It can only be
hoped that they will adopt antibodies which will have
beneficial effects clinically and not only those which
will provide huge profits.
6.8 HUMAN MONOCLONAL ANTIBODIES PRODUCED
As stated previously many workers have attempted to
produce human monoclonal antibodies against a wide range
of antigens. Despite all of the problems described here
antibodies have been produced against a wide range of
antigens. Appendix D gives a list of some of the
antibodies produced so far and although by it is by no
means a complete list, it gives a fair indication of
which types of antigen are recieving the most attention.
6.9 CONCLUDING DISCUSSION
Research into the production of human monoclonal
antibodies continues apace. It should be obvious that
there are many problem areas which still require much
basic research. However despite these problems there
remains an overall optimism that human monoclonals will
soon be routinely produced. The potential uses of human
monoclonals are many and varied and the knowledge which
will be gained from this research is immense.
It seems likely that if in a few years the problems of
genetic instability and low levels of antibody secretion
are not overcome by improvements in tissue culture, then
the molecular biologists will take over. Feeder systems
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and growth factors will require close investigation and
this can only improve our understanding of the immune
system as a whole. It is almost certain that the area of
in vitro immunisation will produce information leading to
a greater understanding of how immune cells regulate
their functions and which cells are important in the
initiation of an immune response and the production of
immunological memory.
Viral transformation experiments will enable us to
dissect the immune response and perhaps shed more light
on the mechanisms involved in immune tolerance in general
and autoimmunity in particular. Studies on transformed
cells which lose antibody secretion may further elucidate
the control mechanisms for secretion. Antibodies binding
to "tumour specific" antigen may help us to understand
the mechanisms underlying neoplasias. Finally any human
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1. Antibody Diluting Buffer






2. Plate Coating Buffer
0.05M NaHCO-
pH 9. 6








pH 9 . 8
5. Tris Buffered Saline
Was prepared using 0.85M NaCl buffered with Tris-HCl
pH 7.6, 0.01M
working solution:
dissolve 17g NaCl in
100ml 0.2M Tris
157ml 0.1N HCl
Then add distilled water to a final volume of 21
157
APPENDIX C
RESULTS OF FUSION AND TRANSFORMATION EXPERIMENTS
Expt. No. partner antigen wells wells wells
seeded growing +
1 KR4 TT 30 0 0
2 KR4 TT 30 0 0
3 NSO TT 60 60 57
4 NSO TT 75 16 5
5 KR4 TT 360 16 10
6 NSO TT 360 360 357
7 Hmy2 TT 360 264 264
8 KR4 TT 360 0 0
9 NSO TT 360 54 7
10 Hmy2 HBs 288 63 0
11 NSO HBS 315 48 0
12 Hmy2 HBs 96 87 0
13 UC-7296 HBs 300 0 0
14 Hmy2 HBs 96 54 1
15 Hmy2 HBs 96 1 0
16 Hmy2 HBs 96 2 0
17 Hmy2 HBs 96 2 0
18 Hmy2 HBs 96 0 0
19 Hmy2 HBs 96 0 0
20 Hmy2 HBs 300 59 0
21 Hmy2 HBs 720 9 0
22 Hmy2 HBs 240 20 0
23 Hmy2 HBs 120 28 1
24 NSO HBs 120 81 1
25 NSO HBs 240 235 0
26 NSO HBs 120 102 0
27 Hmy2 HBs 120 53 0
28 Hmy2 HBs 120 30 0
29 UC-7296 none 300 0 -
30 KR4 HBs 380 0 0
31 KR4 HBs 20 0 0
32 Transf HBs 600 600 59
33 Hmv2 HBs 210 130 0
34 Hmy2 HBs 60 44 0
35 Hmy2 HBs 60 41 0
36 Hmy2 HBs 60 10 0
37 Hmy2 HBs 60 37 0
38 Transf HBs 768 768 75
39 Transf HBs flask •» fusions 46 + 47
40 Hmy2 HBs 24 18 0
41 Hmy2 HBs 34 34 1
42 Hmy2 HBs 40 36 0
43 Hmy2 HBs 43 33 0
44 Hmy2 HBs 60 1 0
45 Hmy2 HBs 33 27 0
46 Hmy2 HBs 230 119 0
47 NSO HBs 120 0 0
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Expt.No. Partner antigen Wells wells wells
seeded growing +
48 PBL HBs 240 ?
49 PBL HBs 240 ? 4
50 NSO HBs 180 4 0
51 NSO HBs 107 13 0
52 NSO HBs 215 133 27
53 NSO HBs 86 3 0
54 Transf HBs 470 470 17
54a NSO HBs 108 3 0
55 NSO HBs 60 Contaminated
56 Transf HBs 420 420 0
57 mouse spleen HBs 720 ? 0
58 NSO HBs 600 60 Contam
59 Transf HBs 480 480 9
60 NSO HBs 40 37 0
61 NSO HBs 85 23 Contam
62 KRl 2 HBs 60 51 Contam
63 NSO HBs 600 20 0
63a KRl 2 HBs 60 0 0
64 NSO kell 130 103 0
65 P653 kell 120 23 Contam
66 NSO kell 240 Contaminated
67 P653 kell 240 Contaminated
68 NSO Brain 300 48 20
159
APPENDIX D.
A SURVEY OF HUMAN MONOCLONAL ANTIBODIES
TARGET REFERENCES
Bacterial Antigens
Diptheria toxin Gigliotti et al.
Gm-ve endotoxin Teng et al. 1983; Teng et al. 1985a, Feely et
al. 198/
Endotoxin A Larrick et al. 1985
Haemophilus influenzae Hunter et al. 1982; Gigliotti et al. 1984;
Brodeur et al. 1987
-Lipid A-core Pol 1ack et al. 1987
Mycobacterium leprae At law et al. 1985; Foung et al . 1985a
Neisseria meningitides Brodeur et al. 1987
Pneunomoccus poly¬
saccharide
Schwaber et al. 1984
Pseudomonas auruginosa Siadak and Lostrom 1985; Sawada et al . 1985
Tetanus toxoid Zurawski et al. 1978; Kozbor and Roder 1981,
1982; Chiorazzi et al. 1982; Teng et al.
1983; Larrick et al. 1983; Tiebout et al.
1984, 1985; Boyd et al. 1984b; Ho et al.
1985; Ichimori et al. 1985; Mirata and
Sugawara, 1987
Tetanus toxin Gigliotti and Insel 1982
Chiamydia Rosen et al. 1983
Viral Antigens
Cytomegalovi rus Emanuel et al. 1984; Matsumoto et al. 1986;
Redmund et al. 1986; Masuho et al. 1987
Epstein-Barr Koizumi et al. 1986














Burnett et al . 1985; Ichimori et al. 1985,
1987; Van Meel et al. 1985; Strieker et al .
1985
Furuya et al.1982
Seigneurin et al. 1983; Evans et al. 1984;
Masuho et al. 1986
Matsushita et al . 1986
Crawford et al. 1983b; Ostberg and Pursch
1983
Croce et al. 1980; Ritts et al. 1983; Van
Meel et al. 1985; Hilfenhaus et al. 1986
Van Meel et al. 1985
Matsushita et al. 1986
Foung et al. 1985a and b, Sugano et al.
1987
Schmidt-Ullrich 1986; Udomsangpetch et al .
1986






Sheep red blood cells
Chicken red blood cells
Foung et al. 1985a; Larrick et al. 1985;
Raubitschek et al. 1985; Goosens et al. 1987
Hirohashi et al. 1986
Boylston et al. 1980; Astaldi et al. 1982;
Crawford et a I. 1983a; Bron et al. T984;
Doyle et aTT T9"85; Melamed et a I . 1985;
Paire et al. 1986; Thompson et al. 1986; Boyd
et al . 1987; Goosens et al . 1987; MacDonald
et al . 1987
Foung et al . 1986
Nowinski et al. 1980
Strike et al. 1984; Terashima et al. 1987

























Hulette et al. 1985; Effross et al. 1986
Alpert et al. 1987
Nishimura et al. 1987
Paulie et al. 1984
Sikora et al. 1982,1983
Wunderlich et al. 1981; Cote et al. 1983,1984,
1985,1986; Campbel1 et al. 1986; Strelkauskas
et al. 1987a; Schoenfield et al. 1987
Abrams et al. 1984
Hirohashi et al. 1982b; Haspel et al. 1985a,b;
Borup-Christensen et al . 1986; Shaw et al.
1987
Hirohashi et al. 1982b; Sugiyama et al. 1986
Hirohashi et al. 1982a; Cote et al. 1983,1984,
1985,1986; Cole et al. 1984,1985a; Murakami et
al. 1985 ~~
Carroll et al. 1986
Irie et al. 1982; Warenius et al. 1983; Watson
et a IT 1983; Kan-Mitchell et a I. 1986;
Yamaguchi et al. 1987.
Andreasen and Olsson 1986
Al-Azzawi et al. 1987
Cote et al. 1983, 1984, 1985, 1986
Simpson et al. 1986
Cote et al. 1983,1986; Cote and Houghton
1985
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Shonfield et al. 1982; Teng et al. 1983;
Massicote et al. 1984; Sasaki et al. 1984,
1985; Casali et~al. 1987
Hamburger et al. 1985
Annamalai et al . 1987
Cote and Houghton 1985
Cote et al. 1986
Murray et al. 1984, Spatz et al. 1987
Satoh et al. 1983; Someya and Kondo 1986;
Simpson-et al. 1986; Cote et al. 1986
Simpson et al. 1986; Cote et al. 1986;
Chiorazzi and Reeves 1987
Garzelli et al. 1984
Simpson et al. 1986
Simpson et al. 1986
Simpson et al. 1986
Eisenbarth et al. 1982; Satoh et al. 1983;
Garzelli et a I. 1984
Satoh et al. 1983; Someya and Kondo 1986
Garzelli et al. 1984
Satoh et al. 1983
Shonfield et al. 1982; Nugent et al. 1987
Hashizuma et al. 1987
Yamoura et al. 1985
Teng et al. 1983
Winger et al. 1983; Isojima et al. 1987




















Garzelli et al. 1984
Dighiero et al. 1983
Tan et al. 1987
Satoh et al. 1983
Cote and Houghton 1985
Haskard and Archer 1984
Ho et al. 1985
Olsson and Haplan 1980
Teng et al. 1983; Bieber et al. 1987
Steinitz et al. 1977,1979
Lane et al. 1982; Bieber and Teng 1987
Yoshie and Ono 1980
Bieber and Teng 1987
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Introduction
Since the first description of monoclonal anti¬
body secreting cell lines by Kohler and Milstein in
1975, rodent monoclonal antibody technology has
been rapidly and successfully applied to a wide
variety of biological problems of both theoretical
and practical importance. In the health care field
for example, this has resulted both in the develop¬
ment of new and improved diagnostic and ther¬
apeutic procedures and an increase in our under¬
standing of human biology. Unfortunately pro¬
gress in the human monoclonal antibody field has
been far less spectacular. Although immortalised
human cell lines secreting specific antibody were
described as long ago as 1977 and their potential
immediately recognised (Steinitz et al., 1977) the
development of human monoclonal antibody tech¬
nology has been a slow, laborious and often unre¬
warding exercise (see later). Nevertheless in spite
of the many problems encountered to date work
has continued unabated, sustained by the widely
held belief that this technology would result in
improved diagnostics and therapeutics and would
Correspondence to: K. James, Department of Surgery, Uni¬
versity of Edinburgh Medical School, Teviot Place, Edinburgh
EH8 9AG, U.K.
0022-1759/87/$03.50 © 1987 Elsevier Science Publishers B.V.
increase our knowledge of the B cell repertoire in
health and disease.
While many technical problems still remain to
be solved, sufficient progress has been made to
encourage further efforts in this field. The aim of
the present review is to evaluate the main ap¬
proaches which have been used to date in human
monoclonal antibody production with the view to
establishing if there are any general guidelines
suggesting possible ways in which the technology
might be improved in the future. Throughout this
discussion the emphasis will be on general techni¬
cal and theoretical principles rather than on pre¬
cise technical details which can be obtained from
the publications cited and a number of recent
reviews (Kozbor and Roder, 1983; Boyd et al.
1984a). For those intending to venture into this
field the recent book edited by Engleman et al.
(1985) is highly recommended as it contains a
detailed methodological appendix.
The principal areas to be covered in this review
will be the procurement of sensitised lymphocytes
for immortalisation, the immortalisation strategies
themselves, procedures for cloning and expanding
antibody-secreting cell lines and future technolo¬
gies. In addition, the potential of human mono¬
clonal antibody technology will be illustrated by a
survey of the range of human monoclonal anti¬




THE BASIC STEPS IN THE PRODUCTION OF HUMAN
MONOCLONAL ANTIBODIES
Fig. 1. This figure outlines the key steps which can be involved
in the production of human monoclonal antibodies. It should
be noted that some of the steps, though desirable, are optional.
These include the enrichment of specific antibody-forming cell
precursors and in vitro stimulation with antigen and/or mito¬
gen.
of their possible applications. However, in order
to set the background to this review the basic
steps currently employed in human monoclonal
antibody production have been summarised in
Fig. 1.
Sources of immune lymphocytes for immortalisa¬
tion
In vivo immunisation
Generally speaking the successful development
of murine monoclonals has not been limited by
the availability of immune lymphocytes. Providing
the substance to be injected was available in ade¬
quate amounts, was non-toxic and immunogenic,
immunisation schedules could be optimised to en¬
sure sufficient immune cells for fusion. Unfor¬
tunately this is not the case with human mono¬
clonal antibody production where the range of
immunogens which can be injected, together with
the immunisation schedules which can be em¬
ployed is limited by ethical and other considera¬
tions. Furthermore, the source of immune lym¬
phocytes is usually restricted to peripheral blood,
which, as will be discussed later, is not the ideal
choice. These shortages, together with our lack of
knowledge on what is the ideal differentiation
stage for fusion (Schwaber et al., 1984) are be¬
lieved by some to have been neglected in a frantic
search to obtain improved fusion partners (Olsson
et ah, 1983; Gigliotti et ah, 1984).
Although these practical and theoretical prob¬
lems have hampered human monoclonal antibody
development lymphocytes specifically immune to
a wide range of target antigens can, and have
been, readily obtained from a variety of sources.
These include donors who have been immunised
following approved schedules or as a result of
disease processes or inadvertent exposure to im¬
munogens. In addition monoclonal antibodies with
a wide range of interesting specificities have been
obtained using lymphocytes from individuals with
no previous record of exposure to the immunogen
in question or history of disease. These various
approaches are summarised in Table I and dis¬
cussed in greater detail below.
As is to be expected monoclonal antibodies to
bacteria and viruses comprise the majority of anti¬
bodies which have been produced following active
immunisation, though some have been generated
using lymphocytes obtained following natural in¬
fection. However, monoclonal antibodies to a
variety of other immunogens have been obtained
using lymphocytes from actively immunised indi¬
viduals. These include monoclonals to colorectal
cancer, Rhesus D, HLA antigens and various
haptens (Table I).
It will also come as no surprise that the great
majority of antibodies generated using lympho¬
cytes from people with active disease are directed
against tumour cell targets and various autoanti-
gens. However, some antibodies against infectious
agents have also been produced using lymphoid
tissues from individuals with ongoing disease. Fi¬
nally lymphocytes from 'non-immunised', 'nor¬
mal' donors have frequently given rise to autoanti¬
bodies reacting with a variety of cell surface and
internal antigens.
In the light of experience with mouse mono¬
clonal antibody production it is reasonable to
assume that the outcome of human immortalisa¬
tion procedures is influenced by the interval be-
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Gigliotti et al., 1984
Hunter et al., 1982
Yoshie et al., 1980
Siadak and Lostrom, 1985
Garzelli et al., 1986
Rosen et al., 1983
Emanuel et al., 1984; Redmund et al., 1986
Koizumi et al., 1986
Van Meel et al., 1985
Strieker et al., 1985
Matsushita et al., 1986
Crawford and Callard, 1983
Van Meel et al., 1985
Van Meel et al., 1985
Schmidt-Ullrich, 1986;
Udomsangpetch et al., 1986
Raubitschek et al., 1985
Bron et al., 1984
Foung et al., 1986
Steinitz et al., 1977, 1979
Gigliotti et al., 1984
Bogard et al., 1985; Teng et al„ 1985a
Gigliotti et al., 1984
Schwaber et al., 1984
Zurawski et al., 1978; Kozbor and Roder, 1981;
Chiorozzi et al., 1982; Gigliotti and Insel, 1982;
Larrick et al., 1983; Gigliotti et al., 1984;
Boyd et al., 1984b; Tiebout et al., 1984, 1985;
Burnett et al., 1985
Burnett et al., 1985
Haspel et al., 1985a,b
Boylston et al., 1980; Crawford et al., 1983;
Doyle et al., 1985; Paire et al., 1986;
Thompson et al., 1986
Hulette et al., 1985; Effros et al., 1986
Olsson and Kaplan, 1980
Lane et al., 1982
Atlaw et al., 1985
Koizumi et al., 1986
Croce et al., 1980
Paulie et al., 1984
Sikora et al., 1982, 1983
Wunderlich et al., 1981; Cote et al., 1983, 1984,
1985, 1986; Campbell et al., 1986;
Strelkauskas et al., 1987a











































Hirohashi et al., 1982b; Borup-Christensen et al., 1986
Hirohashi et al., 1982b
Hirohashi et al., 1982a; Cote et al., 1983, 1984,
1985, 1986; Cole et al., 1984; Murakami et al., 1985
Abrams et al., 1984; Andreasen and Olsson, 1986;
Carroll et al., 1986
Irie et al., 1982; Warenius et al., 1983; Watson et al.,
1983; Kan-Mitchell et al., 1986
Cote et al., 1983,1984, 1985, 1986
Simpson et al., 1986
Cote et al., 1986
Shoenfield et al., 1982; Massicotte et al., 1984;
Sasaki et al., 1984
Shoenfield et al., 1982
Cote et al., 1986
Eisenbarth et al„ 1982
Satoh et al., 1983; Garzelli et al., 1984
Simpson et al., 1986
Simpson et al., 1986
Cote et al„ 1986; Simpson et al., 1986;
Someya et al., 1986
Simpson et al., 1986; Cote et al., 1986
Shoenfield et al., 1986
Kyurchiev et al., 1986
Simpson et al., 1986
Cote et al., 1983,1986
Winger et al., 1983
Winger et al., 1983
Cote et al., 1986
Garzelli et al., 1986
Simpson et al., 1986
Simpson et al., 1986
Simpson et al., 1986
Cote et al., 1986; Simpson et al., 1986
Cote et al., 1986; Simpson et al., 1986
tween boosting and harvesting of the immune
lymphocytes which influence their state of differ¬
entiation and proliferation and their circulatory
properties. Unfortunately for practical reasons
there have been very few studies to determine the
optimum time for harvesting lymphocytes with a
view to immortalisation. Where comparative stud¬
ies have been performed it would appear that the
optimum time for harvesting peripheral blood cells
is 6-7 days (Bogard et al., 1985), while for spleen
it is 3 days post boosting as in the mouse (Schwaber
et al., 1984). These time schedules have been suc¬
cessfully employed by a number of groups in
producing antibodies against bacterial, viral, red
cell and tumour antigens. It should be noted how¬
ever that monoclonals have been produced using
lymphocytes harvested 1-3 months post boosting
(Boyd et al. 1984b; Tiebout et al., 1984, 1985;
Thompson et al., 1986).
While it is obvious that the ability to produce
specific monoclonal antibodies is dependent upon
the immune status of the donor, it is also in¬
fluenced by the state of differentiation, prolifera¬
tion and activation of the cells fused or trans¬
formed. Although at the present time we have
some insight into how these properties influence
9
TABLE II











Tetanus toxoid PBL Fusion (KR4) Not specified Kozbor and Roder, 1984




Tetanus toxoid PBL Fusion (HM-5) PWM Ichimori et al., 1985
11 influenzae Tonsil Fusion (SP2/SP TCGF Brodeur et al., 1987
and SP2/HPT)
Neisseria Tonsil Fusion (SP2/SP TCGF Brodeur et al., 1987
meningitides and SP2/HPT)
Group streptococcus Spleen, tonsil Hmy2, HF2 T cell-depleted, PWM Wasserman et al., 1986
and T cell-irradiated
' feeders
Influenza PBL Transformation T cell depleted Crawford et al., 1983b
before transformation
Rubella PBL Fusion (MNS-2) Not specified Ritts et al., 1983
Rubella PBL Transformation T cells inactivated Hilfenhaus et al., 1986
plus fusion (cyclosporine)
before transformation
Hepatitis B Fusion (HM-5) PWM Ichimori et al., 1985
surface antigen PBL
Herpes simplex Tonsil Fusion (P3X63- PWM Masuho et al., 1986
Ag-Ul)
Cytomegalovirus Spleen Fusion (P3X63- BCGF Matsumoto et al., 1986
Ag-Ul)
Sheep PBL, tonsils Fusion (W1-L2- PWM, AB serum Strike et al., 1984
-729 and HF2)
Blood GpA Spleen Transformation T cell depleted Larrick et al., 1985
+ fusion (SP2/ before trans¬
0Agl4) formation
Forssman antigen Spleen Fusion (NS-1) Not specified Nowinski et al., 1980
Rhesus D PBL SP2/0Agl4 Astaldi et al., 1982
DNP PBL, spleen Fusion T cell depleted, LPS, Teng et al., 1985b
(SHM-D33) MDP, PHA, S. aureus
Cowan I
DNP, KLH, Spleen Fusion (SHM- T cell depleted, LPS, Bieber et al., 1987
sperm whale D33 and D36) MDP, PHA, S. aureus
myoglobin Cowan I
Prostatic acid Spleen Transformation PWM, then T cell Yamaura et al., 1985
phosphatase and fusion depleted
(SP2/0Agl4
and SHM-D33)




KLH-ABS Spleen, tonsil Hmy2 and HF2 T cell-depleted, PWM Wasserman et al., 1986
and T cell-irradiated
feeder
a Conditions specified usually those which gave optimum results.
Note also that antigen dose and time of culture varied.
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Epstein-Barr virus-induced immortalisation proce¬
dures (see later) the relevance of these to fusion
still remains to be established. As stressed by
Schwaber et al. (1984) B cells fuse at some uniden¬
tified stage of differentiation and activation.
In vitro immunisation
In an effort to circumvent the problems of
obtaining suitable immune lymphocytes from
donors, increasing attention is being devoted to in
vitro methods of sensitising and amplifying specific
B cells, an approach which has already been ex¬
tensively used in the development of murine
monoclonals (Reading, 1982; Borrebaeck, 1986).
Unfortunately, however, the in vitro immunisation
of human lymphocytes has been more difficult to
achieve than that of their murine counterpart.
According to Borrebaeck (1986) this could be due
to the fact that human studies have usually been
performed with peripheral blood where there is an
unfavourable ratio of T suppressor cells to B cells
or the circulating B cells are arrested in a phase in
which additional stimuli are required to induce
antigen-specific clonal activation. Whatever the
explanation, Dorfmann has stressed (1985) that
the lack of a well-established technique for the in
vitro immunisation of human blood cells remains
the most significant obstacle to human mono¬
clonal antibody development.
While developments in this area have un¬
doubtedly been slow, progress has been made,
especially in the last 2 years. Thus there are now
reports of a variety of human monoclonal anti¬
body-secreting cell lines which have been obtained
by the immortalisation of lymphocytes which have
been stimulated in vitro with antigen. These in¬
clude antibodies to bacterial, viral, red cell and
other antigens (Table II). Details of the precise
procedures used can be found in the references
listed and elsewhere (see for example Reading,
1982; Hoffman and Hirst, 1985b; Borrebaeck,
1986).
Analysing the results to date the following
points emerge. The in vitro immunisation proce¬
dure has been successfully employed with
lymphocytes from peripheral blood, spleen and
tonsils. As stressed later the small amount of
comparative data available suggests that spleen
and tonsils are superior to peripheral blood (Strike
et al., 1984; Teng et al., 1985b). It should be noted
however that almost all of the studies reported to
date have been undertaken with lymphocytes from
seropositive donors. Indeed attempts to sensitise
cells from seronegative donors with certain anti¬
gens have been unsuccessful (Matsumoto et al.,
1986). In most cases in vitro immunisations have
been performed with lymphocyte preparations ob¬
tained by separation on density gradients. How¬
ever, in a few cases such preparations have also
been depleted of T cells or T suppressor cells (Ts)
by a variety of techniques. These include SRBC
rosetting (Teng et al., 1985a), separation on nylon
wool (Garzelli et al., 1984; Ho et al., 1985;
Yamaura et al., 1985) or Sephadex G-10 columns
(Hoffman and Hirst, 1985a,b), specific lysis with
an anti-suppressor cell (OKT8) monoclonal (La-
gace et al., 1985; Brodeur et al., 1987) or panning
on cimetidine-coated plates (Ho et al., 1985). On
other occasions the lymphocyte-rich suspensions
have been separated into non-adherent and adher¬
ent fractions which have then been reconstituted
to give a more favourable ratio of T helper (TH)
cells (Ho et al., 1985). While there are sound
theoretical reasons for removing Ts cells and en¬
riching T H cells the value of this approach with
respect to in vitro immunisation is still a matter of
debate and will not be resolved until more com¬
parative studies are undertaken (Borrebaeck,
1986). It should be stressed however that deple¬
tion or inactivation of cytotoxic T cells is advisa¬
ble if the stimulated cell lines are to be subse¬
quently immortalised or expanded by EBV trans¬
formation (Crawford et al., 1983, 1985; Larrick et
al., 1985; Yamaura et al., 1985). Of particular
value in this context is the use of cyclosporine A
which has been shown to promote the sponta¬
neous outgrowth in vitro of Epstein-Barr virus-in¬
duced B cell lines (Bird et al., 1981). It should be
noted that other aspects of cell enrichment relat¬
ing particularly to in vivo immunisation will be
considered below.
The success of the in vitro approach is obvi¬
ously influenced by the dose, and possibly the
form, of the immunogen used. While the impure
nature of some of the immunogens employed ren¬
ders precise quantitation difficult it is apparent
that high doses of immunogen may inhibit
(Matsumoto et al., 1986) and that the optimum
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dose may vary from one lymphocyte preparation
to another (Brodeur et al., 1987) as well as from
immunogen to immunogen. It has also been sug¬
gested that the form of the immunogen influences
the isotype of the antibody secreted, insoluble
antigens favouring the production of IgG antibod¬
ies (Ho et al., 1985). Further detailed studies in
this area are obviously desirable.
In most in vitro immunisation procedures
mitogens have been used. PWM has been most
extensively employed but others include LPS, PHA
and Staphylococcus aureus Cowan I (a B cell
stimulant). In some cases mitogen alone has been
found to increase the production of antibody-
secreting hybrids and to exert a synergistic effect
with antigen (Ichimori et al., 1985).
Of particular interest have been recent reports
that the inclusion of the adjuvant peptide (mura-
myl dipeptide) in the culture media greatly en¬
hances the chance of obtaining antibody-specific
hybrids (Teng et al., 1985b). This compound has
also been shown to enhance the generation of
murine monoclonal antibodies following in vitro
sensitisation (Boss, 1984). Another possible ap¬
proach is to use antigen/silica complexes (Olsson
et al., 1985), a procedure previously proposed for
generating murine monoclonals against weakly
immunogenic insoluble proteins (Van Ness et al.,
1984). The success of the in vitro approach is
obviously dependent upon the presence in the
culture of the relevant differentiation and growth
factors. In most cases these have been elicited in
the culture by the added mitogens. On occasions,
however, studies have been performed with exoge-
nously added growth factors. These include un-
fractionated lymphocyte-conditioned media (Strike
et al., 1984; Ho et al., 1985), T cell growth factor
(Brodeur et al., 1987) and B cell growth factor
(Matsumoto et al., 1986). It would appear that the
impure products are of doubtful value (Ho et al.,
1985).
There is also debate about the source of serum
used. Some authors claim that human serum is
essential, at least during the early stages of in vitro
cultivation (Strike et al., 1984; Ho et al., 1985;
Teng et al., 1985b). However it should be noted
that in most reports to date FCS has been success¬
fully employed.
The optimum time for in vitro culture varies
from author to author, presumably reflecting dif¬
ferences in the immune status of the donors as
well as the nature of the immunogenic stimulus. In
some cases 3 days appears to be optimal (Craw¬
ford et al., 1983; Ichimori et al., 1985; Larrick et
al., 1985) while in others, 7 days or more (Yamaura
et al., 1985; Brodeur et al., 1987). It is also inter¬
esting to note that following initial culture with
immunogen, some investigators undertake a fur¬
ther period of culture in the presence or absence
of mitogen prior to immortalisation (Teng et al.,
1985b; Masuho et al., 1986).
The choice of lymphoid tissue
Opinions in this area have been derived largely
from personal experience and considerations of a
theoretical nature rather than detailed, controlled
comparative studies. The latter, of course, are
extremely difficult to perform for even if the rele¬
vant lymphoid tissues were available the varia¬
tions normally experienced in fusion work, even in
experienced laboratories, mean it is difficult to
reach hard and fast conclusions. In addition anal¬
ysis of the data already reported is frequently
complicated by the fact that the results are pre¬
sented as the numbers of hybrids produced rather
than specific antibody-secreting cell lines. Never¬
theless in spite of these difficulties a body of
opinion has emerged to indicate that as in the
mouse (see for example Olsson et al., 1983) spleen,
tonsils, etc., make better fusion partners than pe¬
ripheral blood (Table III). There is some sugges¬
tion, however, that this may depend on the human
fusion partner used and may be less critical where
mouse myelomas are employed (Cote and Hough¬
ton, 1985). From these limited impressions it seems
that peripheral blood lymphocytes are both more
difficult to sensitise in vitro than lymphocytes
from other tissues (see Lagace and Brodeur, 1985;
Borrebaeck, 1986) and give rise to fewer anti-
body-secreting cell lines following immortalisa¬
tion. This inferior performance has been attri¬
buted to a numer of factors and these are sum¬
marised in Table IV. They include inherent de¬
ficiencies in the circulating B cells themselves and
adverse interactions with other cells of the im¬
mune system. In brief, it is beheved that periph¬
eral blood does not contain enough antigen-reac¬
tive specific B cells in the appropriate state of
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TABLE III
THE CHOICE OF LYMPHOID TISSUES FOR HUMAN MONOCLONAL ANTIBODY PRODUCTION
Lymphoid tissue Immunogen Immunisation Immortalisation Best Reference
examined In vivo In vitro Fusion Trans. Both tlssue
Blood, spleen, tonsil Tetanus toxoid + + Spleen/
tonsil Chiorazzi et al., 1982
Blood, nodes a Lung carcinoma + + Nodes Cole et al., 1984
intra-tumour
lymphocytes
Blood, nodes, spleen Miscellaneous




saccharide + + Spleen Schwaber et al., 1984
Blood, tonsil Sheep
erythrocytes + + Tonsil Strike et al., 1984
Blood, node, spleen Miscellaneous
tumours + + Node Glassy et al., 1983
Blood, node, spleen Tetanus toxoid + + Node/
spleen Burnett et al., 1985
Blood, spleen, tonsil Tetanus toxoid
Bombesin + + Spleen/
tonsil Ho et al., 1985
Blood, spleen Miscellaneous
antigens + + Spleen Teng et al., 1985b
Blood, node, spleen. Epstein-
tonsil ' -Barr virus + + Spleen Koizumi et al., 1986
Blood, spleen Miscellaneous
antigens + + Spleen Bieber and Teng, 1987
a Refers to tumour draining lymph nodes.
b Depends on cell line used.
Note the superior performance of spleen, nodes and tonsil was observed with a wide variety of fusion partners both human and
mouse.
differentiation and proliferation. Furthermore pe¬
ripheral blood contains too many suppressor and
cytotoxic cells and not enough antigen-presenting
cells or Th cells.
Although it is apparent that peripheral blood is
not the best source of lymphocytes for human
monoclonal antibody production, for practical and
ethical considerations it will continue to be the
main source in the foreseeable future. In the
meantime, as emphasised elsewhere, methods for
improving the supply of antigen-primed lympho¬
cytes from peripheral blood will remain a priority.
In this context it is interesting to note that ad¬
juvants such as BCG are believed to improve the
efficiency of the immortalisation process by re¬
cruiting the appropriate progenitors into the circu¬
lation (Haspel et al., 1985a,b). This could be im¬
portant in view of claims that bone marrow is an
excellent source of committed B cells for im¬
mortalisation (Seigneurin et al., 1983).
Further comments on cell enrichment
In this section on in vitro immunisation we
stressed the importance of removing Ts cells which
might inhibit the immune response and Tc cells
which could prove deleterious following EBV-in-
duced immortalisation. Of added importance, par¬
ticularly when in vivo immunised lymphocytes are
used, is the specific enrichment of antigen-reactive
cells which are usually present in very low num-
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TABLE IV
POSSIBLE REASONS WHY PERIPHERAL BLOOD
LYMPHOCYTES PERFORM LESS WELL IN HUMAN
MONOCLONAL ANTIBODY PRODUCTION THAN
CELLS FROM OTHER LYMPHOID TISSUES
Reason advanced References
(1) Insufficient B cells
(2) Insufficient memory cells or
antigen specific B cells
(3) Transient appearance
of antigen specific B
cells in blood
following immunisation
(4) Inappropriate state of
differentiation of B cells
(5) Low mitotic activity of
B cells
(6) Contains fewer la positive
macrophages
(7) Contains too many cytotoxic
T cells
(8) Contains suppressor B cells
Cote and Houghton, 1985;
Ho et al., 1986
Seigneurin et al., 1983;
Olsson et al., 1983
Ho et al., 1986
Burnett et al.. 1985
Schwaber et al., 1984;
Cote and Houghton, 1985
Burnett et al., 1985;
Westerwoudt, 1985
Teng et al., 1985
Cote and Houghton, 1985
Cote and Houghton, 1985
bers (1 in 106-107 lymphocytes). As stressed above
this can be achieved partly by incubating the
lymphocytes with antigen (Ho et al., 1985;
Matsumoto et al., 1986) or mitogen alone (Chio-
razzi et al., 1982; Olsson et al., 1983) or both
(Astaldi et al., 1982; Strike et al., 1984; Yamaura
et al., 1985; Matsumoto et al., 1986). Alternative
strategies which are available include rosetting
with red cells bearing the relevant antigen (Steinitz
et al., 1979; Boylston et al., 1980; Doyle et al.,
1985) or panning on antigen-coated wells (Winger
et al., 1983; Cole et al., 1985). Another approach
is to mix the cells with FITC-labelled antigen
followed by fluorescence-activated cell sorting
(Casal et al., 1986). The latter technique is prob¬
ably the most accurate but it is also the most
expensive and least widely available. In addition,
to obtain adequate numbers of specific B cells for
use in current immortalisation strategies involves
extremely long runs in the cell sorter.
Any or all of the above techniques could be
used in the preparation of lymphocytes for im¬
mortalisation but two facts should be borne in
mind when choosing which methods to use. Firstly
the maximum number of antigen-positive cells
should be isolated but possibly more importantly
cells which may have a deleterious effect should
be removed. In general when large numbers of B
cells are available such as from lymph nodes or
spleen then specific B cell enrichment methods are
worth attempting. When lower cell numbers are
available, such as from blood, then the stimulation
techniques can play a role by increasing the total
number of specific cells present.
Procedures for immortalising human B cells
Lymphocyte fusion
Following the development of murine mono¬
clonal antibodies the next logical step was to
apply a similar approach to the production of
human monoclonal antibodies. In the first report
Olsson and Kaplan (1980) produced human hy-
bridoma-secreting monoclonal antibodies against
the 2,4-dinitrophenyl hapten by fusing splenic
lymphocytes with a myeloma cell line. Since this
time fusion has remained probably the most popu¬
lar immortalisation strategy.
Several problems have been encountered using
the fusion technique. The difficulties relating to
the choice of lymphoid tissue have already been
discussed but in the majority of cases peripheral
blood is the only tissue available. A second prob¬
lem encountered is the choice of partner for fu¬
sion. In murine work a few very satisfactory lines
were developed early in the history of the technol¬
ogy. These lines soon became widely available to
most laboratories and so at present there are
relatively few murine myeloma partners in general
use. In the case of human partner lines the oppo¬
site is true; no satisfactory lines were developed
quickly and as a result many laboratories spent a
great deal of time and effort developing their own
partners. This fact is reflected when the literature
is surveyed with many different partner lines hav¬
ing been used, but none having come to dominate
(Table V and Table VI).
The partner lines produced are of several phe-
notypes; myelomas (which are used so successfully
in the murine system) are used very rarely, mainly
because they grow very poorly in culture. The
majority of human fusion partners are lympho-
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TABLE V
SOME CELL LINES CURRENTLY USED AS FUSION PARTNERS IN HUMAN MONOCLONAL ANTIBODY PRODUC¬
TION





SKO-007 U-266 Myeloma - IgE(X) 8-AG Olsson and Kaplan, 1980
RPMI 8226 Myeloma - X 8-AG Abrams et al., 1983
HFB 1 Myeloma - Non-secretor 6-TG Hunter et al., 1982
KMMI Myeloma - G Togawa et al., 1982
RH-L4 Lymphoma NI Non-secretor 8-AG Olsson et al., 1983
NAT-30 Nawalma Lymphoma NI 6-TG Murakami et al., 1985
GM 1500-6TG-AL GM 1500 LCL + IgG2(x) 6-TG Croce et al., 1980
GM 1500-6TG-OA GM 1500 LCL + Hulette et al., 1985
KR4 GM1500-6TG-
-All LCL + IgG2(K) 6-TG, OUA Kozbor et al., 1982
GM 467 Sato et al., 1972
GM 4672 GM 1500 LCL + IgG2(K) 6-TG Croce et al., 1980
ARH-77 LCL + IgG(K) 8-AG Burk et al., 1978
LICR-LON-
-Hmy2 ARH 77 LCL + IgGl(K) 8-AG Edwards et al., 1982
W1-L2 LCL Emanuel et al., 1984
H35-1-1 W1-L2 LCL + IgM( K ) 8-AG Chiorazzi et al., 1982
W1-L2-729 HF2 W1-L2 LCL + IgM( K ) Strike et al., 1984
W1-L2-727 W1-L2 LCL + IgG( K ) Emanuel et al., 1984
UC 729-6 W1-L2 LCL + IgM(ic) 6-TG Glassy et al., 1983
MC/CAR LCL + None Ritts et al., 1983
MC/MNS-2 MC/CAR LCL + IgGl(ic) Ritts et al., 1983
LTR 228 LCL + IgM(K) 6-TG Larrick et al., 1983
LSM 2-7 CRL 1484 LCL + 6-TG Schwaber et al., 1983
HS Sultan LCL + None Lazarus et al.,
GK-5 LCL + K 6-TG Satoh et al., 1983
HO-323 LCL NI Ohashi et al., 1986
KR-12 KR4 X RPMI h/h hybrid
8226 myeloma + IgG2(K + X) 6-TG, OUA Kozbor et al., 1984
SHM-D3 U266 x 63-Ag- m/h hybrid
8.653 myeloma NI Non-secretor 6-TG, OUA, Teng et al., 1983
SBC-H20 B cell X m/h hybrid NI G418
SP2/08 A2 myeloma Non-secretor Foung et al., 1985a
3 HL SHM-D3 X m/h/h NI 6-TG, OUA
B lymphoma hybrid IgM(X) G418 Teng et al., 1985a
myeloma
a h/h = human hybrids used as fusion partners; m/h and m/h/h = mouse human hybrids used as fusion partners.
b
— EBNA, negative; + EBNA, positive; NI, no information.
blastoid cell lines derived by Epstein-Barr virus
transformation of lymphocytes. These lines are
easier to handle in culture than myelomas, but
they may not be in an appropriate differentiation
state for high levels of antibody secretion. Kozbor
et al. (1983, 1985) have stressed that while
myelomas have many polyribosomes, well devel¬
oped golgi apparatus and can secrete large amounts
of antibodies, lymphoblastoid cell lines have few
polyribosomes, sparse golgi apparatus and secrete
relatively little immunoglobin. Several groups have
attempted to improve the fusion rates and growth
characteristics of their existing lymphoblastoid
lines by fusing with either mouse or human
myelomas. It is claimed that these hetero-
myelomas perform better than the original lines in
15
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Teng et al., 1983
Bron et al., 1984
Yamaura et al., 1985
Carroll et al., 1986
Teng et al., 1985b
Ichimori et al., 1985
Van Meel et al., 1985
Carroll et al., 1986
Foung et al., 1985
Brodeur et al., 1987
Carroll et al., 1986
fusion experiments. Fusion of lymphoblastoid cell
lines with mouse myelomas has produced several
useful partners (Teng et al., 1983, 1985a; Foung et
al., 1985a) which give a greater number of stable
hybrids when fused with lymphocytes than do
mouse cells alone (Table VI). Kozbor et al. (1984)
have used the same principle to improve the growth
characteristics of the human myeloma line RPMI
8226, by fusing with their lymphoblastoid line
KR4. The resultant hybrid KR12 shows improved
fusion rates over either of its parents and also
exhibits a phenotype, more like a myeloma than
other lines which may increase the amount of
antibody secreted.
The problems of fusing lymphocytes with hu¬
man partners has encouraged several groups to
fuse with mouse myelomas instead (Wunderlich et
al., 1981; Astaldi et al., 1982; Cote et al., 1984;
Haspel et al., 1985; Hirohashi et al., 1986;
Thompson et al., 1986) (Table VII). It has been
known for many years that heterohybrids prefer¬
entially reject human chromosomes and indeed
this fact has been used to assign genes to particu¬
lar chromosomes (see later). Despite this fact it
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TABLE VII
HUMAN MONOCLONAL ANTIBODIES PRODUCED BY FUSION OF HUMAN LYMPHOCYTES WITH IMMORTAL
PARTNER CELLS
Antigen Lymphoid Fusion partner Immunoglobulin Stability Reference












































































































































Giolotti et al., 1982
Ho et al., 1985
Tiebout et al., 1985
Hunter et al., 1982
Gigliotti et al., 1984
Sawada et al., 1985
Schwaber et al., 1984
Tiebout et al., 1985
Matsumoto et al., 1986
Masuho et al., 1986
Burnett et al., 1985
Schmidt-Ullrich et al., 1986
Astaldi et al., 1982
Haspel et al., 1985a,b
Borup-Christensen et al., 1986
Wunderlich et al., 1981
Cote et al., 1983, 1984,
1985,1986
Murakami et al., 1985
Hirohashi et al., 1986
Olsson et al., 1984
Abrams et al., 1984
Kan-Mitchell et al., 1980
Glassy et al., 1985
Sikora et al., 1982,1983
Kyurkchiev et al., 1986
a Peripheral blood lymphocytes.
b Splenic lymphocytes.
c Tonsular lymphocytes.
d Lymph node lymphocytes.
e Intra-tumoral lymphocytes.
f Mouse cell line.
E Human cell line.
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appears that loss of antibody-secreting lines due
to genetic instability is no worse in heterohybrids
than in murine hybrids (Thompson et al., 1986)
and these lines can be stabilised by early cloning.
The fusion rates achieved when using mouse
myelomas as partners are significantly higher than
those achieved with human partners in compara¬
tive experiments (Cote et al., 1983, 1984,1986).
For the human lines, Abrams et al. (1983)
suggest that LICR-LON-Hmy2, UC729-6 and
HF2 are worth further investigation, although their
study used only seven of the available human
partners. More recently there have been pre¬
liminary reports of detailed studies with a variety
of cell lines including mouse myelomas, hetero-
myelomas, etc. (Usagawa et al., 1986). Among the
various cell lines tested KR-12, SHM-D33, 3HLA-
6 and 3HL3-27 proved the best. It is obvious that
further time-consuming studies in this area will be
necessary before hard and fast conclusions on the
best fusion partners can be reached.
The actual fusion procedures used vary widely
from group to group and workers all have their
own methods of producing hybrids. Due to the
variations between fusions even when the same
experimenter is involved very few comparative
studies are possible (Kadish and Wenc, 1983; Lane
et al., 1984; Dorfman, 1985; Westerwoudt, 1985).
One conclusion which seems to be agreed upon is
that the polyethylene glycol (PEG) preparation
used for fusion plays a major role in hybrid for¬
mation and any new batch must be tested before it
can be used routinely. The studies all recommend
PEGs of different molecular weight and sources
but it appears that if a batch of PEG produces
good yields of hybrids in one experiment then
there is no reason why it should not continue to
do so. In our department one batch of PEG has
produced many successful murine fusions over
several years. The pH of the PEG when it is in
contact with the cells can influence the rate of
fusion (Lane et al., 1984) as can the time the cells
remain in contact with the fusogen (Davidson and
Gerald, 1976). The choice of foetal calf serum and
other supplements used play a major role in the
growth of all cells and will be discussed below.
Lymphocyte transformation
Human lymphocytes can be immortalised by a
second completely different mechanism, namely
viral transformation. The virus used in this tech¬
nique is the Epstein-Barr virus (EBVj and its
normal source is the culture supernatant derived
from the marmoset cell line B95-8 (Miller and
Lipman, 1973). EBV is a herpes virus which pref¬
erentially infects human B lymphocytes, and can
on occasion insert into their genome thus causing
transformation. There is at present some debate as
to which cells are infected with EBV and of these
which go on to become transformed. The receptor
for EBV on human lymphocytes is the C3d (CR2)
complement receptor which is a 140 kDa glyco¬
protein (Frade et al., 1985). It would appear that
EBV can bind to and penetrate all B cells, yet only
a small proportion are transformed. Binding of
killed EBV induces cells to become activated as
does antibody directed against the C3 receptor
suggesting activation and transformation are re¬
lated but separate events. Aman et al. (1985)
suggest that the responsive population is a small
high density resting population while Chan et al.
(1986) claim that the most susceptible population
is an activated large cell population. This popula¬
tion is also sIgM+, sIgD+ and is destined to
secrete IgM. The small resting population on the
other hand gives rise to IgG and IgA secreting
populations, the precursors of these cells being
sIgG+ or IgA+ and slgD". It is also interesting to
note that Chan et al. (1986) suggest that the
susceptibility to transformation may be more de¬
pendent on entry into the cell cycle than the
density of EBV receptor expression. If Chan et
al.'s observations are correct, this would explain
the bias found by many workers towards IgM
secretions, while still explaining IgG and IgA
secretion by some lines. It is interesting to note
that many of the long-lived antibody-secreting cell
lines obtained by EBV transformation secrete IgG
antibodies especially IgGl (Table VIII). As sug¬
gested by others this may indicate that cell lines
secreting IgG antibodies are more stable in culture
or merely reflect a bias in the selection procedures
(Redmond et al., 1986).
The transient activation of B lymphocytes by
EBV binding without subsequent transformation
can be a major problem when attempting to pro¬
duce monoclonal antibodies by this method.
Moreover, it appears that there are other problems
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with transformed cell lines; it is not uncommon
for cell lines to grow well for 1 or 2 months before
their antibody titre suddenly declines. This fall in
antibody titre is often accompanied by a visible
change in cell phenotype from small highly
clumped irregularly shaped cells to larger more
uniformly round single cells. These cells do not
grow as quickly in culture as the irregular cells.
Although early cloning has in some cases res¬
cued antibody-secreting lines, many potentially
useful lines have been lost due to the extremely
poor cloning efficiencies of lymphoblastoid lines.
Many different strategies have been tried to im¬
prove the growth at low cell densities including
early repeated cloning but the fact remains that
the majority of workers find these cells extremely
difficult to clone. It should be noted that viral
transformation has occasionally occurred 'acci-
TABLE VIII
HUMAN MONOCLONAL ANTIBODIES PRODUCED BY EPSTEIN-BARR VIRUS TRANSFORMATION OF HUMAN
LYMPHOCYTES





Tetanus toxoid PBL a G >6 Zurawski et al., 1978
Tetanus toxoid PBL Gl(ic) - Tiebout et al., 1984
Tetanus toxoid PBL G3 > 10 Boyd et al., 1984a,b
Pneumococcal polysaccharide TON b M >3 Yoshie and Ono, 1980
Chlamydia salpingitis PBL G1(K + A) > 12 Rosen et al., 1983
Herpes Simplex II PBL G1 + G2 <2 Evans et al., 1984
Herpes Simplex glycoprotein D BM Gl(tc) >24 Seigneurin et al., 1983
Hepatitis Be PBL - Furuya et al., 1982
Influenza virus PBL G1(ic) > 12 Crawford and Callard, 1983b
Cytomegalovirus PBL GO) > 12 Emanuel et al., 1984
Cytomegalovirus PBL G1(k +A) - Redmond et al., 1986
Epstein-Barr capsid and membrane PBL, LN, TON, SP c G1(k) >8 Koizumi et al., 1986
Plasmodium falciparum PBL M + G 12 Udomsangpetch et al., 1986
Rhesus (D) PBL M 1.5 Boylston et al., 1980
Rhesus (D) PBL G1(K) >9 Crawford et al., 1983
Rhesus (D) PBL G1 and G4 > 10 Doyle et al., 1985
Rhesus (D) PBL G1(K) - Melamed et al., 1985
Blood group A SP M - Raubitschek et al., 1985
Melanoma ITL d M + G _ Watson et al., 1983
Transitional cell carcinoma PBL M >1 Paulie et al., 1984
Lung tumour LN e M - Hirohashi et al., 1982a
Gastric tumour LN M(k) - Hirohashi et al., 1982b
OFA-1 PBL M(k) - Irie et al., 1982
T cell leukaemia LN G1 >2 Matsushita et al., 1986
DNA PBL M > 36 Sasaki et al., 1984
DNA PBL M - Sasaki et al., 1985
DNA, sperm, erythrocytes PBL M + G > 1 Winger et al., 1983
Thyroid antigens PBL M, G + A >6 Garzelli et al., 1984
Neurofibrillary plaques + tangles PBL M + G > 4 Simpson et al., 1986
N.N.P. PBL M(k) - Steinitz et al., 1979




e Lymph node lymphocytes.
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dentally' while fusions with EBV+ partner cells
were being attempted (Boyd et al., 1984a; Strieker
et al., 1985). These 'cell-driven' transformations
appear to lead to more stable cell lines but the
mechanisms underlying this phenomenon have
never been investigated.
Lymphocyte transformation followed by back fusion
Kozbor et al. (1982) successfully combined the
techniques of transformation and cell fusion to
produce hybridomas secreting antibodies directed
against tetanus toxoid. By combining the two ap¬
proaches they gained the advantages of both
methods and avoided some of the disadvantages.
Most of the published work with this technique
has used peripheral blood as the source of
lymphocytes. The major advantage of transfor¬
ming the cells before fusing 2-8 weeks later is that
the fusion rate rises from 20 X 10"7 to over 100 X
10-7 (Kozbor and Roder, 1984). It has been sug¬
gested that the reason peripheral blood fails to
fuse well is that the cells are not in an actively
dividing state and therefore their nuclei do not
fuse with that of the myeloma partner during
mitosis (Burnett et al., 1985). Since EBV causes
the B lymphocytes to become activated even when
transformation does not occur, it allows the
lymphocytes to fuse more efficiently resulting in
higher yields of hybrids.
The hybrids produced by this approach have
the same instability problems as any other hybrids
but these can be overcome by early cloning (since
such hybrids undoubtedly clone more readily and
produce higher levels of specific antibody than
transformants), and have been reported as stable
from 2.5 to greater than 14 months. The antibod¬
ies secreted are representative of the antibodies
being produced by the transformed hnes at the
time of fusion. As a result many of the lines
produce IgM although IgGs (especially IgGl) are
not uncommon. Using this technique antibodies
have been produced against a wide variety of
antigens (Table IX).
Feeder layers
A crucial stage in all of the methods described
above is during the initial culturing when selection
procedure are carried out at reasonably low cell
densities. To try to improve the growth character¬
istics of newly transformed or hybridised cells a
wide variety of feeder cells and conditioned media
have been used. Feeder layers fall into two distinct
groups, cells of the lymphocyte and mononuclear
phagocyte lineage of human or mouse origin and
human cells predominantly either of embryonic
origin or fibroblasts (Table X). Some groups be¬
lieve they greatly improve the chance of isolating
specific antibody-secreting lines (Crawford et al.,
1983, 1985; Rosen et al., 1983; Tiebout et al.,
1984, Teng et al., 1985a) while others feel they are
of limited value (Cote ct al., 1983, 1985; Strike et
al., 1984; Schmidt-Ullrich et al., 1986). Unfor¬
tunately there have been few well designed experi¬
ments to establish the true position. One role
which phagocytic cells may play is to clean up cell
debris arising from the selection process and to
minimise any growth of infectious micro¬
organisms. For example mouse PEC are believed
to be very effective at minimising mycoplasma
contamination (Doyle et al., 1985).
The expansion of human monoclonal cell lines
The approaches used to grow up human mono¬
clonal cell lines of interest have generally followed
those used for mouse monoclonals. They include a
variety of in vitro culture procedures together with
growth in immunodeficient mice or rats (Table
XI). Where relatively small amounts are required
stationary culture in flasks is perfectly adequate
and has been widely used. Larger amounts have
been successfully produced in suspension culture
using spinner flasks (Hunter et al., 1982; Thomp¬
son et al., 1986) and roller bottles (Wunderlich et
al., 1981; Sikora et al., 1983; Thompson et al.,
1986). Others have grown human cell hnes in
immobilised form (Haspel et al., 1985a,b). It is
generally accepted that, where extremely large
amounts of antibody are required (as for example
in therapy), airlift reactors and immobilised cell
technologies are the methods of choice. Further
details on a number of these procedures can be
found in recent reviews (Birch et al., 1985; Duff,
1985; Altschuler et al., 1986).
Scale up in production inevitably introduces
problems not least of which is the cost, availability
and variability of serum supplements used in
medium formulation and their subsequent re¬
moval from the final product. These problems
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TABLE IX
HUMAN MONOCLONAL ANTIBODIES PRODUCED BY EPSTEIN-BARR VIRUS TRANSFORMATION OF HUMAN
LYMPHOCYTES FOLLOWED BY FUSION WITH IMMORTAL PARTNER LINES
Antigen Lymphoid Fusion partner Immunoglobulin Stability Reference
tissue
Species Line isotype secreted
in months
Tetanus toxoid PBL a Hu e KR4 M(k) >7 Kozbor et al., 1982
Tetanus toxoid PBL Hu KR-12 M > 10 Kozbor et al., 1984
Pseudomonas
aeruginosa SP b Hu LTR228 M - Siadek and Lostrom, 1985
Pseudomonas
aeruginosa SP Hu/Mo f F3B6 M - Siadek and Lostrom, 1985
Exotoxin PBL Mo SP2/0 M - Larrick et al., 1985
Mycobacterium
leprae PBL Hu KR4 M > 12 Atlaw et al., 1985
Gram negative
bacteria SP Hu/Mo SHM-D33 M Teng et al., 1985a
Cytomegalovirus PBL Hu W1-L2 G(X) - Emanuel et al., 1984
Rubella \
Rabies >
PBL (human Hu Org MHHI M + G 2.5-6 Van Meel et al., 1985
Hepatitis B j + chimp)
Rhesus D PBL Hu/Mo SHM-D33 G3(A) >8 Bron et al., 1984
Rhesus D PBL Mo X63-Ag- M + G3 > 14 Thompson et al., 1986
8.653
Rhesus G PBL Hu/Mo SBC-H20 G1 - Foung et al., 1985
Blood group A PBL Hu/Mo SBC-H20 - Foung et al., 1985a
Blood group A PBL Mo SP2/0 M - Larrick et al., 1985
HLA PBL Hu GM 1500- M - Hulette et al., 1985
-6TG-OB
Lung carcinoma PBL, LN, c Hu KR4 M > 5 Cole et al., 1984
ITL d
Breast carcinoma PBL Hu KR4 > 4 Campbell et al., 1986
Prostatic acid SP J Hu/Mo SHM-D33 M + G >6 Yamaura et al., 1985
phosphatase \ Mo SP2/0
Rheumatoid
factor PBL Hu KR4 M, G +A - Haskard et al., 1984
a Peripheral blood lymphocytes.
b Splenic lymphocytes.
c Lymph node lymphocytes.
d Intra-tumoral lymphocytes.
e Human cell lines.
f Mouse cell lines.
have led to the development of defined' serum-free'
media for the large scale culture of human and
mouse monoclonal cell lines. While experience
with serum-free media and human cell lines is as
yet limited, it is interesting to note that there are
reports suggesting that when grown in serum
free-media they will produce at least as much, if
not more antibody as cells grown in high con¬
centrations of FCS (Cole et al., 1985b; Glassy et
al., 1985; Teng et al., 1985a). This has led to
suggestions that FCS may contain factors which
impair immunoglobulin production (Glassy et al.,
1985). Nevertheless, it must be emphasised that
the culture of monoclonal antibody-producing cell
lines in serum-free, or media containing low con¬
centrations of serum might render secreted im-
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TABLE X
FEEDER LAYERS USED IN HUMAN MONOCLONAL ANTIBODY PRODUCTION
Feeder used References
Cord blood lymphocytes Sasaki et al., 1984; Melamed et al., 1985
Peripheral blood T cells Winger et al., 1983; Garzelli et al., 1984
Peripheral blood monocytes Bischoff et al., 1982; Olsson et al., 1983; Melamed et al., 1985, Andreasen and Olsson, 1986
Allogeneic peripheral blood leukocytes Kozbor and Roder, 1981; Astaldi et al., 1982; Irie et al., 1982; Crawford et al., 1983;
Paulie et al., 1984; Tiebout et al., 1984; Garzelli et al., 1986; Ho et al., 1986
Schmidt-Ullrich et al., 1986
Lymphoblastoid cell lines Irie et al., 1982; Doyle et al., 1985
Foreskin fibroblasts Zurawski et al., 1978; Emanuel, 1984; Siadak and Lostrom, 1985
Thymus fibroblasts Strike et al., 1984
Fibroblasts not specified Raubitschek et al., 1985; Van Meel et al., 1985
Embryonic lung fibroblasts Steinitz et al., 1979
Embryonic fibroblasts not specified Kozbor and Roder, 1981; Satoh et al., 1983; Watson et al., 1983; Rosen et al., 1983
Embryonic kidney Zurawski et al., 1978
Embryonic lung Evans et al., 1984
Embryonic amnion Zurawski et al., 1978
Endothelial cells Astaldi et al., 1982
Melanoma cells Watson et al., 1983
Mouse thymocytes Nowinski, 1980; Olsson et al., 1983, Teng et al., 1985a
Mouse spleen Kozbor et al., 1981,1982, 1984; Cole et al., 1984; Atlaw et al., 1985
Mouse peritoneal exudate Gigliotti et al., 1982, 1984; Kozbor et al., 1982; Cote et al., 1983,1985;
Satoh et al., 1983; Cole et al., 1984; Haskard et al., 1984; Doyle et al., 1985;
Melamed et al., 1985; Borup-Christensen, 1986; Carroll et al., 1986;
Matsuho et al., 1986; Thompson et al., 1986; Brodeur et al., 1987
TABLE XI
GROWTH OF HUMAN ANTIBODY SECRETING CELL LINES
Procedure References
Stationary culture
Wells or flasks Routinely used
Homogenous suspension culture
Continuous stirred reactor Hunter et al., 1982; Thompson et al., 1986
Airlift reactor
Roller bottles Wunderlich et al., 1981; Sikora et al., 1983; Thompson et al., 1986
Immobilised cells







Abrams et al., 1984; Bron et al., 1984; Insel, 1984; Bogard et al., 1985; Burnett et al., 1985;
Kozbor et al., 1985b; Olsson et al., 1985; Tiebout et al., 1985; Yamaura et al., 1985;
Ware et al., 1985
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munoglobulin more susceptible to the degradation
by endogenous proteases secreted by the hy-
bridoma cell line themselves.
There are a number of reports of attempts to
grow human hybrids in nude mice. From these it
is apparent that human/human hybridomas do
not grow readily in nude mice in spite of their T
cell deficiency. This is perhaps not surprising in
view of the fact that such mice are capable of
rejecting xenogeneic cells by NK and macro-
phage-mediated mechanisms. Improved take can,
however, be achieved by irradiating (350-400 rad)
the nude mice prior to inocculation (Bogard et al.,
1985; Kozbor et al., 1985), by adopting the cells to
in vivo growth (Kozbor et al., 1985) or by mixing
the cells with human skin fibroblasts prior to
inoculation (Olsson and Brams, 1985). But even
with these procedures the take may be as low as
50% (Bogard et al., 1985; Kozbor et al., 1985) or
depends on the route of injection (Olsson and
Brams, 1985).
Fortunately the position with respect to hetero-
hybrids appears to be better several groups report¬
ing that such cells will grow in non-irradiated mice
without adaptation (Bron et al., 1984; Insel et al.,
1984; Burnett et al., 1985; Tiebout et al., 1985;
Yamoura et al., 1985). This observation is perhaps
not surprising in light of previous observations
that human/mouse B cell hybrids express the H-2
haplotype of the murine parent but fail to express
the human HLA antigens which would evoke im¬
mune rejection (Raison et al., 1982). It is, perhaps,
also worth stressing that in our hand such hybrids
normally grow better in vitro.
A number of other observations on the growth
of human hybridomas in mice are worthy of com¬
ment. Recent reports suggest that human/human
hybridomas grow much better in SCID mice (i.e.,
mice with severe combined immunodeficiency
syndrome) than in nude mice (Ware et al., 1985;
Effros et al., 1986). Unfortunately such mice have
to be housed in a special hood and fed sterile diet.
There have also been conflicting reports on the
amounts of immunoglobulin produced in ascites.
According to Kozbor et al. (1985), cells adapted
for growth in nude mice by in vivo passage ex¬
hibited an increase in both tumorigenicity and
immunoglobulin production, properties which
were associated with a change in morphology.
This change was transient as the cells reverted to
their original phenotype on return to in vitro
culture. The differentiation observed in vitro was
attributed to growth factors released during the
inflammatory process induced by pristane treat¬
ment. In contrast, others have observed that hy¬
bridomas adapted for growth in ascites may not
secrete large amounts of immunoglobulin (Olsson
and Brams, 1985).
Finally the problems of growing human cell
lines in nude mice are further compounded by
those of viral contamination, a situation aggra¬
vated by the extreme susceptibility of such mice to
infection. In view of the aforementioned difficul¬
ties it is inevitable that the large scale production
of human monoclonal antibodies for prophylactic,
therapeutic and diagnostic use (such as imaging)
will be dependent upon bulk culture either in
airlift fermenters or immobilised cell systems.
A survey of human monoclonal antibodies
In spite of the many difficulties encountered in
human monoclonal antibody production the
success achieved to date has served to reinforce
the potential of this technology. This success is
illustrated in Table XII which lists many of the
human monoclonals described so far. As is to be
expected the majority of these monoclonals have
been developed with prophylaxis and therapy in
mind and are therefore directed against a wide
range of bacterial, viral, erythrocyte and tumour
antigens. Of particular interest are those derived
from normal individuals or individuals with auto¬
immune diseases which react with autoantigens,
both internal and cell surface. The basic strategies
employed in the production of many of these
antibodies is summarised in Tables VII-IX and
elsewhere in the text.
While the range of human monoclonals de¬
scribed to date is large, it should be recognised
that many of the antibody-secreting cell lines de¬
scribed have proved to be unstable. Furthermore
many of the antibodies have not been adequately
characterised and their specificity is open to ques¬
tion. This is especially true of the monoclonals
reputed to act with tumour and autoantigens.
23
TABLE XII
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Gigliotti et al., 1984
Teng et al., 1983, 1985a
Larrick et al., 1985
Hunter et al., 1982; Gigliotti et al., 1984; Brodeur et al., 1987
Atlaw et al., 1984; Foung et al., 1985a
Brodeur et al., 1987
Schwaber et al., 1984
Sawada et al., 1985; Siadak and Lostrom, 1985
Zurawski et al., 1978; Kozbor and Roder, 1981, 1982; Chiorazzi et al., 1982; Larrick et al., 1983;
Teng et al., 1983; Boyd et al., 1984b; Tiebout et al., 1984, 1985;
Ho et al., 1985; Ichimori et al., 1985
Gigliotti and Insel, 1982
Rosen et al., 1983
Emanuel et al., 1984; Matsumoto et al., 1986; Redmund et al., 1986
Koizumi et al., 1986
Van Meel et al., 1985
Burnett et al., 1985; Ichimori et al., 1985; Strieker et al., 1985;
Van Meel et al., 1985
Furuya et al., 1982
Seigneurin et al., 1983; Evans et al., 1984; Masuho et al., 1986
Matsushita et al., 1986
Crawford and Callard, 1983b; Ostberg and Pursch, 1983
Croce et al., 1980; Ritts et al., 1983; Van Meel et al., 1985;
Hilfenhaus et al., 1986
Van Meel et al., 1985
Matsushita et al., 1986
Foung et al., 1985a,b
Schmidt-Ullrich, 1986; Udomsangpetch et al., 1986
Foung et al., 1985a; Larrick et al., 1985; Raubitschek et al., 1985
Hirohashi et al., 1986
Boylston et al., 1980; Astaldi et al., 1982; Crawford et al., 1983;
Bron et al., 1984; Doyle et al., 1985; Melamed et al., 1985;
Paire et al., 1986; Thompson et al., 1986.
Foung et al., 1986
Nowinski et al., 1980
Strike et al., 1984
Winger et al., 1983
Hulette et al., 1985; Effross et al., 1986
Paulie et al., 1984
Sikora et al., 1982,1983
Wunderlich et al., 1981; Cote et al., 1983, 1984, 1985, 1986;
Campbell et al., 1986; Strelkauskes et al., 1987a
Abrams et al., 1984
Hirohashi et al., 1982b; Haspel et al., 1985a,b;
Borup-Christensen et al., 1986
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Hirohashi et al., 1982b; Sugiyama et al., 1986
Hirohashi et al., 1982a; Cote et al., 1983, 1984, 1985, 1986; Cole et al.,
1984,1985a; Murakami et al., 1985
Carroll et al., 1986 I
Irie et al., 1982; Wa|enius et al., 1983; Watson et al., 1983;
Kan-Mitchell et al., 1986
Andreasen and Olsson, 1986
Cote et al., 1983,1984,1985,1986
Glassy et al., 1985
Simpson et al., 1986
Cote et al., 1983,1986; Cote and Houghton, 1985
Schonfield et al., 1982; Teng et al., 1983; Massicote et al., 1984;
Sasaki et al., 1984,1985
Hamburger et al., 1985
Cote and Houghton, 1985
Cote et al., 1986
Murray et al., 1984
Satoh et al., 1983; Cote et al., 1986; Simpson et al., 1986; Someya and Kondo, 1986
Cote et al., 1986; Simpson et al., 1986
Garzelli et al., 1984
Simpson et al., 1986
Simpson et al., 1986
Simpson et al., 1986
Eisenbarth et al., 1982; Satoh et al., 1983; Garzelli et al., 1984
Satoh et al., 1983; Someya and Kondo, 1986
Garzelli et al., 1984
Satoh et al., 1983
Schonfield et al., 1982
Yamoura et al., 1985
Teng et al., 1983
Winger et al., 1983
Kyurchiev et al., 1986
Garzelli et al., 1984
Dighiero et al., 1983
Satoh et al., 1983
Cote and Houghton, 1985
Haskard and Archer, 1984
Ho et al., 1985
Olsson and Kaplan, 1980
Teng et al., 1983; Bieber et al., 1987
Steinitz et al., 1977,1979
Lane et al., 1982; Bieber and Teng, 1987
Yoshie and Ono, 1980
Bieber and Teng, 1987
Note. For precise details of the specificity of these antibodies the readers should consult the original references. It must be
stressed however that in many instances the antibodies have not been adequately characterised.
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The application of human monoclonal antibody
technology
It is the widespread recognition of the marked
potential of human monoclonal antibodies that
has sustained work in this area despite major
technical difficulties. The advantages of the tech¬
nology have been emphasised on numerous occa¬
sions and in certain instances realised. In brief
they include the possibility of new or improved
diagnostics, prophylactics and therapeutics and
novel ways of probing the B cell repertoire in
health and disease. These various uses are sum¬
marised in Table XIII and some are commented
on in further detail below. For a detailed survey of
the potential therapeutic application of human
monoclonals, the readers should consult a recent
review by Larrick and Bourla (1986).
Attempts to develop human monoclonals of
diagnostic importance have usually been prompted
by difficulties experienced in producing mouse
monoclonals of the desired specificity. This has
been attributed to the failure of the mouse to
recognise the relevant antigens against a back¬
ground of relatively immunodominant epitopes.
Obvious examples in this area are monoclonals to
the Rhesus D antigen and HLA determinants. The
human approach has, of course, been given further
impetus because of the possible therapeutic value
of monoclonal antibodies to the antigens in ques¬
tion.
Understandably it is the prophylactic and ther¬
apeutic potential of monoclonal antibodies which
has attracted most attention to date with the main
emphasis being in the infectious diseases and
cancer fields. The possibilities in these areas are
quite varied and can readily be illustrated with
reference to infectious diseases. The most obvious
use is in the passive therapy of infections or in the
passive enhancement of the response to vaccines.
As stressed by others this form of therapy is of
considerable interest in those cases where the in¬
fectious agent in question is either resistant or
proving increasingly difficult to manage by con¬
ventional forms of therapy, e.g., infection with
Gram-negative microorganisms (Sasawada et al.,
1985; Teng et al., 1985a) and Malaria falciparum
(Schmidt-Ullrich et al., 1986).
Immortalising B cells from either actively im¬
munised individuals or individuals suffering or
recovering from infection also provides valuable
information on the ontogeny of the immune re¬
sponse and on the antigens which can elicit pro¬
tective antibody. This knowledge can be of
paramount importance in developing vaccines
from either recombinant or natural sources and
cannot be readily obtained using murine-derived
monoclonals. These human monoclonal antibodies
can also be used to purify immunogenic peptides
for use in vaccines and as anti-idiotype vaccines
themselves. More recently there has been interest
in the possibihty of using monoclonals of this kind
to target drugs to microorganisms.
Many of the aforementioned apphcations have
also stimulated the intensive programme of work
on human anti-tumour monoclonals. Of particular
interest in this area has been their use in identify¬
ing putative tumour-specific antigens, as anti-idio-
type vaccines and as reagents for imaging and
targeting tumours.
There are of course other important therapeutic
applications some of which have been prompted
by the success already achieved with monoclonals
of murine origin. Of especial importance in this
context are monoclonals which can be used to
modulate the immune response. This includes an¬
tibodies against human lymphocyte subsets, anti¬
gens of the major histocompatability complex and
soluble mediators of immunity including inter-
leukins which might be used to reverse graft rejec¬
tion and treat autoimmune diseases.
More recently the potential of human mono¬
clonal antibodies as probes for identifying candi¬
date antigens for contraceptive vaccines has also
been emphasised (Kyurchiev et al., 1986). To date
most work in this area has been performed with
mouse monoclonals and as with other vaccines it
remains to be established that the mouse recog¬
nises the relevant epitopes.
While the aforementioned uses have been
largely responsible for sustained interest in human
monoclonal antibody technology, what is perhaps
less well appreciated is the contribution it has
made, and will continue to make, to our under¬
standing of the B cell repertoire in health and
disease (Glassy et al., 1983, 1986; Winger et al.,
1983; Cote and Houghton, 1985; Cote et al., 1986).
The ability to clone, expand and hopefully im-
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TABLE XIII
PROPOSED USES OF HUMAN MONOCLONAL ANTIBODIES
Example
(A) Diagnostic andmonitoring
(1) Viral infections, e.g., cytomegalovirus
HTLV-1
(2) Other infections, e.g., chlamydia
(3) Malignancies, e.g., leukaemia, colorectal
carcinoma, melanoma, etc.
(4) Red cell typing, e.g., Rhesus incompatibility
(5) Tissue typing, e.g., HLA antigens
(6) Immunopathology, e.g., antibodies to pathological
and normal cell components
(B) Prophylactic and therapeutic
(1) General comment on value as prophylactic
and therapeutic
(2) Treatment of infectious diseases
(a) identifying immunogenic epitopes for use
in vaccines
(b) purifying immunogenic peptides for use
in vaccines
(c) investigating regions of genome coding
immunogenic peptides
(d) as anti-idiotype vaccines
(e) passive therapy of infections,
e.g., Gram-negative, CMV, HTLV-1, haemophilus
influenzae
(f) passive enhancement of response to vaccines
(3) Treatment of malignancies
(a) identifying immunogenic peptides for vaccines
(b) as anti-idiotype vaccines
(c) as therapeutic agents (either alone or
drug conjugates)
(d) imaging or localisation of tumours
(4) General application as immunomodulators
e.g. antibodies to suppressor cells,
interleukins,
anti idiotypes
(5) Therapy of autoimmune diseases
(6) Management of transplant patients
e.g., antibodies to histocompatibility
antigens
(7) Prevention of Rhesus incompatibility
(8) In contraception
(a) as contraceptive per se
(b) in identifying immunogenic peptides for
use in contraceptive vaccines
Reference
Emanuel et al., 1986
Matsushita et al., 1986
Rosen et al., 1983
Glassy et al., 1983; Cole et al., 1984;01sson et al., 1984;
Haspel et al., 1985a,b; Matsushita et al., 1985;
Andreasen et al., 1986; Kan-Mitchell et al., 1986;
Smith et al., 1987; Strelkauskas, 1987a
Crawford et al., 1983a; Bron et al., 1984
Steinitz et al., 1977; Hulette et al., 1985; Effros et al., 1986
Haspel et al., 1985a,b; Imam et al., 1986;
Simpson et al., 1986; Kan-Mitchell et al., 1986
Gigliotti and Insel, 1982; Glassy et al., 1983
Ichimori et al., 1985; Koizumi et al., 1986;
Larrick and Bourla, 1986
Atlaw et al., 1985; Matsushita et al., 1986; Schmidt-
Ullrich et al., 1986
Schmidt-Ullrich et al., 1986
Schmidt-Ullrich et al., 1986
Atlaw et al., 1985; Matsushita et al. 1986;
Schmidt-Ullrich et al., 1986
Hunter et al., 1982; Emanuel et al., 1984
Atlaw et al., 1985
Kan-Mitchell et al., 1986
Gaffar et al., 1986a
Glassy et al., 1983; Sikora et al., 1983; Cole et al., 1984;
Haspel et al., 1985a,b; Matsushita et al., 1985;
Borup-Christensen et al., 1986; Andreasen et al., 1987;
Sikora et al., 1987; Smith and Teng, 1987;
Strelkauskas, 1987a
Sikora, 1983; Glassy et al., 1985; Borup-Christensen
et al., 1986; Burnett et al., 1987; Sikora et al., 1987;
Strelkauskas et al., 1987a
Dorfman et al., 1985
Sasaki et al., 1984
Croce et al., 1980; Sasaki et al., 1984; Chiorazzi, 1986
Hulette et al., 1985; Effros et al., 1986
Crawford et al., 1983; Bron et al., 1984
Kyurchiev et al., 1986




(C) Investigating the immune system in health and disease
(1) Studying the normal B cell repertoire in
health and disease
(2) Examining the specificity/activity of B
cells in micro environments e.g. tumour,
synovial cavity
(3) Analysing the relevance of humoral immunity
in situations of clinical importance
(a) infection
(b) malignancy
(c) autoimmunity and tolerance
Reference
Glassy et al., 1983; Winger et ah, 1983; Cote et ah, 1985, 1986
Glassy et ah, 1983; Watson et al., 1983; Winger et al., 1983
Matsushita et al., 1986; Redmond et ah, 1986.
Sikora et ah, 1982; Watson et al., 1983; Paulie et ah, 1984;
Glassy et ah, 1985, 1987; Andreasen et ah, 1986; Cote et al., 1986;
Kan-Mitchell et ah, 1986; Smith and Teng, 1987
Eisenbarth et ah, 1982; Shoenfield et ah, 1982; Glassy et al., 1983;
Satoh et ah, 1983; Sasaki et ah, 1984; Chiorazzi, 1986
Chiorazzi, 1986
Smith and Teng, 1987
Satoh et ah, 1983
Bron et ah, 1984
Carrol et al., 1986
(d) allergic disorders
(4) Characterising and isolating antigens of
clinical relevance
(a) antigens for use in vaccines - see above
(b) tumour antigens
(c) autoantigens
(d) red cell antigens
(5) Studying the molecular biology of the
immunoglobulin locus
mortalise specific antibody-secreting cells not only
facilitates the analysis of the humoral immune
response to microorganisms and tumours (referred
to above) but also permits the more detailed in¬
vestigation of such basic immune phenomena as
autoimmunity and tolerance. This approach is
especially advantageous when one wishes to in¬
vestigate the properties of B cells in distinct mi-
croenvironments such as tumours, synovial cavi¬
ties, etc.
Studies to date have shown that within the
human B cell repertoire there are precursors capa¬
ble of recognising and responding to a wide variety
of normal and abnormal cell components (Table
XII). Furthermore it would seem that the majority
of these B cell precursors are programmed against
intracellular components rather than cell surface
components (see Cote et al., 1984, 1985, 1986). As
suggested by Cote et al. (1985) this could reflect
differences in susceptibility to tolerance induction
of cell surface and intracellular antigens. It is
readily apparent that further studies in this area
will both increase our understanding of basic im¬
mune phenomena and provide a wide range of
valuable reagents for use in other studies.
Limitations of current technology
Throughout this review we have emphasised the
problems in relation to the supply of suitable
immune lymphocytes for fusion and transforma¬
tion together with the low efficiency of the im¬
mortalisation processes themselves. The other
major limitation of human antibody-secreting cell
lines is the low levels of immunoglobulin synthe-
sised together with the all too frequent loss of this
function.
These problems are common to transformed
cell lines, hybrids and heterohybrids and are gen¬
erally attributed to either overgrowth by non-
secreting lymphocyte 'contaminants' or to the loss
of structural genes coding for immunoglobulin.
The former explanation is perhaps most ap¬
propriate following EBV transformation where
cells are polyclonally activated and cloning in
most hands is difficult. On the other hand the loss
of regulatory genes is believed to be particularly
relevant to heterohybrids which are regarded as
being chromosomally unstable, preferentially
segregating human chromosomes (Kozbor and
Croce, 1985; Teng et al., 1985). Indeed as previ-
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ously remarked the instability of human lympho¬
cyte heterohybrids has been used by Croce and
others to map genes to chromosomes (see, for
example, Croce et al. 1980b; Erikson et al., 1981).
In this context it is interesting to note that karyo¬
type analysis reveals that heterohybrids prefer¬
entially retain chromosome 14 coding for the heavy
chain and lose chromosome 2 which codes for the
k light chain (Croce, 1980b). Furthermore they
usually have five times as many mouse as human
chromosomes (Raison et al., 1982; Teng et al.,
1985b). It has also been suggested that stable
translocations of human immunoglobulin genes
onto mouse chromosomes may occur following
fusion (Cote et al., 1984, 1985). While this is an
interesting possibility, to the best of our know¬
ledge it still remains to be demonstrated.
Unfortunately in most instances the reasons for
the decline in antibody secretion by human mono¬
clonal cell lines has not been adequately followed
up. In almost every case synthesis has been as¬
sessed by measuring either total immunoglobulin
or specific antibody in culture supernatants, the
possible presence of immunoglobulin in the cyto¬
plasm being ignored. As a result it is difficult to
distinguish between defects in synthesis and secre¬
tion. From a consideration of the literature it is
now apparent that the loss of immunoglobulin
secretion observed with most cell lines, together
with the low levels they secrete initially, can be
attributed to a variety of factors (Table XIV).
These include deficits in growth and differentia¬
tion factors and their receptors, structural and
regulatory gene defects and imperfections in the
synthetic and secretory machinery of the cells. The
latter are believed to be largely due to quantitative
and functional deficiencies in rough endoplasmic
reticulum, polyribosomes and the Golgi apparatus
(Kozbor et al., 1983; Sikora et al., 1983; Kozbor
and Croce, 1985). A number of these suggested
defects are worthy of further comment.
An area which has been overlooked is that of
defects unrelated to the expression of immuno¬
globulin genes. These include shortages in endoge¬
nous or exogenous growth and differentiation fac¬
tors (Winger et al., 1983) or their receptors
(Melamed et al., 1985). In this context it should be
noted that the problem with many human anti¬
body-secreting cell lines is not one of proliferation
TABLE XIV
POSSIBLE REASONS FOR LOW OR ABSENT IM¬
MUNOGLOBULIN SYNTHESIS BY HUMAN MONO¬
CLONAL CELL LINES
Suggested defect References
Inhibitory effect of mycoplasma
or other microorganisms
Overgrowth of secreting cells
by non-secretors




receptors for growth and
differentiation factors
Loss or inappropriate incor¬
poration of structural genes









regulatory genes or other
defects in regulation




Defects in the secretory
machinery of the cell
Van Meel et al., 1985
Zurawski et al., 1978
Winger et al., 1983
Melamed et al., 1985
Schwaber et al., 1984;
Teng et al., 1985b
Schwaber et al., 1984;
Sahagan et al., 1986
Raison et al., 1982;
Schwaber et al., 1984;
Kozbor and Croce, 1985
Sikora et al., 1983;
Kozbor and Croce, 1985;
Teng et al., 1985
Kozbor and Croce, 1985;
Teng et al., 1985;
Gaffar et al., 1986b
but inadequate immunoglobulin secretion. Fur¬
thermore attempts to improve antibody secretion
by co-cultivation with HLA-Dr-matched specific
helper T cells or antibody to HLA-Dr, which is
believed to substitute for T cell help, have not
been successful (Crawford, 1985).
Of especial interest are proposed mechanisms
relating to the expression of structural genes for
immunoglobulin. The theories that have advanced
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include the loss of such genes, their inappropriate
integration or inadequate gene dosage (Table XIV).
As the secretion of heavy chain is dependent upon
the presence of functional light chains, immuno¬
globulin secretion might fail if the relevant light
chain genes are preferentially lost or fail to func¬
tion (Kohler et al., 1976; Pepe et ah, 1986). If such
a mechanism is involved one would expect hetero-
hybridomas to produce a preponderance of hu¬
man monoclonals with X light chains in view of
reports that the chromosome 2 carrying the k
chain gene is preferentially lost (Croce et al.,
1980b).
Although the selective loss of structural genes is
a simple and hence attractive proposition, there is
evidence to indicate that it is not without its
limitations. For example isoenzyme-mapping stud¬
ies on non-secreting human/mouse heterohybrids
indicate that they still carried the heavy chain
gene chromosome (nos. 14) and could be induced
to re-express immunoglobulin by stimulation with
LPS (Raison et al., 1982). Furthermore Schwaber
and his colleagues (1984) have shown that back
fusion with normal peripheral blood lymphocytes
may also re-activate secretion, an observation we
have confirmed in our own laboratory. These ob¬
servations are highly suggestive that the defect in
many human monoclonal cell lines is due either to
a failure of regulatory genes or some other aspect
of regulation (Raison et al., 1982; Schwaber et al.,
1984).
Finally the morphology of the human cell lines
generated to data should not be overlooked. Gen¬
erally speaking they have been found to have a
less well developed rough endoplasmic reticulum
than mature plasma cells and have numerous free
polyribosomes (Kozbor et al., 1983; Larrick et al.,
1983). These structural abnormalities could lead to
impaired translation, assembly and secretion of
immunoglobulin.
Strategies for the future
From our previous comments it is obvious that
the production of human monoclonals is still a
chance affair involving considerable effort and
dedication. It is also equally apparent that at the
present time there is no simple answer to the
many problems which beset this work. Neverthe¬
less there are areas which are worthy of more
detailed consideration and these are listed in Ta¬
ble XV; some are also discussed in further detail
below.
Supply of immune lymphocytes
As emphasised elsewhere in this review this still
represents a major obstacle with respect to human
monoclonal development. Flowever, we believe
that improvements in this area are possible both
with regards to immunisation protocols and
lymphocyte selection procedures. In situations
where active immunisation is feasible we need to
optimise injection and bleeding protocols. This
will undoubtedly require a better understanding of
the factors influencing the activation, prolifera¬
tion, differentiation and circulation of committed
B cell precursors. Furthermore, where feasible, it
will be interesting to establish whether adjuvants
such as BCG can be used to increase the circulat¬
ing pool of committed B cell precursors or their
activated progeny.
It is obvious that vital information in this and
other areas (see below) will be obtained by de¬
tailed cell surface phenotype analysis using specific
monoclonal antibodies in conjunction with flow
cytometry or immunocytochemical techniques. Of
particular value in this respect will be mono¬
clonals against B cell differentiation antigens,
growth factor receptors and specific markers of
activated B cells (Susuki et al., 1986). Whatever
advances are achieved in in vivo immunisation we
firmly believe like others that the future of human
monoclonal antibody technology will be largely
dependent upon advances in in vitro immunisa¬
tion procedures (Dorfman, 1985; Borrebaeck,
1986). This approach permits both the specific
expansion of B cell precursors and the develop¬
ment of antibodies against immunogens which
cannot be safely administered in vivo. The value
of this approach, like its in vivo counterpart, will
be significantly enhanced as our knowledge of the
events associated with lymphocyte triggering, pro¬
liferation and differentiation, increases and as
techniques for affecting class switching are
evolved. However, before this approach can be
effectively exploited a number of factors will re¬
quire extensive investigation. These include the
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TABLE XV
KEY AREAS FOR FUTURE RESEARCH IN HUMAN MONOCLONAL ANTIBODY PRODUCTION
Improved immunisation strategies
Selection of immune B cells
Immortalisation procedures -
Lymphocyte cloning techniques -
Regulation of B cell growth -
Regulation of immunoglobulin synthesis and secretion -







Optimisation of existing technologies
Improved B cell lines
More efficient fusion procedures, e.g., electrofusion
Alternative immortalisation strategies, e.g., transfection
Alternative cloning techniques, e.g., micromanipulation,
fluorescence activated cell sorter
Use of recombinant growth and differentiation factors
Growth factor effects
Growth factor receptor expression
Expression of immunoglobulin structural genes
Role of regulatory genes
Human antibody molecules
Hybrid antibody molecules
Mixed antibody protein molecules
Site-directed antibody mutants
source of lymphoid cells, the dose and form of
immunogen, the influence of mitogens and ad¬
juvants, the value of growth and differentiation
factors and the optimum culture time.
Of general importance with respect to the out¬
come of both in vitro immunisation and im¬
mortalisation steps is the cellular composition of
the lymphocyte suspensions used. It is generally
accepted that the chance of obtaining specific
antibody-secreting hybrids is improved by enrich¬
ing the relevant antibody-secreting precursors and
such procedures should be followed where feasi¬
ble. Of additional importance is the non-B cell
content of the reaction mixture. Thus the outcome
of in vitro immunisation will depend on the close
interaction of B cells, antigen-presenting cells and
helper and suppressor T cells and as stressed
earlier the outgrowth of transformed B cells is
impaired by cytotoxic T cells. However, what is
perhaps less well appreciated is that NK cells can
inhibit the proliferation and immunoglobulin-
secreting capacity of B cells including those trans¬
formed by EBV (James and Ritchie, 1984; Kuwano
et al., 1986). Further studies on the effects of
specific enrichment of plasma cell precursors and
the removal of inhibitory cells (such as Tc and
NK) should lead to improvements in both in vitro
immunisation techniques and immortalisation
procedures.
Immortalisation procedures
The most widely used immortalisation proce¬
dures in the immediate future will still continue to
be EBV transformation and cell fusion or a com¬
bination of these procedures. Like others we
strongly believe that these procedures are far from
optimised and require further basic investigation,
especially of the cell populations most susceptible
to transformation or fusion.
As stressed earlier there appears to be some
confusion over the subset of B lymphocytes which
is immortalised by EBV and activated to secrete
immunoglobulin. Thus according to Aman et al.
(1984) it is a small high density resting population
while Chan et al. (1986) claim that it is a large
cycling population. It is also worth noting that
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twice as many B cells are induced to secrete
immunoglobulin as are immortalised (Tosato et
al., 1985), an observation of importance when
screening for stable antibody-secreting hybrids. In
spite of the above the enrichment of the 'relevant'
B cell population (along with the removal of Tc
and NK cells) would obviously facilitate the pro¬
duction of monoclonals by this procedure.
The alternative cell-driven EBV transformation
procedure also requires further evaluation (Siadak
and Lostrom, 1985). This technique which in¬
volves cocultivation of normal B lymphocytes with
a HAT-sensitive EBV-transformed B cell line is
reputed to be simple, reproducible and more effi¬
cient than conventional transformation and fusion
procedures.
The most obvious limitation as far as the fusion
process itself is concerned still remains the lack of
suitable non-secreting fusion partners capable of
producing stable hybrids secreting high levels of
antibody. While much effort has been directed
towards the development of suitable fusion
partners, few, if any, perform like their murine
counterparts. Nevertheless, what is encouraging
from the authors' viewpoint is the success achieved
to date with mouse and mouse/human fusion
partners. As stressed earlier a number of investiga¬
tors have found them to fuse better, and the
resultant hybrids clone easier and secrete more
antibody, than human hybrids and contrary to
general opinion, they have proved to be relatively
stable (Tables VI and VII). Furthermore, as previ¬
ously indicated, they grow better in nude mice and
we have also found them easier to grow in tissue
culture (personal observations). Thus until better
human cell lines are developed, we would stress
that mouse and mouse/human fusion partners
should not be ignored.
Almost without exception the fusion process
itself has been performed with PEG. In view of
the low efficiency of this process, the wide varia¬
tion in fusion efficiency noted between PEG from
different manufacturers and from batch to batch,
and its relative toxicity, alternative methods of
fusion should also be considered. As stressed by
Dorfmann (1985) more efficient procedures would
be a great advantage, especially where the num¬
bers of lymphocytes available is limited, as for
example may be the case following in vitro im¬
munisation or when the lymphocytes have been
isolated from, say, a tumour. One process which
might be suitable for fusing small numbers of cells
is the electrofusion technique developed by
Zimmerman and co-workers (Bischoff et al., 1982;
Zimmerman and Vienken, 1982). Although this
technique has not been widely used to date it is
reputed to be 100000 times more effective than
the PEG method (Dorfmann, 1985) and has also
been applied to the production of T cell hy-
bridomas (Gravekamp et al., 1985). Furthermore
its potential has been enhanced by the recent
development of avidin-biotin techniques for 'lin¬
king' specific antibody-forming B cells and
myeloma cells, prior to electrofusion (Lo et al.,
1984; Wojchowski and Sytkowski, 1986). It is also
conceivable that some time in the near future
procedures will be developed involving the fusion
of single cells, followed by the expansion of the
hybrid in carefully formulated material containi. g
growth and differentiation factors produced by
recombinant techniques. This procedure could take
advantage of the sophisticated single cell proce¬
dures developed by Nossal and his colleagues (see
for example Nossal and Pike, 1983; Pike et al.,
1984).
With current immortalisation procedures clon¬
ing will still remain a major problem. Trans¬
formed cells undoubtedly clone less readily than
hybrid cells and human hybrids less efficiently
than their murine counterparts. Cloning proce¬
dures will obviously be facilitated as highly puri¬
fied growth factors become more readily available
and as our knowledge of their mode of action
increases. In the meantime there are alternatives
to the widely used dilution and soft agar cloning
techniques. These include the micromanipulation
of single cells (Thompson et al., 1986) and as
advocated by Shay (1985) fluorescent-activated
cell sorter-based cloning techniques.
Improving stability and immunoglobulin secretion
Considerable effort will have to be directed
towards improving the levels of antibody secreted
by human cell lines and to ensuring that high
levels of secretion are sustained. While this might
be partly solved by improvements in immunisa¬
tion, selection and immortalisation, other strate¬
gies will be necessary. The most obvious approach
32
is to frequently enrich antibody-secreting cell lines
and to pursue a rigorous cloning policy. The former
procedure has been successfully applied to cell
lines secreting anti-red cell antibodies (see, for
example, Crawford, 1985; Doyle et al., 1985).
Other approaches would seem appropriate in
view of the observations that cell lines which have
stopped secreting immunoglobulin can be re¬
activated either by fusion with normal lympho¬
cytes (Schwaber et al., 1984) or by stimulation
with LPS (Raison et al., 1982). As previously
stressed these observations, which have been
largely overlooked, suggest that the failure of hu¬
man cell lines to secrete immunoglobulin may be a
consequence of defects in the function of regu¬
latory genes or synthetic and secreting mecha¬
nisms.
In view of this possibility any techniques for
enhancing gene expression would appear worthy
of investigation. This might simply involve back
fusion, stimulation with LPS or treatment with
phorbol esters. The latter approach has been shown
to enhance receptor expression and immuno¬
globulin secretion by B cells (Polke et al., 1986)
and is of considerable importance in view of re¬
cent suggestions that senescence in human anti¬
body-secreting cell lines might be associated with
a decline in growth factor receptor expression
(Melamed et al., 1985). More sophisticated ap¬
proaches would involve transfecting cells with
specific enhancer sequences (Teng et al., 1985b) or
by gene-silencing techniques involving demethyl-
ation of the genome (Olsson and Brams, 1985).
Whichever approach is used to improve specific
antibody secretion we believe that when important
cell lines cease to secrete immunoglobulin, gene
probes and specific antisera should be used to
establish if the basic defect is due to the loss of the
relevant structural genes, defects in transcription
or translation or a failure of assembly and secre¬
tion. A better understanding of the nature of the
defect could eventually lead to improved correc¬
tive measures. It should be stressed, however, that
these approaches will only be of value when the
fusion partner also lacks the relevant structural
genes.
Gene-cloning strategies
In this review we have been concerned with
conventional approaches to human monoclonal
antibody production. We have also indicated that
genetic engineering procedures might be used to
improve the secretion of specific antibody by im¬
mortalised cell lines. It should be stressed that
genetic engineering procedures have already been
successfully applied to the cloning and expression
of immunoglobulin genes themselves. Although
there are still problems to overcome the achieve¬
ments to date are extremely encouraging and
worthy of comment for they open up the way to
establishing stable cell lines producing antibodies
with unique properties (Aguila et al., 1986). Thus
so far complete immunoglobulin molecules have
been produced by expressing mouse H and L
chain genes in E. coli (Boss et al., 1984), yeast
(Wood et al., 1985) and myeloma cell lines (Neu-
berger, 1985), using conventional recombinant
procedures employing vectors.
A less sophisticated approach has been to either
transfect antibody-secreting cells with calcium-
precipitated DNA from permanent cell lines
(Jonak et al., 1984) or alternatively, permanent
cell lines with similar preparations from anti¬
body-producing cell lines (Strelkauskas et al.,
1987b).
There are also reports on the cloning and
expression of human heavy and light chain genes
using recombinant procedures. However, of par¬
ticular interest are the reports describing the con¬
struction, cloning and expression of genes coding
for hybrid molecules containing mouse variable
and human constant region domains. This ap¬
proach, which has recently been reviewed by Oi
and Morrison (1986), enables one to produce
'humanised' monoclonal antibodies against im-
munogens which cannot be injected into humans
or which fail to elicit a good immune response in
vitro or in vivo. The genes have been introduced
into myeloma cells by both spheroplast fusion
(Jones et al., 1986; Sharon et al., 1986) and elec-
troporation techniques (Sahagan et al., 1986). The
immunoglobulin produced by these recombinants
retains the specificity of the original mouse anti¬
body and it will intrinsically be less immunogenic
in man than the original mouse antibody. Using
this approach chimeric antibodies have been pro¬
duced against haptens (Boulianne et al., 1986),
tumour antigens (Sahagan et al., 1986) and other
33
antigens (Takeda et al., 1985).
More recently the potential of the technology
has been further advanced. Thus Jones et al. (1986)
have replaced the genes coding for the hypervaria-
ble (complementarity-determining) region of the
H chain with genes coding for the hypervariable
region of a murine monoclonal heavy chain.
Exploitation of this kind of approach should lead
to hybrid molecules of even weaker immunogeni-
city. Sharon et al. (1986) on the other hand have
shown how the site-directed mutagenesis approach
can be used to alter the specificity and idiotype
expression of murine monoclonals. This approach
involves the insertion of specific oligonucleotide
sequences into heavy chain variable region genes
and could enable the development of antibodies
with novel specificities.
Finally the potential of this technique for pro¬
ducing antibodies with novel effector functions
should not be overlooked. Thus Neuberger and his
colleagues (Neuberger et al., 1984; Neuberger,
1985) have expressed in myeloma cells genes cod¬
ing for the F(ab')2 region of mouse immuno¬
globulin linked to genes for either enzymes or
c-myc antigenic determinants. Human constructs
of this type could prove extremely useful in diag¬
nosis, targeting and imaging.
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